U.S. patent application number 11/537879 was filed with the patent office on 2007-07-26 for cytokine receptor zalpha11.
This patent application is currently assigned to ZymoGenetics, Inc.. Invention is credited to Darrell C. Conklin, Angela K. Hammond, Julia E. Novak, Scott R. Presnell.
Application Number | 20070172917 11/537879 |
Document ID | / |
Family ID | 27493162 |
Filed Date | 2007-07-26 |
United States Patent
Application |
20070172917 |
Kind Code |
A1 |
Presnell; Scott R. ; et
al. |
July 26, 2007 |
CYTOKINE RECEPTOR ZALPHA11
Abstract
Novel polypeptides, polynucleotides encoding the polypeptides,
and related compositions and methods are disclosed for zalpha11, a
novel cytokine receptor. The polypeptides may be used within
methods for detecting ligands that stimulate the proliferation
and/or development of hematopoietic, lymphoid and myeloid cells in
vitro and in vivo. Ligand-binding receptor polypeptides can also be
used to block ligand activity in vitro and in vivo. The
polynucleotides encoding zalpha11, are located on chromosome 16,
and can be used to identify a region of the genome associated with
human disease states. The present invention also includes methods
for producing the protein, uses therefor and antibodies
thereto.
Inventors: |
Presnell; Scott R.; (Tacoma,
WA) ; Conklin; Darrell C.; (Seattle, WA) ;
Novak; Julia E.; (Bainbridge Island, WA) ; Hammond;
Angela K.; (Maple Valley, WA) |
Correspondence
Address: |
ZYMOGENETICS, INC.;INTELLECTUAL PROPERTY DEPARTMENT
1201 EASTLAKE AVENUE EAST
SEATTLE
WA
98102-3702
US
|
Assignee: |
ZymoGenetics, Inc.
|
Family ID: |
27493162 |
Appl. No.: |
11/537879 |
Filed: |
October 2, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10864249 |
Jun 9, 2004 |
|
|
|
11537879 |
Oct 2, 2006 |
|
|
|
10243072 |
Sep 13, 2002 |
6803451 |
|
|
10864249 |
Jun 9, 2004 |
|
|
|
09628127 |
Jul 28, 2000 |
|
|
|
10243072 |
Sep 13, 2002 |
|
|
|
09404641 |
Sep 23, 1999 |
6576744 |
|
|
09628127 |
Jul 28, 2000 |
|
|
|
60100896 |
Sep 23, 1998 |
|
|
|
60123546 |
Mar 9, 1999 |
|
|
|
60142574 |
Jul 6, 1999 |
|
|
|
Current U.S.
Class: |
435/69.1 ;
435/320.1; 435/325; 435/69.7; 530/350; 536/23.5 |
Current CPC
Class: |
C07K 16/2866 20130101;
C07H 21/04 20130101; C07K 2317/32 20130101; C07K 16/1232 20130101;
C07K 2319/00 20130101; C07K 14/715 20130101 |
Class at
Publication: |
435/069.1 ;
435/069.7; 435/320.1; 435/325; 530/350; 536/023.5 |
International
Class: |
C12P 21/06 20060101
C12P021/06; C07H 21/04 20060101 C07H021/04; C07K 14/705 20060101
C07K014/705 |
Claims
1. A method of producing a polypeptide comprising: culturing a cell
comprising an expression vector, wherein the expression vector
comprises the following operably linked elements: a transcription
promoter; a DNA construct encoding a polypeptide, wherein the
polypeptide comprises: a DNA segment encoding a polypeptide
consisting of an amino acid sequence as shown in SEQ ID NO:2 from
amino acid number 20 (Cys), to amino acid number 538 (Ser), wherein
the polypeptide further comprises a WSXWS motif as shown in SEQ ID
NO:3, and wherein a Trp residue in the WSXWS motif (SEQ ID NO:3) is
mannosylated; a transcription terminator, and wherein the promoter
is operably linked to the DNA construct, and the DNA construct is
operably linked to the transcription terminator, wherein the cell
expresses a polypeptide encoded by the DNA construct; and isolating
the polypeptide produced by the cell.
2. The method according to claim 1, wherein the expression vector
further comprising a secretory signal sequence operably linked to
the DNA segment.
3. A method of producing a soluble receptor polypeptide comprising:
culturing a cell comprising an expression vector, wherein the
expression vector comprises the following operably linked elements:
a transcription promoter; a DNA construct encoding a polypeptide,
wherein the polypeptide comprises: a DNA segment encoding a
polypeptide consisting of an amino acid sequence as shown in SEQ ID
NO:2 from amino acid number 20 (Cys), to amino acid number 237
(His), wherein the polypeptide further comprises a WSXWS motif as
shown in SEQ ID NO:3, and wherein a Trp residue in the WSXWS motif
(SEQ ID NO:3) is mannosylated; a transcription terminator, and
wherein the promoter is operably linked to the DNA construct, and
the DNA construct is operably linked to the transcription
terminator, wherein the cell expresses a polypeptide encoded by the
DNA construct; and isolating the soluble receptor polypeptide
produced by the cell.
4. The method according to claim 3, wherein the expression vector
further comprising a secretory signal sequence operably linked to
the DNA segment.
5. The method according to claim 3, wherein the polypeptide encoded
by the DNA segment further comprises a biotin/avidin label,
radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent
marker, chemiluminescent marker, toxin, cytotoxic molecule or an
immunoglobulin Fc domain.
6. A method of producing a fusion protein comprising: culturing a
cell comprising an expression vector, wherein the expression vector
comprises the following operably linked elements: a transcription
promoter; a DNA construct encoding a fusion protein, wherein the
fusion protein comprises: (i) a first DNA segment encoding a
polypeptide consisting of a sequence of amino acid residues
selected from the group consisting of: (a) the amino acid sequence
of SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number
237 (His); (b) the amino acid sequence of SEQ ID NO:2 from amino
acid number 20 (Cys) to amino acid number 255 (Leu); (c) the amino
acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys), to
amino acid number 538 (Ser); and wherein the polypeptide further
comprises a WSXWS motif as shown in SEQ ID NO:3, and wherein a Trp
residue in the WSXWS motif (SEQ ID NO:3) is mannosylated; and (ii)
at least one other DNA segment encoding an additional polypeptide,
wherein the first and other DNA segments are connected in-frame;
and wherein the first and other DNA segments encode the fusion
protein; a transcription terminator, and wherein the promoter is
operably linked to the DNA construct, and the DNA construct is
operably linked to the transcription terminator, wherein the cell
expresses a polypeptide encoded by the DNA construct; and isolating
the polypeptide produced by the cell.
7. The method according to claim 6, wherein the expression vector
further comprising a secretory signal sequence operably linked to
the DNA segment.
Description
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of copending U.S. patent
application Ser. No. 10/864,249, filed Jun. 9, 2004, which claims
benefit of Provisional Application 60/100,896, filed on Sep. 23,
1998, Provisional Application 60/123,546, filed on Mar. 3, 1999,
Provisional Application 60/142,574, filed on Jul. 6, 1999, all of
which are incorporated herein by reference. Under 35 U.S.C. .sctn.
119(e)(1), this application claims benefit of said Provisional
Applications. Additionally, this application claims benefit of
application Ser. No. 09/404,641 filed on Sep. 23, 1999, issued as
U.S. Pat. No. 6,576,744, and application Ser. No. 10/243,072 filed
Sep. 13, 2002, issued as U.S. Pat. No. 6,803,451, under 35 U.S.C.
35 .sctn. 120.
BACKGROUND OF THE INVENTION
[0002] Hormones and polypeptide growth factors control
proliferation and differentiation of cells of multicellular
organisms. These diffusible molecules allow cells to communicate
with each other and act in concert to form cells and organs, and to
repair damaged tissue. Examples of hormones and growth factors
include the steroid hormones (e.g. estrogen, testosterone),
parathyroid hormone, follicle stimulating hormone, the
interleukins, platelet derived growth factor (PDGF), epidermal
growth factor (EGF), granulocyte-macrophage colony stimulating
factor (GM-CSF), erythropoietin (EPO) and calcitonin.
[0003] Hormones and growth factors influence cellular metabolism by
binding to receptors. Receptors may be integral membrane proteins
that are linked to signaling pathways within the cell, such as
second messenger systems. Other classes of receptors are soluble
molecules, such as the transcription factors. Of particular
interest are receptors for cytokines, molecules that promote the
proliferation and/or differentiation of cells. Examples of
cytokines include erythropoietin (EPO), which stimulates the
development of red blood cells; thrombopoietin (TPO), which
stimulates development of cells of the megakaryocyte lineage; and
granulocyte-colony stimulating factor (G-CSF), which stimulates
development of neutrophils. These cytokines are useful in restoring
normal blood cell levels in patients suffering from anemia,
thrombocytopenia, and neutropenia or receiving chemotherapy for
cancer.
[0004] The demonstrated in vivo activities of these cytokines
illustrate the enormous clinical potential of, and need for, other
cytokines, cytokine agonists, and cytokine antagonists. The present
invention addresses these needs by providing new a hematopoietic
cytokine receptor, as well as related compositions and methods.
[0005] The present invention provides such polypeptides for these
and other uses that should be apparent to those skilled in the art
from the teachings herein.
SUMMARY OF THE INVENTION
[0006] Within one aspect, the present invention provides an
isolated polynucleotide that encodes a zalpha11 polypeptide
comprising a sequence of amino acid residues that is at least 90%
identical to an amino acid sequence selected from the group
consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2
from amino acid number 20 (Cys), to amino acid number 237 (His);
(b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid
number 20 (Cys), to amino acid number 255 (Leu); (c) the amino acid
sequence as shown in SEQ ID NO:2 from amino acid number 256 (Lys),
to amino acid number 538 (Ser); (d) the amino acid sequence as
shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid
number 538 (Ser); and (e) the amino acid sequence as shown in SEQ
ID NO:2 from amino acid number 1 (Met) to amino acid number 538
(Ser), wherein the amino acid percent identity is determined using
a FASTA program with ktup=1, gap opening penalty=10, gap extension
penalty=1, and substitution matrix=BLOSUM62, with other parameters
set as default. Within one embodiment, the isolated polynucleotide
disclosed above comprises a sequence of polynucleotides that is
selected from the group consisting of: (a) a polynucleotide
sequence as shown in SEQ ID NO:4 from nucleotide 1 to nucleotide
1614; (b) a polynucleotide sequence as shown in SEQ ID NO:1 from
nucleotide 126 to nucleotide 779; (c) a polynucleotide sequence as
shown in SEQ ID NO:1 from nucleotide 126 to nucleotide 833; (d) a
polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 834
to nucleotide 1682; (e) a polynucleotide sequence as shown in SEQ
ID NO:1 from nucleotide 126 to nucleotide 1682; and (f) a
polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 69
to nucleotide 1682. Within another embodiment, the isolated
polynucleotide disclosed above comprises a sequence of amino acid
residues selected from the group consisting of: (a) the amino acid
sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys),
to amino acid number 237 (His); (b) the amino acid sequence as
shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid
number 255 (Leu); (c) the amino acid sequence as shown in SEQ ID
NO:2 from amino acid number 256 (Lys), to amino acid number 538
(Ser); (d) the amino acid sequence as shown in SEQ ID NO:2 from
amino acid number 20 (Cys), to amino acid number 538 (Ser); and (e)
the amino acid sequence as shown in SEQ ID NO:2 from amino acid
number 1 (Met) to amino acid number 538 (Ser). Within another
embodiment, the isolated polynucleotide disclosed above consists of
a sequence of amino acid residues selected from the group
consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2
from amino acid number 20 (Cys), to amino acid number 237 (His);
(b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid
number 20 (Cys), to amino acid number 255 (Leu); (c) the amino acid
sequence as shown in SEQ ID NO:2 from amino acid number 256 (Lys),
to amino acid number 538 (Ser); (d) the amino acid sequence as
shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid
number 538 (Ser); and (e) the amino acid sequence as shown in SEQ
ID NO:2 from amino acid number 1 (Met) to amino acid number 538
(Ser). Within another embodiment, the isolated polynucleotide
disclosed above further comprises a WSWSX domain. Within another
embodiment, the isolated polynucleotide disclosed above further
comprises a transmembrane domain. Within another embodiment, the
isolated polynucleotide disclosed above comprises a transmembrane
domain consisting of residues 238 (Leu) to 255 (Leu) of SEQ ID
NO:2. Within another embodiment, the isolated polynucleotide
disclosed above further comprises an intracellular domain. Within
another embodiment, the isolated polynucleotide disclosed above
comprises an intracellular domain consists of residues 256 (Lys) to
538 (Ser) of SEQ ID NO:2. Within another embodiment, the isolated
polynucleotide disclosed above comprises an intracellular domain
which domain further comprises Box I and Box II sites. comprises an
intracellular domain wherein the polypeptide further comprises an
affinity tag.
[0007] Within a second aspect, the present invention provides an
expression vector comprising the following operably linked
elements: a transcription promoter; a DNA segment encoding a
zalpha11 polypeptide having an amino acid sequence as shown in SEQ
ID NO:2 from amino acid number 20 (Cys), to amino acid number 538
(Ser); and a transcription terminator, wherein the promoter is
operably linked to the DNA segment, and the DNA segment is operably
linked to the transcription terminator. Within one embodiment, the
expression vector disclosed above further comprises a secretory
signal sequence operably linked to the DNA segment.
[0008] Within a third aspect, the present invention provides a
cultured cell comprising an expression vector as disclosed above,
wherein the cell expresses a polypeptide encoded by the DNA
segment.
[0009] Within a fourth aspect, the present invention provides an
expression vector comprising: a transcription promoter; a DNA
segment encoding a zalpha11 polypeptide having an amino acid
sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys),
to amino acid number 237 (His); and a transcription terminator,
wherein the promoter, DNA segment, and terminator are operably
linked. Within one embodiment, the expression vector disclosed
above further comprises a secretory signal sequence operably linked
to the DNA segment. Within another embodiment, the expression
vector disclosed above further comprises a transmembrane domain
operably linked to the DNA segment. Within another embodiment, the
expression vector disclosed above further comprises a transmembrane
domain consisting of residues 238 (Leu) to 255 (Leu) of SEQ ID
NO:2. Within another embodiment, the expression vector disclosed
above further comprises an intracellular domain operably linked to
the DNA segment. Within another embodiment, the expression vector
disclosed above further comprises an intracellular domain
consisting of residues 256 (Lys) to 538 (Ser) of SEQ ID NO:2.
[0010] Within another aspect, the present invention provides a
cultured cell into which has been introduced an expression vector
according to claim 15, wherein the cell expresses a soluble
receptor polypeptide encoded by the DNA segment. Within one
embodiment, the cultured cell disclosed above is dependent upon an
exogenously supplied hematopoietic growth factor for
proliferation.
[0011] Within another aspect, the present invention provides a DNA
construct encoding a fusion protein, the DNA construct comprising:
a first DNA segment encoding a polypeptide having a sequence of
amino acid residues selected from the group consisting of: (a) the
amino acid sequence of SEQ ID NO:2 from amino acid number 1 (Met),
to amino acid number 19 (Gly); (b) the amino acid sequence of SEQ
ID NO:2 from amino acid number 20 (Cys) to amino acid number 237
(His); (c) the amino acid sequence of SEQ ID NO:2 from amino acid
number 20 (Cys) to amino acid number 255 (Leu); (d) the amino acid
sequence of SEQ ID NO:2 from amino acid number 238 (Leu) to amino
acid number 255 (Leu); (e) the amino acid sequence of SEQ ID NO:2
from amino acid number 238 (Leu) to amino acid number 538 (Ser);
(f) the amino acid sequence of SEQ ID NO:2 from amino acid number
256 (Lys) to amino acid number 538 (Ser); and (g) the amino acid
sequence of SEQ ID NO:2 from amino acid number 20 (Cys), to amino
acid number 538 (Ser); and at least one other DNA segment encoding
an additional polypeptide, wherein the first and other DNA segments
are connected in-frame; and wherein the first and other DNA
segments encode the fusion protein.
[0012] Within another aspect, the present invention provides an
expression vector comprising the following operably linked
elements: a transcription promoter; a DNA construct encoding a
fusion protein as disclosed above; and a transcription terminator,
wherein the promoter is operably linked to the DNA construct, and
the DNA construct is operably linked to the transcription
terminator.
[0013] Within another aspect, the present invention provides a
cultured cell comprising an expression vector as disclosed above,
wherein the cell expresses a polypeptide encoded by the DNA
construct.
[0014] Within another aspect, the present invention provides a
method of producing a fusion protein comprising: culturing a cell
as disclosed above; and isolating the polypeptide produced by the
cell.
[0015] Within another aspect, the present invention provides an
isolated polypeptide comprising a sequence of amino acid residues
that is at least 90% identical to an amino acid sequence selected
from the group consisting of: (a) the amino acid sequence as shown
in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid
number 237 (His); (b) the amino acid sequence as shown in SEQ ID
NO:2 from amino acid number 20 (Cys), to amino acid number 255
(Leu); (c) the amino acid sequence as shown in SEQ ID NO:2 from
amino acid number 256 (Lys), to amino acid number 538 (Ser); (d)
the amino acid sequence as shown in SEQ ID NO:2 from amino acid
number 20 (Cys), to amino acid number 538 (Ser); and (e) the amino
acid sequence as shown in SEQ ID NO:2 from amino acid number 1
(Met) to amino acid number 538 (Ser), wherein the amino acid
percent identity is determined using a FASTA program with ktup=1,
gap opening penalty=10, gap extension penalty=1, and substitution
matrix=BLOSUM62, with other parameters set as default. Within one
embodiment, the isolated polypeptide disclosed above comprises a
sequence of amino acid residues selected from the group consisting
of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino
acid number 20 (Cys), to amino acid number 237 (His); (b) the amino
acid sequence as shown in SEQ ID NO:2 from amino acid number 20
(Cys), to amino acid number 255 (Leu); (c) the amino acid sequence
as shown in SEQ ID NO:2 from amino acid number 256 (Lys), to amino
acid number 538 (Ser); (d) the amino acid sequence as shown in SEQ
ID NO:2 from amino acid number 20 (Cys), to amino acid number 538
(Ser); and (e) the amino acid sequence as shown in SEQ ID NO:2 from
amino acid number 1 (Met) to amino acid number 538 (Ser).
[0016] Within another embodiment, the isolated polypeptide
disclosed above consists of a sequence of amino acid residues
selected from the group consisting of: (a) the amino acid sequence
as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino
acid number 237 (His); (b) the amino acid sequence as shown in SEQ
ID NO:2 from amino acid number 20 (Cys), to amino acid number 255
(Leu); (c) the amino acid sequence as shown in SEQ ID NO:2 from
amino acid number 256 (Lys), to amino acid number 538 (Ser); (d)
the amino acid sequence as shown in SEQ ID NO:2 from amino acid
number 20 (Cys), to amino acid number 538 (Ser); and (e) the amino
acid sequence as shown in SEQ ID NO:2 from amino acid number 1
(Met) to amino acid number 538 (Ser). Within another embodiment,
the isolated polypeptide disclosed above further contains a WSXWS
motif (SEQ ID NO:3). Within another embodiment, the isolated
polypeptide disclosed above further comprises a transmembrane
domain. Within another embodiment, the isolated polypeptide
disclosed above further comprises a transmembrane domain, wherein
the transmembrane domain consists of residues 238 (Leu) to 255
(Leu) of SEQ ID NO:2. Within another embodiment, the isolated
polypeptide disclosed above further comprises an intracellular
domain. Within another embodiment, the isolated polypeptide
disclosed above further comprises an intracellular domain, wherein
the intracellular domain consists of residues 256 (Lys) to 538
(Ser) of SEQ ID NO:2. Within another embodiment, the isolated
polypeptide disclosed above further comprises an intracellular
domain, wherein the intracellular domain further comprises Box I
and Box II sites.
[0017] Within another aspect, the present invention provides a
method of producing a zalpha11 polypeptide comprising: culturing a
cell as disclosed above; and isolating the zalpha11 polypeptide
produced by the cell.
[0018] Within another aspect, the present invention provides an
isolated polypeptide comprising an amino acid sequence selected
from the group consisting of: (a) the amino acid sequence as shown
in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid
number 237 (His); and wherein the polypeptide is substantially free
of transmembrane and intracellular domains ordinarily associated
with hematopoietic receptors. Within another embodiment, the
isolated polypeptide disclosed above comprises an affinity tag.
[0019] Within another aspect, the present invention provides a
method of producing a zalpha11 polypeptide comprising: culturing a
cell as disclosed above; and isolating the zalpha11 polypeptide
produced by the cell.
[0020] Within another aspect, the present invention provides a
method of producing an antibody to zalpha11 polypeptide comprising:
inoculating an animal with a polypeptide selected from the group
consisting of: (a) a polypeptide consisting of 9 to 519 amino
acids, wherein the polypeptide consists of a contiguous sequence of
amino acids in SEQ ID NO:2 from amino acid number 20 (Cys), to
amino acid number 538 (Ser); (b) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys),
to amino acid number 237 (His); (c) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid number 101 (Leu)
to amino acid number 122 (Gly); (d) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid number 141 (Asn)
to amino acid number 174 (Ala); (e) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid number 193 (Cys)
to amino acid number 261 (Val); (f) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid number 51 (Trp)
to amino acid number 61 (Glu); (g) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid 136 (Ile) to
amino acid number 143 (Glu); (h) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid 187 (Pro) to
amino acid number 195 (Ser); (i) a polypeptide consisting of the
amino acid sequence of SEQ ID NO:2 from amino acid number 223 (Phe)
to amino acid number 232 (Glu); and (j) a polypeptide consisting of
the amino acid sequence of SEQ ID NO:2 from amino acid number 360
(Glu) to amino acid number 368 (Asp); and wherein the polypeptide
elicits an immune response in the animal to produce the antibody;
and isolating the antibody from the animal.
[0021] Within another aspect, the present invention provides an
antibody produced by the method disclosed above, which specifically
binds to a zalpha11 polypeptide. Within one embodiment, the
antibody disclosed above is a monoclonal antibody.
[0022] Within another aspect, the present invention provides an
antibody which specifically binds to a polypeptide as disclosed
above.
[0023] Within another aspect, the present invention provides a
method of detecting, in a test sample, the presence of a modulator
of zalpha11 protein activity, comprising: culturing a cell into
which has been introduced an expression vector as disclosed above,
wherein the cell expresses the zalpha11 protein encoded by the DNA
segment in the presence and absence of a test sample; and comparing
levels of activity of zalpha11 in the presence and absence of a
test sample, by a biological or biochemical assay; and determining
from the comparison, the presence of modulator of zalpha11 activity
in the test sample.
[0024] Within another aspect, the present invention provides a
method for detecting a zalpha11 receptor ligand within a test
sample, comprising: contacting a test sample with a polypeptide
comprising an amino acid sequence as shown in SEQ ID NO:2 from
amino acid number 20 (Cys), to amino acid number 237 (His); and
detecting the binding of the polypeptide to a ligand in the sample.
Within one embodiment, the method disclosed above further comprises
a polypeptide comprising transmembrane and intracellular domains.
Within another embodiment, the method disclosed above further
comprises a polypeptide wherein the polypeptide is membrane bound
within a cultured cell, and the detecting step comprises measuring
a biological response in the cultured cell. Within another
embodiment, the method disclosed above further comprises a
polypeptide wherein the polypeptide is membrane bound within a
cultured cell, and the detecting step comprises measuring a
biological response in the cultured cell, wherein the biological
response is cell proliferation or activation of transcription of a
reporter gene. Within another embodiment, the method disclosed
above further comprises a polypeptide wherein the polypeptide is
immobilized on a solid support.
[0025] These and other aspects of the invention will become evident
upon reference to the following detailed description of the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] FIG. 1 is a Hopp/Woods hydrophilicity plot of human
zalpha11.
[0027] FIG. 2 is an alignment of human zalpha11 (zalpha) (SEQ ID
NO: 2) and mouse zalpha11 (muzalp) (SEQ ID NO: 85).
DETAILED DESCRIPTION OF THE INVENTION
[0028] Prior to setting forth the invention in detail, it may be
helpful to the understanding thereof to define the following
terms:
[0029] The term "affinity tag" is used herein to denote a
polypeptide segment that can be attached to a second polypeptide to
provide for purification or detection of the second polypeptide or
provide sites for attachment of the second polypeptide to a
substrate. In principal, any peptide or protein for which an
antibody or other specific binding agent is available can be used
as an affinity tag. Affinity tags include a poly-histidine tract,
protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al.,
Methods Enzmol. 198:3, 1991), glutathione S transferase (Smith and
Johnson, Gene 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et
al., Proc. Natl. Acad. Sci. USA 82:7952-4, 1985), substance P,
Flag.TM. peptide (Hopp et al., Biotechnology 6:1204-10, 1988),
streptavidin binding peptide, or other antigenic epitope or binding
domain. See, in general, Ford et al., Protein Expression and
Purification 2: 95-107, 1991. DNAs encoding affinity tags are
available from commercial suppliers (e.g., Pharmacia Biotech,
Piscataway, N.J.).
[0030] The term "allelic variant" is used herein to denote any of
two or more alternative forms of a gene occupying the same
chromosomal locus. Allelic variation arises naturally through
mutation, and may result in phenotypic polymorphism within
populations. Gene mutations can be silent (no change in the encoded
polypeptide) or may encode polypeptides having altered amino acid
sequence. The term allelic variant is also used herein to denote a
protein encoded by an allelic variant of a gene.
[0031] The terms "amino-terminal" and "carboxyl-terminal" are used
herein to denote positions within polypeptides. Where the context
allows, these terms are used with reference to a particular
sequence or portion of a polypeptide to denote proximity or
relative position. For example, a certain sequence positioned
carboxyl-terminal to a reference sequence within a polypeptide is
located proximal to the carboxyl terminus of the reference
sequence, but is not necessarily at the carboxyl terminus of the
complete polypeptide.
[0032] The term "complement/anti-complement pair" denotes
non-identical moieties that form a non-covalently associated,
stable pair under appropriate conditions. For instance, biotin and
avidin (or streptavidin) are prototypical members of a
complement/anti-complement pair. Other exemplary
complement/anti-complement pairs include receptor/ligand pairs,
antibody/antigen (or hapten or epitope) pairs, sense/antisense
polynucleotide pairs, and the like. Where subsequent dissociation
of the complement/anti-complement pair is desirable, the
complement/anti-complement pair preferably has a binding affinity
of <10.sup.9 M.sup.-1.
[0033] The term "complements of a polynucleotide molecule" is a
polynucleotide molecule having a complementary base sequence and
reverse orientation as compared to a reference sequence. For
example, the sequence 5' ATGCACGGG 3' is complementary to 5'
CCCGTGCAT 3'.
[0034] The term "contig" denotes a polynucleotide that has a
contiguous stretch of identical or complementary sequence to
another polynucleotide. Contiguous sequences are said to "overlap"
a given stretch of polynucleotide sequence either in their entirety
or along a partial stretch of the polynucleotide. For example,
representative contigs to the polynucleotide sequence
5'-ATGGCTTAGCTT-3' are 5'-TAGCTTgagtct-3' and
3'-gtcgacTACCGA-5'.
[0035] The term "degenerate nucleotide sequence" denotes a sequence
of nucleotides that includes one or more degenerate codons (as
compared to a reference polynucleotide molecule that encodes a
polypeptide). Degenerate codons contain different triplets of
nucleotides, but encode the same amino acid residue (i.e., GAU and
GAC triplets each encode Asp).
[0036] The term "expression vector" is used to denote a DNA
molecule, linear or circular, that comprises a segment encoding a
polypeptide of interest operably linked to additional segments that
provide for its transcription. Such additional segments include
promoter and terminator sequences, and may also include one or more
origins of replication, one or more selectable markers, an
enhancer, a polyadenylation signal, etc. Expression vectors are
generally derived from plasmid or viral DNA, or may contain
elements of both.
[0037] The term "isolated", when applied to a polynucleotide,
denotes that the polynucleotide has been removed from its natural
genetic milieu and is thus free of other extraneous or unwanted
coding sequences, and is in a form suitable for use within
genetically engineered protein production systems. Such isolated
molecules are those that are separated from their natural
environment and include cDNA and genomic clones. Isolated DNA
molecules of the present invention are free of other genes with
which they are ordinarily associated, but may include naturally
occurring 5' and 3' untranslated regions such as promoters and
terminators. The identification of associated regions will be
evident to one of ordinary skill in the art (see for example, Dynan
and Tijan, Nature 316:774-78, 1985).
[0038] An "isolated" polypeptide or protein is a polypeptide or
protein that is found in a condition other than its native
environment, such as apart from blood and animal tissue. In a
preferred form, the isolated polypeptide is substantially free of
other polypeptides, particularly other polypeptides of animal
origin. It is preferred to provide the polypeptides in a highly
purified form, i.e. greater than 95% pure, more preferably greater
than 99% pure. When used in this context, the term "isolated" does
not exclude the presence of the same polypeptide in alternative
physical forms, such as dimers or alternatively glycosylated or
derivatized forms.
[0039] The term "operably linked", when referring to DNA segments,
indicates that the segments are arranged so that they function in
concert for their intended purposes, e.g., transcription initiates
in the promoter and proceeds through the coding segment to the
terminator.
[0040] The term "ortholog" denotes a polypeptide or protein
obtained from one species that is the functional counterpart of a
polypeptide or protein from a different species. Sequence
differences among orthologs are the result of speciation.
[0041] "Paralogs" are distinct but structurally related proteins
made by an organism. Paralogs are believed to arise through gene
duplication. For example, .alpha.-globin, .beta.-globin, and
myoglobin are paralogs of each other.
[0042] A "polynucleotide" is a single- or double-stranded polymer
of deoxyribonucleotide or ribonucleotide bases read from the 5' to
the 3' end. Polynucleotides include RNA and DNA, and may be
isolated from natural sources, synthesized in vitro, or prepared
from a combination of natural and synthetic molecules. Sizes of
polynucleotides are expressed as base pairs (abbreviated "bp"),
nucleotides ("nt"), or kilobases ("kb"). Where the context allows,
the latter two terms may describe polynucleotides that are
single-stranded or double-stranded. When the term is applied to
double-stranded molecules it is used to denote overall length and
will be understood to be equivalent to the term "base pairs". It
will be recognized by those skilled in the art that the two strands
of a double-stranded polynucleotide may differ slightly in length
and that the ends thereof may be staggered as a result of enzymatic
cleavage; thus all nucleotides within a double-stranded
polynucleotide molecule may not be paired.
[0043] A "polypeptide" is a polymer of amino acid residues joined
by peptide bonds, whether produced naturally or synthetically.
Polypeptides of less than about 10 amino acid residues are commonly
referred to as "peptides".
[0044] The term "promoter" is used herein for its art-recognized
meaning to denote a portion of a gene containing DNA sequences that
provide for the binding of RNA polymerase and initiation of
transcription. Promoter sequences are commonly, but not always,
found in the 5' non-coding regions of genes.
[0045] A "protein" is a macromolecule comprising one or more
polypeptide chains. A protein may also comprise non-peptidic
components, such as carbohydrate groups. Carbohydrates and other
non-peptidic substituents may be added to a protein by the cell in
which the protein is produced, and will vary with the type of cell.
Proteins are defined herein in terms of their amino acid backbone
structures; substituents such as carbohydrate groups are generally
not specified, but may be present nonetheless.
[0046] The term "receptor" is used herein to denote a
cell-associated protein, or a polypeptide subunit of such a
protein, that binds to a bioactive molecule (the "ligand") and
mediates the effect of the ligand on the cell. Binding of ligand to
receptor results in a conformational change in the receptor (and,
in some cases, receptor multimerization, i.e., association of
identical or different receptor subunits) that causes interactions
between the effector domain(s) and other molecule(s) in the cell.
These interactions in turn lead to alterations in the metabolism of
the cell. Metabolic events that are linked to receptor-ligand
interactions include gene transcription, phosphorylation,
dephosphorylation, cell proliferation, increases in cyclic AMP
production, mobilization of cellular calcium, mobilization of
membrane lipids, cell adhesion, hydrolysis of inositol lipids and
hydrolysis of phospholipids. Cell-surface cytokine receptors are
characterized by a multi-domain structure as discussed in more
detail below. These receptors are anchored in the cell membrane by
a transmembrane domain characterized by a sequence of hydrophobic
amino acid residues (typically about 21-25 residues), which is
commonly flanked by positively charged residues (Lys or Arg). In
general, receptors can be membrane bound, cytosolic or nuclear;
monomeric (e.g., thyroid stimulating hormone receptor,
beta-adrenergic receptor) or multimeric (e.g., PDGF receptor,
growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF
receptor, erythropoietin receptor and IL-6 receptor). The term
"receptor polypeptide" is used to denote complete receptor
polypeptide chains and portions thereof, including isolated
functional domains (e.g., ligand-binding domains).
[0047] A "secretory signal sequence" is a DNA sequence that encodes
a polypeptide (a "secretory peptide") that, as a component of a
larger polypeptide, directs the larger polypeptide through a
secretory pathway of a cell in which it is synthesized. The larger
peptide is commonly cleaved to remove the secretory peptide during
transit through the secretory pathway.
[0048] A "soluble receptor" is a receptor polypeptide that is not
bound to a cell membrane. Soluble receptors are most commonly
ligand-binding receptor polypeptides that lack transmembrane and
cytoplasmic domains. Soluble receptors can comprise additional
amino acid residues, such as affinity tags that provide for
purification of the polypeptide or provide sites for attachment of
the polypeptide to a substrate, or immunoglobulin constant region
sequences. Many cell-surface receptors have naturally occurring,
soluble counterparts that are produced by proteolysis. Soluble
receptor polypeptides are said to be substantially free of
transmembrane and intracellular polypeptide segments when they lack
sufficient portions of these segments to provide membrane anchoring
or signal transduction, respectively.
[0049] The term "splice variant" is used herein to denote
alternative forms of RNA transcribed from a gene. Splice variation
arises naturally through use of alternative splicing sites within a
transcribed RNA molecule, or less commonly between separately
transcribed RNA molecules, and may result in several mRNAs
transcribed from the same gene. Splice variants may encode
polypeptides having altered amino acid sequence. The term splice
variant is also used herein to denote a protein encoded by a splice
variant of an mRNA transcribed from a gene.
[0050] Molecular weights and lengths of polymers determined by
imprecise analytical methods (e.g., gel electrophoresis) will be
understood to be approximate values. When such a value is expressed
as "about" X or "approximately" X, the stated value of X will be
understood to be accurate to .+-.10%.
[0051] All references cited herein are incorporated by reference in
their entirety.
[0052] The present invention is based in part upon the discovery of
a novel DNA sequence that encodes a protein having the structure of
a class I cytokine receptor. The deduced amino acid sequence
indicated that the encoded receptor belongs to the receptor
subfamily that includes the IL-2 receptor .beta.-subunit and the
.beta.-common receptor (i.e., IL3, IL-5, and GM-CSF receptor
.beta.-subunits). Analysis of the tissue distribution of the mRNA
corresponding to this novel DNA showed expression in lymph node,
peripheral blood leukocytes (PBLs), spleen, and thymus. Moreover,
the mRNA was abundant in the Raji cell line (ATCC No. CCL-86)
derived from a Burkitt's lymphoma. The polypeptide has been
designated zalpha11.
[0053] The novel zalpha11 polypeptides of the present invention
were initially identified by querying an EST database. An EST was
found and its corresponding cDNA was sequenced. The novel
polypeptide encoded by the cDNA showed homology with class I
cytokine receptors. The zalpha11 polynucleotide sequence encodes
the entire coding sequence of the predicted protein. Zalpha11 is a
novel cytokine receptor that may be involved in an apoptotic
cellular pathway, cell-cell signaling molecule, growth factor
receptor, or extracellular matrix associated protein with growth
factor hormone activity, or the like.
[0054] The sequence of the zalpha11 polypeptide was deduced from a
single clone that contained its corresponding polynucleotide
sequence. The clone was obtained from a spinal cord library. Other
libraries that might also be searched for such sequences include
PBL, thymus, spleen, lymph node, human erythroleukemia cell lines
(e.g., TF-1), Raji cells, acute monocytic leukemia cell lines,
other lymphoid and hematopoietic cell lines, and the like.
[0055] The nucleotide sequence of a representative
zalpha11-encoding DNA is described in SEQ ID NO:1 (from nucleotide
69 to 1682), and its deduced 538 amino acid sequence is described
in SEQ ID NO:2. In its entirety, the zalpha11 polypeptide (SEQ ID
NO:2) represents a full-length polypeptide segment (residue 1 (Met)
to residue 538 (Ser) of SEQ ID NO:2). The domains and structural
features of the zalpha11 polypeptide are further described
below.
[0056] Analysis of the zalpha11 polypeptide encoded by the DNA
sequence of SEQ ID NO:1 revealed an open reading frame encoding 538
amino acids (SEQ ID NO:2) comprising a predicted secretory signal
peptide of 19 amino acid residues (residue 1 (Met) to residue 19
(Gly) of SEQ ID NO:2), and a mature polypeptide of 519 amino acids
(residue 20 (Cys) to residue 538 (Ser) of SEQ ID NO:2). In addition
to the WSXWS motif (SEQ ID NO:3) corresponding to residues 214 to
218 of SEQ ID NO:2, the receptor comprises a cytokine-binding
domain of approximately 200 amino acid residues (residues 20 (Cys)
to 237 (His) of SEQ ID NO:2); a domain linker (residues 120 (Pro)
to 123 (Pro) of SEQ ID NO:2); a penultimate strand region (residues
192 (Lys) to 202 (Ala) of SEQ ID NO:2); a transmembrane domain
(residues 238 (Leu) to 255 (Leu) of SEQ ID NO:2); complete
intracellular signaling domain (residues 256 (Lys) to 538 (Ser) of
SEQ ID NO:2) which contains a "Box I" signaling site (residues 267
(Ile) to 273 (Pro) of SEQ ID NO:2), and a "Box II" signaling site
(residues 301 (Leu) to 304 (Gly) of SEQ ID NO:2). Those skilled in
the art will recognize that these domain boundaries are
approximate, and are based on alignments with known proteins and
predictions of protein folding. In addition to these domains,
conserved receptor features in the encoded receptor include (as
shown in SEQ ID NO:2) a conserved Trp residue at position 138, and
a conserved Arg residue at position 201. Moreover the zalpha11
receptor contains conserved Cys residues typical of class I
cytokine receptors, shown in residues 25, 35, 65, and 81 of SEQ ID
NO:2. The corresponding polynucleotides encoding the zalpha11
polypeptide regions, domains, motifs, residues and sequences
described above are as shown in SEQ ID NO:1.
[0057] The presence of transmembrane regions, and conserved and low
variance motifs generally correlates with or defines important
structural regions in proteins. Regions of low variance (e.g.,
hydrophobic clusters) are generally present in regions of
structural importance (Sheppard, P. et al., supra.). Such regions
of low variance often contain rare or infrequent amino acids, such
as Tryptophan. The regions flanking and between such conserved and
low variance motifs may be more variable, but are often
functionally significant because they may relate to or define
important structures and activities such as binding domains,
biological and enzymatic activity, signal transduction, cell-cell
interaction, tissue localization domains and the like.
[0058] The regions of conserved amino acid residues in zalpha11,
described above, can be used as tools to identify new family
members. For instance, reverse transcription-polymerase chain
reaction (RT-PCR) can be used to amplify sequences encoding the
conserved regions from RNA obtained from a variety of tissue
sources or cell lines. In particular, highly degenerate primers
designed from the zalpha11 sequences are useful for this purpose.
Designing and using such degenerate primers may be readily
performed by one of skill in the art.
[0059] The present invention provides polynucleotide molecules,
including DNA and RNA molecules, that encode the zalpha11
polypeptides disclosed herein. Those skilled in the art will
recognize that, in view of the degeneracy of the genetic code,
considerable sequence variation is possible among these
polynucleotide molecules. SEQ ID NO:4 is a degenerate DNA sequence
that encompasses all DNAs that encode the zalpha11 polypeptide of
SEQ ID NO:2. Those skilled in the art will recognize that the
degenerate sequence of SEQ ID NO:4 also provides all RNA sequences
encoding SEQ ID NO:2 by substituting U for T. Thus, zalpha11
polypeptide-encoding polynucleotides comprising nucleotide 1 to
nucleotide 1614 of SEQ ID NO:4 and their RNA equivalents are
contemplated by the present invention. Table 1 sets forth the
one-letter codes used within SEQ ID NO:4 to denote degenerate
nucleotide positions. "Resolutions" are the nucleotides denoted by
a code letter. "Complement" indicates the code for the
complementary nucleotide(s). For example, the code Y denotes either
C or T, and its complement R denotes A or G, A being complementary
to T, and G being complementary to C. TABLE-US-00001 TABLE 1
Nucleotide Resolution Complement Resolution A A T T C C G G G G C C
T T A A R A|G Y C|T Y C|T R A|G M A|C K G|T K G|T M A|C S C|G S C|G
W A|T W A|T H A|C|T D A|G|T B C|G|T V A|C|G V A|C|G B C|G|T D A|G|T
H A|C|T N A|C|G|T N A|C|G|T
[0060] The degenerate codons used in SEQ ID NO:4, encompassing all
possible codons for a given amino acid, are set forth in Table 2.
TABLE-US-00002 TABLE 2 One Amino Letter Degenerate Acid Code Codons
Codon Cys C TGC TGT TGY Ser S AGC AGT TCA TCC TCG TCT WSN Thr T ACA
ACC ACG ACT ACN Pro P CCA CCC CCG CCT CCN Ala A GCA GCC GCG GCT GCN
Gly G GGA GGC GGG GGT GGN Asn N AAC AAT AAY Asp D GAC GAT GAY Glu E
GAA GAG GAR Gln Q CAA CAG CAR His H CAC CAT CAY Arg R AGA AGG CGA
CGC CGG CGT MGN Lys K AAA AAG AAR Met M ATG ATG Ile I ATA ATC ATT
ATH Leu L CTA CTC CTG CTT TTA TTG YTN Val V GTA GTC GTG GTT GTN Phe
F TTC TTT TTY Tyr Y TAC TAT TAY Trp W TGG TGG Ter .cndot. TAA TAG
TGA TRR Asn|Asp B RAY Glu|Gln Z SAR Any X NNN
[0061] One of ordinary skill in the art will appreciate that some
ambiguity is introduced in determining a degenerate codon,
representative of all possible codons encoding each amino acid. For
example, the degenerate codon for serine (WSN) can, in some
circumstances, encode arginine (AGR), and the degenerate codon for
arginine (MGN) can, in some circumstances, encode serine (AGY). A
similar relationship exists between codons encoding phenylalanine
and leucine. Thus, some polynucleotides encompassed by the
degenerate sequence may encode variant amino acid sequences, but
one of ordinary skill in the art can easily identify such variant
sequences by reference to the amino acid sequence of SEQ ID NO:2.
Variant sequences can be readily tested for functionality as
described herein.
[0062] One of ordinary skill in the art will also appreciate that
different species can exhibit "preferential codon usage." In
general, see, Grantham, et al., Nuc. Acids Res. 8:1893-912, 1980;
Haas, et al. Curr. Biol. 6:315-24, 1996; Wain-Hobson, et al., Gene
13:355-64, 1981; Grosjean and Fiers, Gene 18:199-209, 1982; Holm,
Nuc. Acids Res. 14:3075-87, 1986; Ikemura, J. Mol. Biol.
158:573-97, 1982. As used herein, the term "preferential codon
usage" or "preferential codons" is a term of art referring to
protein translation codons that are most frequently used in cells
of a certain species, thus favoring one or a few representatives of
the possible codons encoding each amino acid (See Table 2). For
example, the amino acid Threonine (Thr) may be encoded by ACA, ACC,
ACG, or ACT, but in mammalian cells ACC is the most commonly used
codon; in other species, for example, insect cells, yeast, viruses
or bacteria, different Thr codons may be preferential. Preferential
codons for a particular species can be introduced into the
polynucleotides of the present invention by a variety of methods
known in the art. Introduction of preferential codon sequences into
recombinant DNA can, for example, enhance production of the protein
by making protein translation more efficient within a particular
cell type or species. Therefore, the degenerate codon sequence
disclosed in SEQ ID NO:4 serves as a template for optimizing
expression of polynucleotides in various cell types and species
commonly used in the art and disclosed herein. Sequences containing
preferential codons can be tested and optimized for expression in
various species, and tested for functionality as disclosed
herein.
[0063] Within preferred embodiments of the invention the isolated
polynucleotides will hybridize to similar sized regions of SEQ ID
NO:1, or a sequence complementary thereto, under stringent
conditions. In general, stringent conditions are selected to be
about 5.degree. C. lower than the thermal melting point (T.sub.m)
for the specific sequence at a defined ionic strength and pH. The
T.sub.m is the temperature (under defined ionic strength and pH) at
which 50% of the target sequence hybridizes to a perfectly matched
probe. Numerous equations for calculating T.sub.m are known in the
art, and are specific for DNA, RNA and DNA-RNA hybrids and
polynucleotide probe sequences of varying length (see, for example,
Sambrook et al, Molecular Cloning: A Laboratory Manual, Second
Edition (Cold Spring Harbor Press 1989); Ausubel et al., (eds.),
Current Protocols in Molecular Biology (John Wiley and Sons, Inc.
1987); Berger and Kimmel (eds.), Guide to Molecular Cloning
Techniques (Academic Press, Inc. 1987); and Wetmur, Crit. Rev.
Biochem. Mol. Biol. 26:227 (1990)). Sequence analysis software such
as OLIGO 6.0 (LSR; Long Lake, Minn.) and Primer Premier 4.0
(Premier Biosoft International; Palo Alto, Calif.), as well as
sites on the Internet, are available tools for analyzing a given
sequence and calculating T.sub.m based on user defined criteria.
Such programs can also analyze a given sequence under defined
conditions and identify suitable probe sequences. Typically,
hybridization of longer polynucleotide sequences (e.g., >50 base
pairs) is performed at temperatures of about 20-25.degree. C. below
the calculated T.sub.m. For smaller probes (e.g., <50 base
pairs) hybridization is typically carried out at the T.sub.m or
5-10.degree. C. below. This allows for the maximum rate of
hybridization for DNA-DNA and DNA-RNA hybrids. Higher degrees of
stringency at lower temperatures can be achieved with the addition
of formamide which reduces the T.sub.m of the hybrid about
1.degree. C. for each 1% formamide in the buffer solution. Suitable
stringent hybridization conditions are equivalent to about a 5 h to
overnight incubation at about 42.degree. C. in a solution
comprising: about 40-50% formamide, up to about 6.times.SSC, about
5.times. Denhardt's solution, zero up to about 10% dextran sulfate,
and about 10-20 .mu.g/ml denatured commercially-available carrier
DNA. Generally, such stringent conditions include temperatures of
20-70.degree. C. and a hybridization buffer containing up to
6.times.SSC and 0-50% formamide; hybridization is then followed by
washing filters in up to about 2.times.SSC. For example, a suitable
wash stringency is equivalent to 0.1.times.SSC to 2.times.SSC, 0.1%
SDS, at 55.degree. C. to 65.degree. C. Different degrees of
stringency can be used during hybridization and washing to achieve
maximum specific binding to the target sequence. Typically, the
washes following hybridization are performed at increasing degrees
of stringency to remove non-hybridized polynucleotide probes from
hybridized complexes. Stringent hybridization and wash conditions
depend on the length of the probe, reflected in the Tm,
hybridization and wash solutions used, and are routinely determined
empirically by one of skill in the art.
[0064] As previously noted, the isolated polynucleotides of the
present invention include DNA and RNA. Methods for preparing DNA
and RNA are well known in the art. In general, RNA is isolated from
a tissue or cell that produces large amounts of zalpha11 RNA. Such
tissues and cells are identified by Northern blotting (Thomas,
Proc. Natl. Acad. Sci. USA 77:5201, 1980), and include PBLs,
spleen, thymus, and lymph tissues, Raji cells, human
erythroleukemia cell lines (e.g., TF-1), acute monocytic leukemia
cell lines, other lymphoid and hematopoietic cell lines, and the
like. Total RNA can be prepared using guanidinium isothiocyanate
extraction followed by isolation by centrifugation in a CsCl
gradient (Chirgwin et al., Biochemistry 18:52-94, 1979). Poly
(A).sup.+ RNA is prepared from total RNA using the method of Aviv
and Leder (Proc. Natl. Acad. Sci. USA 69:1408-12, 1972).
Complementary DNA (cDNA) is prepared from poly(A).sup.+ RNA using
known methods. In the alternative, genomic DNA can be isolated.
Polynucleotides encoding zalpha11 polypeptides are then identified
and isolated by, for example, hybridization or polymerase chain
reaction (PCR) (Mullis, U.S. Pat. No. 4,683,202).
[0065] A full-length clone encoding zalpha11 can be obtained by
conventional cloning procedures. Complementary DNA (cDNA) clones
are preferred, although for some applications (e.g., expression in
transgenic animals) it may be preferable to use a genomic clone, or
to modify a cDNA clone to include at least one genomic intron.
Methods for preparing cDNA and genomic clones are well known and
within the level of ordinary skill in the art, and include the use
of the sequence disclosed herein, or parts thereof, for probing or
priming a library. Expression libraries can be probed with
antibodies to zalpha11, receptor fragments, or other specific
binding partners.
[0066] The polynucleotides of the present invention can also be
synthesized using DNA synthesis machines. Currently the method of
choice is the phosphoramidite method. If chemically synthesized
double stranded DNA is required for an application such as the
synthesis of a gene or a gene fragment, then each complementary
strand is made separately. The production of short polynucleotides
(60 to 80 bp) is technically straightforward and can be
accomplished by synthesizing the complementary strands and then
annealing them. However, for producing longer polynucleotides
(>300 bp), special strategies are usually employed, because the
coupling efficiency of each cycle during chemical DNA synthesis is
seldom 100%. To overcome this problem, synthetic genes
(double-stranded) are assembled in modular form from
single-stranded fragments that are from 20 to 100 nucleotides in
length.
[0067] One method for building a synthetic gene requires the
initial production of a set of overlapping, complementary
oligonucleotides, each of which is between 20 to 60 nucleotides
long. Each internal section of the gene has complementary 3' and 5'
terminal extensions designed to base pair precisely with an
adjacent section. Thus, after the gene is assembled, process is
completed by sealing the nicks along the backbones of the two
strands with T4 DNA ligase. In addition to the protein coding
sequence, synthetic genes can be designed with terminal sequences
that facilitate insertion into a restriction endonuclease site of a
cloning vector. Moreover, other sequences should can be added that
contain signals for proper initiation and termination of
transcription and translation.
[0068] An alternative way to prepare a full-length gene is to
synthesize a specified set of overlapping oligonucleotides (40 to
100 nucleotides). After the 3' and 5' short overlapping
complementary regions (6 to 10 nucleotides) are annealed, large
gaps still remain, but the short base-paired regions are both long
enough and stable enough to hold the structure together. The gaps
are filled and the DNA duplex is completed via enzymatic DNA
synthesis by E. coli DNA polymerase I. After the enzymatic
synthesis is completed, the nicks are sealed with T4 DNA ligase.
Double-stranded constructs are sequentially linked to one another
to form the entire gene sequence which is verified by DNA sequence
analysis. See Glick and Pasternak, Molecular Biotechnology,
Principles & Applications of Recombinant DNA, (ASM Press,
Washington, D.C. 1994); Itakura et al., Annu. Rev. Biochem. 53:
323-56, 1984 and Climie et al., Proc. Natl. Acad. Sci. USA
87:633-7, 1990.
[0069] The present invention further provides counterpart
polypeptides and polynucleotides from other species (orthologs).
These species include, but are not limited to mammalian, avian,
amphibian, reptile, fish, insect and other vertebrate and
invertebrate species. Of particular interest are zalpha11
polypeptides from other mammalian species, including murine,
porcine, ovine, bovine, canine, feline, equine, and other primate
polypeptides. Orthologs of human zalpha11 can be cloned using
information and compositions provided by the present invention in
combination with conventional cloning techniques. For example, a
cDNA can be cloned using mRNA obtained from a tissue or cell type
that expresses zalpha11 as disclosed herein. Suitable sources of
mRNA can be identified by probing Northern blots with probes
designed from the sequences disclosed herein. A library is then
prepared from mRNA of a positive tissue or cell line. A
zalpha11-encoding cDNA can then be isolated by a variety of
methods, such as by probing with a complete or partial human cDNA
or with one or more sets of degenerate probes based on the
disclosed sequences. A cDNA can also be cloned using PCR (Mullis,
supra.), using primers designed from the representative human
zalpha11 sequence disclosed herein. Within an additional method,
the cDNA library can be used to transform or transfect host cells,
and expression of the cDNA of interest can be detected with an
antibody to zalpha11 polypeptide. Similar techniques can also be
applied to the isolation of genomic clones.
[0070] Cytokine receptor subunits are characterized by a
multi-domain structure comprising an extracellular domain, a
transmembrane domain that anchors the polypeptide in the cell
membrane, and an intracellular domain. The extracellular domain may
be a ligand-binding domain, and the intracellular domain may be an
effector domain involved in signal transduction, although
ligand-binding and effector functions may reside on separate
subunits of a multimeric receptor. The ligand-binding domain may
itself be a multi-domain structure. Multimeric receptors include
homodimers (e.g., PDGF receptor .alpha..alpha. and .beta..beta.
isoforms, erythropoietin receptor, MPL, and G-CSF receptor),
heterodimers whose subunits each have ligand-binding and effector
domains (e.g., PDGF receptor .alpha..beta. isoform), and multimers
having component subunits with disparate functions (e.g., IL-2,
IL-3, IL-4, IL-5, IL-6, IL-7, and GM-CSF receptors). Some receptor
subunits are common to a plurality of receptors. For example, the
AIC2B subunit, which cannot bind ligand on its own but includes an
intracellular signal transduction domain, is a component of IL-3
and GM-CSF receptors. Many cytokine receptors can be placed into
one of four related families on the basis of the structure and
function. Hematopoietic receptors, for example, are characterized
by the presence of a domain containing conserved cysteine residues
and the WSXWS motif (SEQ ID NO:3). Cytokine receptor structure has
been reviewed by Urdal, Ann. Reports Med. Chem. 26:221-228, 1991
and Cosman, Cytokine 5:95-106, 1993. Under selective pressure for
organisms to acquire new biological functions, new receptor family
members likely arise from duplication of existing receptor genes
leading to the existence of multi-gene families. Family members
thus contain vestiges of the ancestral gene, and these
characteristic features can be exploited in the isolation and
identification of additional family members. Thus, the cytokine
receptor superfamily is subdivided into several families, for
example, the immunoglobulin family (including CSF-1, MGF, IL-1, and
PDGF receptors); the hematopoietin family (including IL-2 receptor
.beta.-subunit, GM-CSF receptor .alpha.-subunit, GM-CSF receptor
.beta.-subunit; and G-CSF, EPO, IL-3, IL-4, IL-5, IL-6, IL-7, and
IL-9 receptors); TNF receptor family (including TNF (p80) TNF (p60)
receptors, CD27, CD30, CD40, Fas, and NGF receptor).
[0071] Analysis of the zalpha11 sequence suggests that it is a
member of the same receptor subfamily as the IL-2 receptor
.beta.-subunit, IL-3, IL-4, and IL-6 receptors. Certain receptors
in this subfamily (e.g., G-CSF) associate to form homodimers that
transduce a signal. Other members of the subfamily (e.g., IL-6,
IL-11, and LIF receptors) combine with a second subunit (termed a
.beta.-subunit) to bind ligand and transduce a signal. Specific
.beta.-subunits associate with a plurality of specific cytokine
receptor subunits. For example, the .beta.-subunit gp130 (Hibi et
al., Cell 63:1149-1157, 1990) associates with receptor subunits
specific for IL-6, IL-11, and LIF (Gearing et al., EMBO J.
10:2839-2848, 1991; Gearing et al., U.S. Pat. No. 5,284,755).
Oncostatin M binds to a heterodimer of LIF receptor and gp130. CNTF
binds to trimeric receptors comprising CNTF receptor, LIF receptor,
and gp 130 subunits.
[0072] A polynucleotide sequence for the mouse ortholog of human
zalpha11 has been identified and is shown in SEQ ID NO:84 and the
corresponding amino acid sequence shown in SEQ ID NO: 85. Analysis
of the mouse zalpha11 polypeptide encoded by the DNA sequence of
SEQ ID NO:84 revealed an open reading frame encoding 529 amino
acids (SEQ ID NO:85) comprising a predicted secretory signal
peptide of 19 amino acid residues (residue 1 (Met) to residue 19
(Ser) of SEQ ID NO:85), and a mature polypeptide of 510 amino acids
(residue 20 (Cys) to residue 529 (Ser) of SEQ ID NO:2). In addition
to the WSXWS motif (SEQ ID NO:3) corresponding to residues 214 to
218 of SEQ ID NO:85, the receptor comprises a cytokine-binding
domain of approximately 200 amino acid residues (residues 20 (Cys)
to 237 (His) of SEQ ID NO:85); a domain linker (residues 120 (Pro)
to 123 (Pro) of SEQ ID NO:85); a penultimate strand region
(residues 192 (Lys) to 202 (Ala) of SEQ ID NO:85); a transmembrane
domain (residues 238 (Met) to 254 (Leu) of SEQ ID NO:85); complete
intracellular signaling domain (residues 255 (Lys) to 529 (Ser) of
SEQ ID NO:85) which contains a "Box I" signaling site (residues 266
(Ile) to 273 (Pro) of SEQ ID NO:85), and a "Box II" signaling site
(residues 301 (Ile) to 304 (Val) of SEQ ID NO:2). A comparison of
the human and mouse amino acid sequences reveals that both the
human and orthologous polypeptides contain corresponding structural
features described above (See, FIG. 2). The mature sequence for the
mouse zalpha11 begins at Cys.sub.20 (as shown in SEQ ID NO:85),
which corresponds to Cys.sub.20 (as shown in SEQ ID NO:2) in the
human sequence. There is about 63% identity between the mouse and
human sequences over the entire amino acid sequence corresponding
to SEQ ID NO:2 and SEQ ID NO:85. There is about 69% identity a
between the mouse and human zalpha11 sequences over the
extracellular cytokine binding domain corresponding to residues 20
(Cys) to 237 (His) of SEQ ID NO:2 and residues 20 (Cys) to 237
(His) of SEQ ID NO:85. There is about 60% identity a between the
mouse and human zalpha11 sequences over the intracellular
signalling domain corresponding to residues 256 (Lys) to 538 (Ser)
of SEQ ID NO:2, and residues 255 (Lys) to 529 (Ser) of SEQ ID
NO:85. The above percent identities were determined using a FASTA
program with ktup=1, gap opening penalty=12, gap extension
penalty=2, and substitution matrix=BLOSUM62, with other parameters
set as default. The corresponding polynucleotides encoding the
mouse zalpha11 polypeptide regions, domains, motifs, residues and
sequences described above are as shown in SEQ ID NO:84.
[0073] Those skilled in the art will recognize that the sequence
disclosed in SEQ ID NO:1 represents a single allele of human
zalpha11 and that allelic variation and alternative splicing are
expected to occur. Allelic variants of this sequence can be cloned
by probing cDNA or genomic libraries from different individuals
according to standard procedures. Allelic variants of the DNA
sequence shown in SEQ ID NO:1, including those containing silent
mutations and those in which mutations result in amino acid
sequence changes, are within the scope of the present invention, as
are proteins which are allelic variants of SEQ ID NO:2. cDNAs
generated from alternatively spliced mRNAs, which retain the
properties of the zalpha11 polypeptide are included within the
scope of the present invention, as are polypeptides encoded by such
cDNAs and mRNAs. Allelic variants and splice variants of these
sequences can be cloned by probing cDNA or genomic libraries from
different individuals or tissues according to standard procedures
known in the art.
[0074] The present invention also provides isolated zalpha11
polypeptides that are substantially similar to the polypeptides of
SEQ ID NO:2 and their orthologs. The term "substantially similar"
is used herein to denote polypeptides having at least 70%, more
preferably at least 80%, sequence identity to the sequences shown
in SEQ ID NO:2 or their orthologs. Such polypeptides will more
preferably be at least 90% identical, and most preferably 95% or
more identical to SEQ ID NO:2 or its orthologs.) Percent sequence
identity is determined by conventional methods. See, for example,
Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and Henikoff
and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992.
Briefly, two amino acid sequences are aligned to optimize the
alignment scores using a gap opening penalty of 10, a gap extension
penalty of 1, and the "blosum 62" scoring matrix of Henikoff and
Henikoff (ibid.) as shown in Table 3 (amino acids are indicated by
the standard one-letter codes). The percent identity is then
calculated as: Total .times. .times. number .times. .times. of
.times. .times. identical .times. .times. matches [ length .times.
.times. of .times. .times. the .times. .times. longer .times.
.times. sequence .times. .times. plus .times. .times. the .times.
number .times. .times. of .times. .times. gaps .times. .times.
introduced .times. .times. into .times. .times. the .times. .times.
.times. longer sequence .times. .times. in .times. .times. order
.times. .times. to .times. .times. align .times. .times. the
.times. .times. two .times. .times. sequences ] .times. 100
##EQU1## TABLE-US-00003 TABLE 3 A R N D C Q E G H I L K M F P S T W
Y V A 4 R -1 5 N -2 0 6 D -2 -2 1 6 C 0 -3 -3 -3 9 Q -1 1 0 0 -3 5
E -1 0 0 2 -4 2 5 G 0 -2 0 -1 -3 -2 -2 6 H -2 0 1 -1 -3 0 0 -2 8 I
-1 -3 -3 -3 -1 -3 -3 -4 -3 4 L -1 -2 -3 -4 -1 -2 -3 -4 -3 2 4 K -1
2 0 -1 -3 1 1 -2 -1 -3 -2 5 M -1 -1 -2 -3 -1 0 -2 -3 -2 1 2 -1 5 F
-2 -3 -3 -3 -2 -3 -3 -3 -1 0 0 -3 0 6 P -1 -2 -2 -1 -3 -1 -1 -2 -2
-3 -3 -1 -2 -4 7 S 1 -1 1 0 -1 0 0 0 -1 -2 -2 0 -1 -2 -1 4 T 0 -1 0
-1 -1 -1 -1 -2 -2 -1 -1 -1 -1 -2 -1 1 5 W -3 -3 -4 -4 -2 -2 -3 -2
-2 -3 -2 -3 -1 1 -4 -3 -2 11 Y -2 -2 -2 -3 -2 -1 -2 -3 2 -1 -1 -2
-1 3 -3 -2 -2 2 7 V 0 -3 -3 -3 -1 -2 -2 -3 -3 3 1 -2 1 -1 -2 -2 0
-3 -1 4
[0075] Sequence identity of polynucleotide molecules is determined
by similar methods using a ratio as disclosed above.
[0076] Those skilled in the art appreciate that there are many
established algorithms available to align two amino acid sequences.
The "FASTA" similarity search algorithm of Pearson and Lipman is a
suitable protein alignment method for examining the level of
identity shared by an amino acid sequence disclosed herein and the
amino acid sequence of a putative variant zsig57. The FASTA
algorithm is described by Pearson and Lipman, Proc. Nat'l Acad.
Sci. USA 85:2444 (1988), and by Pearson, Meth. Enzymol. 183:63
(1990).
[0077] Briefly, FASTA first characterizes sequence similarity by
identifying regions shared by the query sequence (e.g., SEQ ID
NO:2) and a test sequence that have either the highest density of
identities (if the ktup variable is 1) or pairs of identities (if
ktup=2), without considering conservative amino acid substitutions,
insertions, or deletions. The ten regions with the highest density
of identities are then rescored by comparing the similarity of all
paired amino acids using an amino acid substitution matrix, and the
ends of the regions are "trimmed" to include only those residues
that contribute to the highest score. If there are several regions
with scores greater than the "cutoff" value (calculated by a
predetermined formula based upon the length of the sequence and the
ktup value), then the trimmed initial regions are examined to
determine whether the regions can be joined to form an approximate
alignment with gaps. Finally, the highest scoring regions of the
two amino acid sequences are aligned using a modification of the
Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol.
Biol. 48:444 (1970); Sellers, SIAM J. Appl. Math. 26:787 (1974)),
which allows for amino acid insertions and deletions. Preferred
parameters for FASTA analysis are: ktup=1, gap opening penalty=10,
gap extension penalty=1, and substitution matrix=BLOSUM62, with
other parameters set as default. These parameters can be introduced
into a FASTA program by modifying the scoring matrix file
("SMATRIX"), as explained in Appendix 2 of Pearson, Meth. Enzymol.
183:63 (1990).
[0078] FASTA can also be used to determine the sequence identity of
nucleic acid molecules using a ratio as disclosed above. For
nucleotide sequence comparisons, the ktup value can range between
one to six, preferably from three to six, most preferably three,
with other parameters set as default.
[0079] The BLOSUM62 table (Table 3) is an amino acid substitution
matrix derived from about 2,000 local multiple alignments of
protein sequence segments, representing highly conserved regions of
more than 500 groups of related proteins (Henikoff and Henikoff,
Proc. Nat'l Acad. Sci. USA 89:10915 (1992)). Accordingly, the
BLOSUM62 substitution frequencies can be used to define
conservative amino acid substitutions that may be introduced into
the amino acid sequences of the present invention. Although it is
possible to design amino acid substitutions based solely upon
chemical properties (as discussed below), the language
"conservative amino acid substitution" preferably refers to a
substitution represented by a BLOSUM62 value of greater than -1.
For example, an amino acid substitution is conservative if the
substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3.
According to this system, preferred conservative amino acid
substitutions are characterized by a BLOSUM62 value of at least 1
(e.g., 1, 2 or 3), while more preferred conservative amino acid
substitutions are characterized by a BLOSUM62 value of at least 2
(e.g., 2 or 3).
[0080] Variant zalpha11 polypeptides or substantially homologous
zalpha11 polypeptides are characterized as having one or more amino
acid substitutions, deletions or additions. These changes are
preferably of a minor nature, that is conservative amino acid
substitutions (see Table 4) and other substitutions that do not
significantly affect the folding or activity of the polypeptide;
small deletions, typically of one to about 30 amino acids; and
small amino- or carboxyl-terminal extensions, such as an
amino-terminal methionine residue, a small linker peptide of up to
about 20-25 residues, or an affinity tag. The present invention
thus includes polypeptides of from about 489 to about 568 amino
acid residues that comprise a sequence that is at least 80%,
preferably at least 90%, and more preferably 95% or more identical
to the corresponding region of SEQ ID NO:2. Polypeptides comprising
affinity tags can further comprise a proteolytic cleavage site
between the zalpha11 polypeptide and the affinity tag. Suitable
sites include thrombin cleavage sites and factor Xa cleavage sites.
TABLE-US-00004 TABLE 4 Conservative amino acid substitutions Basic:
arginine lysine histidine Acidic: glutamic acid aspartic acid
Polar: glutamine asparagine Hydrophobic: leucine isoleucine valine
Aromatic: phenylalanine tryptophan tyrosine Small: glycine alanine
serine threonine methionine
[0081] The present invention further provides a variety of other
polypeptide fusions and related multimeric proteins comprising one
or more polypeptide fusions. For example, a zalpha11 polypeptide
can be prepared as a fusion to a dimerizing protein as disclosed in
U.S. Pat. Nos. 5,155,027 and 5,567,584. Preferred dimerizing
proteins in this regard include immunoglobulin constant region
domains. Immunoglobulin-zalpha11 polypeptide fusions can be
expressed in genetically engineered cells to produce a variety of
multimeric zalpha11 analogs. Auxiliary domains can be fused to
zalpha11 polypeptides to target them to specific cells, tissues, or
macromolecules (e.g., collagen). A zalpha11 polypeptide can be
fused to two or more moieties, such as an affinity tag for
purification and a targeting domain. Polypeptide fusions can also
comprise one or more cleavage sites, particularly between domains.
See, Tuan et al., Connective Tissue Research 34:1-9, 1996.
[0082] The proteins of the present invention can also comprise
non-naturally occurring amino acid residues. Non-naturally
occurring amino acids include, without limitation,
trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline,
trans-4-hydroxyproline, N-methylglycine, allo-threonine,
methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine,
nitroglutamine, homoglutamine, pipecolic acid, thiazolidine
carboxylic acid, dehydroproline, 3- and 4-methylproline,
3,3-dimethylproline, tert-leucine, norvaline, 2-azaphenylalanine,
3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine.
Several methods are known in the art for incorporating
non-naturally occurring amino acid residues into proteins. For
example, an in vitro system can be employed wherein nonsense
mutations are suppressed using chemically aminoacylated suppressor
tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA
are known in the art. Transcription and translation of plasmids
containing nonsense mutations is carried out in a cell-free system
comprising an E. coli S30 extract and commercially available
enzymes and other reagents. Proteins are purified by
chromatography. See, for example, Robertson et al., J. Am. Chem.
Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991;
Chung et al., Science 259:806-9, 1993; and Chung et al., Proc.
Natl. Acad. Sci. USA 90:10145-9, 1993). In a second method,
translation is carried out in Xenopus oocytes by microinjection of
mutated mRNA and chemically aminoacylated suppressor tRNAs
(Turcatti et al., J. Biol. Chem. 271:19991-8, 1996). Within a third
method, E. coli cells are cultured in the absence of a natural
amino acid that is to be replaced (e.g., phenylalanine) and in the
presence of the desired non-naturally occurring amino acid(s)
(e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine,
or 4-fluorophenylalanine). The non-naturally occurring amino acid
is incorporated into the protein in place of its natural
counterpart. See, Koide et al., Biochem. 33:7470-7476, 1994.
Naturally occurring amino acid residues can be converted to
non-naturally occurring species by in vitro chemical modification.
Chemical modification can be combined with site-directed
mutagenesis to further expand the range of substitutions (Wynn and
Richards, Protein Sci. 2:395-403, 1993).
[0083] A limited number of non-conservative amino acids, amino
acids that are not encoded by the genetic code, non-naturally
occurring amino acids, and unnatural amino acids may be substituted
for zalpha11 amino acid residues.
[0084] Essential amino acids in the polypeptides of the present
invention can be identified according to procedures known in the
art, such as site-directed mutagenesis or alanine-scanning
mutagenesis (Cunningham and Wells, Science 244: 1081-5, 1989; Bass
et al., Proc. Natl. Acad. Sci. USA 88:4498-502, 1991). In the
latter technique, single alanine mutations are introduced at every
residue in the molecule, and the resultant mutant molecules are
tested for biological activity (e.g. ligand binding and signal
transduction) as disclosed below to identify amino acid residues
that are critical to the activity of the molecule. See also, Hilton
et al., J. Biol. Chem. 271:4699-4708, 1996. Sites of
ligand-receptor, protein-protein or other biological interaction
can also be determined by physical analysis of structure, as
determined by such techniques as nuclear magnetic resonance,
crystallography, electron diffraction or photoaffinity labeling, in
conjunction with mutation of putative contact site amino acids.
See, for example, de Vos et al., Science 255:306-312, 1992; Smith
et al., J. Mol. Biol. 224:899-904, 1992; Wlodaver et al., FEBS
Lett. 309:59-64, 1992. The identities of essential amino acids can
also be inferred from analysis of homologies with related
receptors.
[0085] Determination of amino acid residues that are within regions
or domains that are critical to maintaining structural integrity
can be determined. Within these regions one can determine specific
residues that will be more or less tolerant of change and maintain
the overall tertiary structure of the molecule. Methods for
analyzing sequence structure include, but are not limited to,
alignment of multiple sequences with high amino acid or nucleotide
identity and computer analysis using available software (e.g., the
Insight II.RTM. viewer and homology modeling tools; MSI, San Diego,
Calif.), secondary structure propensities, binary patterns,
complementary packing and buried polar interactions (Barton,
Current Opin. Struct. Biol. 5:372-376, 1995 and Cordes et al.,
Current Opin. Struct. Biol. 6:3-10, 1996). In general, when
designing modifications to molecules or identifying specific
fragments determination of structure will be accompanied by
evaluating activity of modified molecules.
[0086] Amino acid sequence changes are made in zalpha11
polypeptides so as to minimize disruption of higher order structure
essential to biological activity. For example, when the zalpha11
polypeptide comprises one or more helices, changes in amino acid
residues will be made so as not to disrupt the helix geometry and
other components of the molecule where changes in conformation
abate some critical function, for example, binding of the molecule
to its binding partners. The effects of amino acid sequence changes
can be predicted by, for example, computer modeling as disclosed
above or determined by analysis of crystal structure (see, e.g.,
Lapthom et al., Nat. Struct. Biol. 2:266-268, 1995). Other
techniques that are well known in the art compare folding of a
variant protein to a standard molecule (e.g., the native protein).
For example, comparison of the cysteine pattern in a variant and
standard molecules can be made. Mass spectrometry and chemical
modification using reduction and alkylation provide methods for
determining cysteine residues which are associated with disulfide
bonds or are free of such associations (Bean et al., Anal. Biochem.
201:216-226, 1992; Gray, Protein Sci. 2:1732-1748, 1993; and
Patterson et al., Anal. Chem. 66:3727-3732, 1994). It is generally
believed that if a modified molecule does not have the same
disulfide bonding pattern as the standard molecule folding would be
affected. Another well known and accepted method for measuring
folding is circular dichrosism (CD). Measuring and comparing the CD
spectra generated by a modified molecule and standard molecule is
routine (Johnson, Proteins 7:205-214, 1990). Crystallography is
another well known method for analyzing folding and structure.
Nuclear magnetic resonance (NMR), digestive peptide mapping and
epitope mapping are also known methods for analyzing folding and
structural similarities between proteins and polypeptides (Schaanan
et al., Science 257:961-964, 1992).
[0087] A Hopp/Woods hydrophilicity profile of the zalpha11 protein
sequence as shown in SEQ ID NO:2 can be generated (Hopp et al.,
Proc. Natl. Acad. Sci. 78:3824-3828, 1981; Hopp, J. Immun. Meth.
88:1-18, 1986 and Triquier et al., Protein Engineering 11:153-169,
1998). See, FIG. 1. The profile is based on a sliding six-residue
window. Buried G, S, and T residues and exposed H, Y, and W
residues were ignored. For example, in zalpha11, hydrophilic
regions include amino acid residues 55 through 60 of SEQ ID NO: 2,
amino acid residues 56 through 61 of SEQ ID NO: 2, amino acid
residues 139 through 144 of SEQ ID NO: 2, amino acid residues 227
through 232 of SEQ ID NO: 2, and amino acid residues 364 through
369 of SEQ ID NO: 2.
[0088] Those skilled in the art will recognize that hydrophilicity
or hydrophobicity will be taken into account when designing
modifications in the amino acid sequence of a zalpha11 polypeptide,
so as not to disrupt the overall structural and biological profile.
Of particular interest for replacement are hydrophobic residues
selected from the group consisting of Val, Leu and Ile or the group
consisting of Met, Gly, Ser, Ala, Tyr and Trp. For example,
residues tolerant of substitution could include such residues as
shown in SEQ ID NO: 2. However, Cysteine residues could be
relatively intolerant of substitution.
[0089] The identities of essential amino acids can also be inferred
from analysis of sequence similarity between class I cytokine
receptor family members with zalpha11. Using methods such as
"FASTA" analysis described previously, regions of high similarity
are identified within a family of proteins and used to analyze
amino acid sequence for conserved regions. An alternative approach
to identifying a variant zalpha11 polynucleotide on the basis of
structure is to determine whether a nucleic acid molecule encoding
a potential variant zalpha11 polynucleotide can hybridize to a
nucleic acid molecule having the nucleotide sequence of SEQ ID
NO:1, as discussed above.
[0090] Other methods of identifying essential amino acids in the
polypeptides of the present invention are procedures known in the
art, such as site-directed mutagenesis or alanine-scanning
mutagenesis (Cunningham and Wells, Science 244:1081 (1989), Bass et
al., Proc. Natl Acad. Sci. USA 88:4498 (1991), Coombs and Corey,
"Site-Directed Mutagenesis and Protein Engineering," in Proteins:
Analysis and Design, Angeletti (ed.), pages 259-311 (Academic
Press, Inc. 1998)). In the latter technique, single alanine
mutations are introduced at every residue in the molecule, and the
resultant mutant molecules are tested for biological activity as
disclosed below to identify amino acid residues that are critical
to the activity of the molecule. See also, Hilton et al., J. Biol.
Chem. 271:4699 (1996).
[0091] The present invention also includes functional fragments of
zalpha11 polypeptides and nucleic acid molecules encoding such
functional fragments. A "functional" zalpha11 or fragment thereof
defined herein is characterized by its proliferative or
differentiating activity, by its ability to induce or inhibit
specialized cell functions, or by its ability to bind specifically
to an anti-zalpha11 antibody or zalpha11 ligand (either soluble or
immobilized). As previously described herein, zalpha11 is
characterized by a class I cytokine receptor structure. Thus, the
present invention further provides fusion proteins encompassing:
(a) polypeptide molecules comprising an extracellular or
intracellular domain described herein; and (b) functional fragments
comprising one or more of these domains. The other polypeptide
portion of the fusion protein may be contributed by another class I
cytokine receptor, for example, IL-2 receptor .beta.-subunit and
the .beta.-common receptor (i.e., IL3, IL-5, and GM-CSF receptor
.beta.-subunits), or by a non-native and/or an unrelated secretory
signal peptide that facilitates secretion of the fusion
protein.
[0092] Routine deletion analyses of nucleic acid molecules can be
performed to obtain functional fragments of a nucleic acid molecule
that encodes a zalpha11 polypeptide. As an illustration, DNA
molecules having the nucleotide sequence of SEQ ID NO:1 or
fragments thereof, can be digested with Bal31 nuclease to obtain a
series of nested deletions. These DNA fragments are then inserted
into expression vectors in proper reading frame, and the expressed
polypeptides are isolated and tested for zalpha11 activity, or for
the ability to bind anti-zalpha11 antibodies or zalpha11 ligand.
One alternative to exonuclease digestion is to use
oligonucleotide-directed mutagenesis to introduce deletions or stop
codons to specify production of a desired zalpha11 fragment.
Alternatively, particular fragments of a zalpha11 polynucleotide
can be synthesized using the polymerase chain reaction.
[0093] Standard methods for identifying functional domains are
well-known to those of skill in the art. For example, studies on
the truncation at either or both termini of interferons have been
summarized by Horisberger and Di Marco, Pharmac. Ther. 66:507
(1995). Moreover, standard techniques for functional analysis of
proteins are described by, for example, Treuter et al., Molec. Gen.
Genet. 240:113 (1993); Content et al., "Expression and preliminary
deletion analysis of the 42 kDa 2-5A synthetase induced by human
interferon," in Biological Interferon Systems, Proceedings of
ISIR-TNO Meeting on Interferon Systems, Cantell (ed.), pages 65-72
(Nijhoff 1987); Herschman, "The EGF Receptor," in Control of Animal
Cell Proliferation 1, Boynton et al., (eds.) pages 169-199
(Academic Press 1985); Coumailleau et al., J. Biol. Chem. 270:29270
(1995); Fukunaga et al., J. Biol. Chem. 270:25291 (1995); Yamaguchi
et al., Biochem. Pharmacol. 50:1295 (1995); and Meisel et al.,
Plant Molec. Biol. 30:1 (1996).
[0094] Multiple amino acid substitutions can be made and tested
using known methods of mutagenesis and screening, such as those
disclosed by Reidhaar-Olson and Sauer (Science 241:53-57, 1988) or
Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-2156, 1989).
Briefly, these authors disclose methods for simultaneously
randomizing two or more positions in a polypeptide, selecting for
functional polypeptide, and then sequencing the mutagenized
polypeptides to determine the spectrum of allowable substitutions
at each position. Other methods that can be used include phage
display (e.g., Lowman et al., Biochem. 30:10832-10837, 1991; Ladner
et al., U.S. Pat. No. 5,223,409; Huse, WIPO Publication WO
92/062045) and region-directed mutagenesis (Derbyshire et al., Gene
46:145, 1986; Ner et al., DNA 7:127, 1988).
[0095] Variants of the disclosed zalpha11 DNA and polypeptide
sequences can be generated through DNA shuffling as disclosed by
Stemmer, Nature 370:389-91, 1994, Stemmer, Proc. Natl. Acad. Sci.
USA 91:10747-51, 1994 and WIPO Publication WO 97/20078. Briefly,
variant DNAs are generated by in vitro homologous recombination by
random fragmentation of a parent DNA followed by reassembly using
PCR, resulting in randomly introduced point mutations. This
technique can be modified by using a family of parent DNAs, such as
allelic variants or DNAs from different species, to introduce
additional variability into the process. Selection or screening for
the desired activity, followed by additional iterations of
mutagenesis and assay provides for rapid "evolution" of sequences
by selecting for desirable mutations while simultaneously selecting
against detrimental changes.
[0096] Mutagenesis methods as disclosed herein can be combined with
high-throughput, automated screening methods to detect activity of
cloned, mutagenized zalpha11 receptor polypeptides in host cells.
Preferred assays in this regard include cell proliferation assays
and biosensor-based ligand-binding assays, which are described
below. Mutagenized DNA molecules that encode active receptors or
portions thereof (e.g., ligand-binding fragments, signaling
domains, and the like) can be recovered from the host cells and
rapidly sequenced using modern equipment. These methods allow the
rapid determination of the importance of individual amino acid
residues in a polypeptide of interest, and can be applied to
polypeptides of unknown structure.
[0097] In addition, the proteins of the present invention (or
polypeptide fragments thereof) can be joined to other bioactive
molecules, particularly other cytokines, to provide
multi-functional molecules. For example, one or more helices from
zalpha11 can be joined to other cytokines to enhance their
biological properties or efficiency of production.
[0098] The present invention thus provides a series of novel,
hybrid molecules in which a segment comprising one or more of the
helices of zalpha11 is fused to another polypeptide. Fusion is
preferably done by splicing at the DNA level to allow expression of
chimeric molecules in recombinant production systems. The resultant
molecules are then assayed for such properties as improved
solubility, improved stability, prolonged clearance half-life,
improved expression and secretion levels, and pharmacodynamics.
Such hybrid molecules may further comprise additional amino acid
residues (e.g. a polypeptide linker) between the component proteins
or polypeptides.
[0099] Using the methods discussed herein, one of ordinary skill in
the art can identify and/or prepare a variety of polypeptide
fragments or variants of SEQ ID NO:2 that retain the signal
transduction or ligand binding activity. For example, one can make
a zalpha11 "soluble receptor" by preparing a variety of
polypeptides that are substantially homologous to the
cytokine-binding domain (residues 20 (Cys) to 237 (His) of SEQ ID
NO:2 or allelic variants or species orthologs thereof) and retain
ligand-binding activity of the wild-type zalpha11 protein. Such
polypeptides may include additional amino acids from, for example,
part or all of the transmembrane and intracellular domains. Such
polypeptides may also include additional polypeptide segments as
generally disclosed herein such as labels, affinity tags, and the
like.
[0100] For any zalpha11 polypeptide, including variants, soluble
receptors, and fusion polypeptides or proteins, one of ordinary
skill in the art can readily generate a fully degenerate
polynucleotide sequence encoding that variant using the information
set forth in Tables 1 and 2 above.
[0101] The zalpha11 polypeptides of the present invention,
including full-length polypeptides, biologically active fragments,
and fusion polypeptides, can be produced in genetically engineered
host cells according to conventional techniques. Suitable host
cells are those cell types that can be transformed or transfected
with exogenous DNA and grown in culture, and include bacteria,
fungal cells, and cultured higher eukaryotic cells. Eukaryotic
cells, particularly cultured cells of multicellular organisms, are
preferred. Techniques for manipulating cloned DNA molecules and
introducing exogenous DNA into a variety of host cells are
disclosed by Sambrook et al., Molecular Cloning: A Laboratory
Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, N.Y., 1989, and Ausubel et al., eds., Current Protocols in
Molecular Biology, John Wiley and Sons, Inc., NY, 1987.
[0102] In general, a DNA sequence encoding a zalpha11 polypeptide
is operably linked to other genetic elements required for its
expression, generally including a transcription promoter and
terminator, within an expression vector. The vector will also
commonly contain one or more selectable markers and one or more
origins of replication, although those skilled in the art will
recognize that within certain systems selectable markers may be
provided on separate vectors, and replication of the exogenous DNA
may be provided by integration into the host cell genome. Selection
of promoters, terminators, selectable markers, vectors and other
elements is a matter of routine design within the level of ordinary
skill in the art. Many such elements are described in the
literature and are available through commercial suppliers.
[0103] To direct a zalpha11 polypeptide into the secretory pathway
of a host cell, a secretory signal sequence (also known as a leader
sequence, prepro sequence or pre sequence) is provided in the
expression vector. The secretory signal sequence may be that of
zalpha11, or may be derived from another secreted protein (e.g.,
t-PA) or synthesized de novo. The secretory signal sequence is
operably linked to the zalpha11 DNA sequence, i.e., the two
sequences are joined in the correct reading frame and positioned to
direct the newly synthesized polypeptide into the secretory pathway
of the host cell. Secretory signal sequences are commonly
positioned 5' to the DNA sequence encoding the polypeptide of
interest, although certain secretory signal sequences may be
positioned elsewhere in the DNA sequence of interest (see, e.g.,
Welch et al., U.S. Pat. No. 5,037,743; Holland et al., U.S. Pat.
No. 5,143,830).
[0104] Alternatively, the secretory signal sequence contained in
the polypeptides of the present invention is used to direct other
polypeptides into the secretory pathway. The present invention
provides for such fusion polypeptides. A signal fusion polypeptide
can be made wherein a secretory signal sequence derived from amino
acid 1 (Met) to amino acid 19 (Gly) of SEQ ID NO:2 is operably
linked to another polypeptide using methods known in the art and
disclosed herein. The secretory signal sequence contained in the
fusion polypeptides of the present invention is preferably fused
amino-terminally to an additional peptide to direct the additional
peptide into the secretory pathway. Such constructs have numerous
applications known in the art. For example, these novel secretory
signal sequence fusion constructs can direct the secretion of an
active component of a normally non-secreted protein. Such fusions
may be used in vivo or in vitro to direct peptides through the
secretory pathway.
[0105] Cultured mammalian cells are suitable hosts within the
present invention. Methods for introducing exogenous DNA into
mammalian host cells include calcium phosphate-mediated
transfection (Wigler et al., Cell 14:725, 1978; Corsaro and
Pearson, Somatic Cell Genetics 7:603, 1981: Graham and Van der Eb,
Virology 52:456, 1973), electroporation (Neumann et al., EMBO J.
1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et
al., ibid.), and liposome-mediated transfection (Hawley-Nelson et
al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, 1993, and
viral vectors (Miller and Rosman, BioTechniques 7:980-90, 1989;
Wang and Finer, Nature Med. 2:714-716, 1996). The production of
recombinant polypeptides in cultured mammalian cells is disclosed,
for example, by Levinson et al., U.S. Pat. No. 4,713,339; Hagen et
al., U.S. Pat. No. 4,784,950; Palmiter et al., U.S. Pat. No.
4,579,821; and Ringold, U.S. Pat. No. 4,656,134. Suitable cultured
mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC
No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL
10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol.
36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No.
CCL 61) cell lines. Additional suitable cell lines are known in the
art and available from public depositories such as the American
Type Culture Collection, Rockville, Md. In general, strong
transcription promoters are preferred, such as promoters from SV-40
or cytomegalovirus. See, e.g., U.S. Pat. No. 4,956,288. Other
suitable promoters include those from metallothionein genes (U.S.
Pat. Nos. 4,579,821 and 4,601,978) and the adenovirus major late
promoter.
[0106] Drug selection is generally used to select for cultured
mammalian cells into which foreign DNA has been inserted. Such
cells are commonly referred to as "transfectants". Cells that have
been cultured in the presence of the selective agent and are able
to pass the gene of interest to their progeny are referred to as
"stable transfectants." A preferred selectable marker is a gene
encoding resistance to the antibiotic neomycin. Selection is
carried out in the presence of a neomycin-type drug, such as G-418
or the like. Selection systems can also be used to increase the
expression level of the gene of interest, a process referred to as
"amplification." Amplification is carried out by culturing
transfectants in the presence of a low level of the selective agent
and then increasing the amount of selective agent to select for
cells that produce high levels of the products of the introduced
genes. A preferred amplifiable selectable marker is dihydrofolate
reductase, which confers resistance to methotrexate. Other drug
resistance genes (e.g. hygromycin resistance, multi-drug
resistance, puromycin acetyltransferase) can also be used.
Alternative markers that introduce an altered phenotype, such as
green fluorescent protein, or cell surface proteins such as CD4,
CD8, Class I MHC, placental alkaline phosphatase may be used to
sort transfected cells from untransfected cells by such means as
FACS sorting or magnetic bead separation technology.
[0107] Other higher eukaryotic cells can also be used as hosts,
including plant cells, insect cells and avian cells. The use of
Agrobacterium rhizogenes as a vector for expressing genes in plant
cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore)
11:47-58, 1987. Transformation of insect cells and production of
foreign polypeptides therein is disclosed by Guarino et al., U.S.
Pat. No. 5,162,222 and WIPO publication WO 94/06463. Insect cells
can be infected with recombinant baculovirus, commonly derived from
Autographa californica nuclear polyhedrosis virus (AcNPV). See,
King, L. A. and Possee, R. D., The Baculovirus Expression System: A
Laboratory Guide, London, Chapman & Hall; O'Reilly, D. R. et
al., Baculovirus Expression Vectors: A Laboratory Manual, New York,
Oxford University Press., 1994; and, Richardson, C. D., Ed.,
Baculovirus Expression Protocols. Methods in Molecular Biology,
Totowa, N.J., Humana Press, 1995. A second method of making
recombinant zalpha11 baculovirus utilizes a transposon-based system
described by Luckow (Luckow, V. A, et al., J Virol 67:4566-79,
1993). This system, which utilizes transfer vectors, is sold in the
Bac-to-Bac.TM. kit (Life Technologies, Rockville, Md.). This system
utilizes a transfer vector, pFastBac1.TM. (Life Technologies)
containing a Tn7 transposon to move the DNA encoding the zalpha11
polypeptide into a baculovirus genome maintained in E. coli as a
large plasmid called a "bacmid." See, Hill-Perkins, M. S. and
Possee, R. D., J Gen Virol 71:971-6, 1990; Bonning, B. C. et al., J
Gen Virol 75:1551-6, 1994; and, Chazenbalk, G. D., and Rapoport,
B., J Biol Chem 270:1543-9, 1995. In addition, transfer vectors can
include an in-frame fusion with DNA encoding an epitope tag at the
C- or N-terminus of the expressed zalpha11 polypeptide, for
example, a Glu-Glu epitope tag (Grussenmeyer, T. et al., Proc.
Natl. Acad. Sci. 82:7952-4, 1985). Using a technique known in the
art, a transfer vector containing zalpha11 is transformed into E.
Coli, and screened for bacmids which contain an interrupted lacZ
gene indicative of recombinant baculovirus. The bacmid DNA
containing the recombinant baculovirus genome is isolated, using
common techniques, and used to transfect Spodoptera frugiperda
cells, e.g. Sf9 cells. Recombinant virus that expresses zalpha11 is
subsequently produced. Recombinant viral stocks are made by methods
commonly used in the art.
[0108] The recombinant virus is used to infect host cells,
typically a cell line derived from the fall armyworm, Spodoptera
frugiperda. See, in general, Glick and Pasternak, Molecular
Biotechnology: Principles and Applications of Recombinant DNA, ASM
Press, Washington, D.C., 1994. Another suitable cell line is the
High FiveO.TM. cell line (Invitrogen) derived from Trichoplusia ni
(U.S. Pat. No. 5,300,435). Commercially available serum-free media
are used to grow and maintain the cells. Suitable media are Sf900
II.TM. (Life Technologies) or ESF 921.TM. (Expression Systems) for
the Sf9 cells; and Ex-cellO405.TM. (JRH Biosciences, Lenexa, Kans.)
or Express FiveO.TM. (Life Technologies) for the T. ni cells.
Procedures used are generally described in available laboratory
manuals (King, L. A. and Possee, R. D., ibid.; O'Reilly, D. R. et
al., ibid.; Richardson, C. D., ibid.). Subsequent purification of
the zalpha11 polypeptide from the supernatant can be achieved using
methods described herein.
[0109] Fungal cells, including yeast cells, can also be used within
the present invention. Yeast species of particular interest in this
regard include Saccharomyces cerevisiae, Pichia pastoris, and
Pichia methanotica. Methods for transforming S. cerevisiae cells
with exogenous DNA and producing recombinant polypeptides therefrom
are disclosed by, for example, Kawasaki, U.S. Pat. No. 4,599,311;
Kawasaki et al., U.S. Pat. No. 4,931,373; Brake, U.S. Pat. No.
4,870,008; Welch et al., U.S. Pat. No. 5,037,743; and Murray et
al., U.S. Pat. No. 4,845,075. Transformed cells are selected by
phenotype determined by the selectable marker, commonly drug
resistance or the ability to grow in the absence of a particular
nutrient (e.g., leucine). A preferred vector system for use in
Saccharomyces cerevisiae is the POT1 vector system disclosed by
Kawasaki et al. (U.S. Pat. No. 4,931,373), which allows transformed
cells to be selected by growth in glucose-containing media.
Suitable promoters and terminators for use in yeast include those
from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Pat. No.
4,599,311; Kingsman et al., U.S. Pat. No. 4,615,974; and Bitter,
U.S. Pat. No. 4,977,092) and alcohol dehydrogenase genes. See also
U.S. Pat. Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454.
Transformation systems for other yeasts, including Hansenula
polymorpha, Schizosaccharomyces pombe, Kluyveromyces lactis,
Kluyveromyces fragilis, Ustilago maydis, Pichia pastoris, Pichia
methanolica, Pichia guillermondii and Candida maltosa are known in
the art. See, for example, Gleeson et al., J. Gen. Microbiol.
132:3459-3465, 1986 and Cregg, U.S. Pat. No. 4,882,279. Aspergillus
cells may be utilized according to the methods of McKnight et al.,
U.S. Pat. No. 4,935,349. Methods for transforming Acremonium
chrysogenum are disclosed by Sumino et al., U.S. Pat. No.
5,162,228. Methods for transforming Neurospora are disclosed by
Lambowitz, U.S. Pat. No. 4,486,533.
[0110] The use of Pichia methanolica as host for the production of
recombinant proteins is disclosed in WIPO Publications WO 97/17450,
WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in
transforming P. methanolica will commonly be prepared as
double-stranded, circular plasmids, which are preferably linearized
prior to transformation. For polypeptide production in P.
methanolica, it is preferred that the promoter and terminator in
the plasmid be that of a P. methanolica gene, such as a P.
methanolica alcohol utilization gene (AUG1 or AUG2). Other useful
promoters include those of the dihydroxyacetone synthase (DHAS),
formate dehydrogenase (FMD), and catalase (CAT) genes. To
facilitate integration of the DNA into the host chromosome, it is
preferred to have the entire expression segment of the plasmid
flanked at both ends by host DNA sequences. A preferred selectable
marker for use in Pichia methanolica is a P. methanolica ADE2 gene,
which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC
4.1.1.21), which allows ade2 host cells to grow in the absence of
adenine. For large-scale, industrial processes where it is
desirable to minimize the use of methanol, it is preferred to use
host cells in which both methanol utilization genes (AUG1 and AUG2)
are deleted. For production of secreted proteins, host cells
deficient in vacuolar protease genes (PEP4 and PRB1) are preferred.
Electroporation is used to facilitate the introduction of a plasmid
containing DNA encoding a polypeptide of interest into P.
methanolica cells. It is preferred to transform P. methanolica
cells by electroporation using an exponentially decaying, pulsed
electric field having a field strength of from 2.5 to 4.5 kV/cm,
preferably about 3.75 kV/cm, and a time constant (t) of from 1 to
40 milliseconds, most preferably about 20 milliseconds.
[0111] Prokaryotic host cells, including strains of the bacteria
Escherichia coli, Bacillus and other genera are also useful host
cells within the present invention. Techniques for transforming
these hosts and expressing foreign DNA sequences cloned therein are
well known in the art (see, e.g., Sambrook et al., ibid.). When
expressing a zalpha11 polypeptide in bacteria such as E. coli, the
polypeptide may be retained in the cytoplasm, typically as
insoluble granules, or may be directed to the periplasmic space by
a bacterial secretion sequence. In the former case, the cells are
lysed, and the granules are recovered and denatured using, for
example, guanidine isothiocyanate or urea. The denatured
polypeptide can then be refolded and dimerized by diluting the
denaturant, such as by dialysis against a solution of urea and a
combination of reduced and oxidized glutathione, followed by
dialysis against a buffered saline solution. In the latter case,
the polypeptide can be recovered from the periplasmic space in a
soluble and functional form by disrupting the cells (by, for
example, sonication or osmotic shock) to release the contents of
the periplasmic space and recovering the protein, thereby obviating
the need for denaturation and refolding.
[0112] Transformed or transfected host cells are cultured according
to conventional procedures in a culture medium containing nutrients
and other components required for the growth of the chosen host
cells. A variety of suitable media, including defined media and
complex media, are known in the art and generally include a carbon
source, a nitrogen source, essential amino acids, vitamins and
minerals. Media may also contain such components as growth factors
or serum, as required. The growth medium will generally select for
cells containing the exogenously added DNA by, for example, drug
selection or deficiency in an essential nutrient which is
complemented by the selectable marker carried on the expression
vector or co-transfected into the host cell. P. methanolica cells
are cultured in a medium comprising adequate sources of carbon,
nitrogen and trace nutrients at a temperature of about 25.degree.
C. to 35.degree. C. Liquid cultures are provided with sufficient
aeration by conventional means, such as shaking of small flasks or
sparging of fermentors. A preferred culture medium for P.
methanolica is YEPD (2% D-glucose, 2% Bacto.TM. Peptone (Difco
Laboratories, Detroit, Mich.), 1% Bacto.TM. yeast extract (Difco
Laboratories), 0.004% adenine and 0.006% L-leucine).
[0113] Within one aspect of the present invention, a zalpha11
cytokine receptor (including transmembrane and intracellular
domains) is produced by a cultured cell, and the cell is used to
screen for ligands for the receptor, including the natural ligand,
as well as agonists and antagonists of the natural ligand. To
summarize this approach, a cDNA or gene encoding the receptor is
combined with other genetic elements required for its expression
(e.g., a transcription promoter), and the resulting expression
vector is inserted into a host cell. Cells that express the DNA and
produce functional receptor are selected and used within a variety
of screening systems.
[0114] Mammalian cells suitable for use in expressing the novel
receptors of the present invention and transducing a
receptor-mediated signal include cells that express a
.beta.-subunit, such as gp130, and cells that co-express gp130 and
LIF receptor (Gearing et al., EMBO J. 10:2839-2848, 1991; Gearing
et al., U.S. Pat. No. 5,284,755). In this regard it is generally
preferred to employ a cell that is responsive to other cytokines
that bind to receptors in the same subfamily, such as IL-6 or LIF,
because such cells will contain the requisite signal transduction
pathway(s). Preferred cells of this type include the human TF-1
cell line (ATCC number CRL-2003) and the DA-1 cell line (Branch et
al., Blood 69:1782, 1987; Broudy et al., Blood 75:1622-1626, 1990).
In the alternative, suitable host cells can be engineered to
produce a .beta.-subunit or other cellular component needed for the
desired cellular response. For example, the murine cell line BaF3
(Palacios and Steinmetz, Cell 41:727-734, 1985; Mathey-Prevot et
al., Mol. Cell. Biol. 6: 4133-4135, 1986), a baby hamster kidney
(BHK) cell line, or the CTLL-2 cell line (ATCC TIB-214) can be
transfected to express the mouse gp130 subunit, or mouse gp130 and
LIF receptor, in addition to zalpha11. It is generally preferred to
use a host cell and receptor(s) from the same species, however this
approach allows cell lines to be engineered to express multiple
receptor subunits from any species, thereby overcoming potential
limitations arising from species specificity. In the alternative,
species homologs of the human receptor cDNA can be cloned and used
within cell lines from the same species, such as a mouse cDNA in
the BaF3 cell line. Cell lines that are dependent upon one
hematopoietic growth factor, such as IL-3, can thus be engineered
to become dependent upon a zalpha11 ligand.
[0115] Cells expressing functional zalpha11 are used within
screening assays. A variety of suitable assays are known in the
art. These assays are based on the detection of a biological
response in the target cell. One such assay is a cell proliferation
assay. Cells are cultured in the presence or absence of a test
compound, and cell proliferation is detected by, for example,
measuring incorporation of tritiated thymidine or by calorimetric
assay based on the metabolic breakdown of Alymar Blue.TM. (AccuMed,
Chicago, Ill.) or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) (Mosman, J. Immunol. Meth. 65: 55-63,
1983). An alternative assay format uses cells that are further
engineered to express a reporter gene. The reporter gene is linked
to a promoter element that is responsive to the receptor-linked
pathway, and the assay detects activation of transcription of the
reporter gene. A preferred promoter element in this regard is a
serum response element, or SRE (see, for example, Shaw et al., Cell
56:563-572, 1989). A preferred such reporter gene is a luciferase
gene (de Wet et al., Mol. Cell. Biol. 7:725, 1987). Expression of
the luciferase gene is detected by luminescence using methods known
in the art (e.g., Baumgartner et al., J. Biol. Chem.
269:19094-29101, 1994; Schenborn and Goiffin, Promega Notes 41:11,
1993). Luciferase assay kits are commercially available from, for
example, Promega Corp., Madison, Wis. Target cell lines of this
type can be used to screen libraries of chemicals, cell-conditioned
culture media, fungal broths, soil samples, water samples, and the
like. For example, a bank of cell- or tissue-conditioned media
samples can be assayed on a target cell to identify cells that
produce ligand. Positive cells are then used to produce a cDNA
library in a mammalian cell expression vector, which is divided
into pools, transfected into host cells, and expressed. Media
samples from the transfected cells are then assayed, with
subsequent division of pools, retransfection, subculturing, and
re-assay of positive cells to isolate a clonal cell line expressing
the ligand. Media samples conditioned by kidney, liver, spleen,
thymus, other lymphoid tissues, or T-cells are preferred sources of
ligand for use in screening procedures.
[0116] A natural ligand for zalpha11 can also be identified by
mutagenizing a cytokine-dependent cell line expressing zalpha11 and
culturing it under conditions that select for autocrine growth. See
WIPO publication WO 95/21930. Within a typical procedure, cells
expressing zalpha11 are mutagenized, such as with EMS. The cells
are then allowed to recover in the presence of the required
cytokine, then transferred to a culture medium lacking the
cytokine. Surviving cells are screened for the production of a
ligand for zalpha11, such as by adding soluble (ligand-binding)
receptor polypeptide to the culture medium or by assaying
conditioned media on wild-type cells and transfected cells
expressing the zalpha11. Preferred cell lines for use within this
method include cells that are transfected to express gp130 or gp130
in combination with LIF receptor. Preferred such host cell lines
include transfected CTLL-2 cells (Gillis and Smith, Nature
268:154-156, 1977) and transfected BaF3 cells.
[0117] Moreover, a secretion trap method employing zalpha11 soluble
receptor polypeptide can be used to isolate a zalpha11 ligand
(Aldrich, et al, Cell 87: 1161-1169, 1996). A cDNA expression
library prepared from a known or suspected ligand source is
transfected into COS-7 cells. The cDNA library vector generally has
an SV40 origin for amplification in COS-7 cells, and a CMV promoter
for high expression. The transfected COS-7 cells are grown in a
monolayer and then fixed and permeabilized. Tagged or
biotin-labeled zalpha11 soluble receptor, described herein, is then
placed in contact with the cell layer and allowed to bind cells in
the monolayer that express an anti-complementary molecule, i.e., a
zalpha11 ligand. A cell expressing a ligand will thus be bound with
receptor molecules. An anti-tag antibody (anti-Ig for Ig fusions,
M2 or anti-FLAG for FLAG-tagged fusions, streptavidin, and the
like) which is conjugated with horseradish peroxidase (HRP) is used
to visualize these cells to which the tagged or biotin-labeled
zalpha11 soluble receptor has bound. The HRP catalyzes deposition
of a tyramide reagent, for example, tyramide-FITC. A
commercially-available kit can be used for this detection (for
example, Renaissance TSA-Direct.TM. Kit; NEN Life Science Products,
Boston, Mass.). Cells which express zalpha11 receptor ligand will
be identified under fluorescence microscopy as green cells and
picked for subsequent cloning of the ligand using procedures for
plasmid rescue as outlined in Aldrich, et al, supra., followed by
subsequent rounds of secretion trap assay until single clones are
identified.
[0118] As a receptor, the activity of zalpha11 polypeptide can be
measured by a silicon-based biosensor microphysiometer which
measures the extracellular acidification rate or proton excretion
associated with receptor binding and subsequent physiologic
cellular responses. An exemplary device is the Cytosensor.TM.
Microphysiometer manufactured by Molecular Devices, Sunnyvale,
Calif. A variety of cellular responses, such as cell proliferation,
ion transport, energy production, inflammatory response, regulatory
and receptor activation, and the like, can be measured by this
method. See, for example, McConnell, H. M. et al., Science
257:1906-1912, 1992; Pitchford, S. et al., Meth. Enzymol.
228:84-108, 1997; Arimilli, S. et al., J. Immunol. Meth. 212:49-59,
1998; Van Liefde, I. Et al., Eur. J. Pharmacol. 346:87-95, 1998.
The microphysiometer can be used for assaying eukaryotic,
prokaryotic, adherent or non-adherent cells. By measuring
extracellular acidification changes in cell media over time, the
microphysiometer directly measures cellular responses to various
stimuli, including agonists, ligands, or antagonists of the
zalpha11 polypeptide. Preferably, the microphysiometer is used to
measure responses of a zalpha11-expressing eukaryotic cell,
compared to a control eukaryotic cell that does not express
zalpha11 polypeptide. Zalpha11-expressing eukaryotic cells comprise
cells into which zalpha11 has been transfected, as described
herein, creating a cell that is responsive to zalpha11-modulating
stimuli, or are cells naturally expressing zalpha11, such as
zalpha11-expressing cells derived from lymphoid, spleen, thymus
tissue or PBLs. Differences, measured by an increase or decrease in
extracellular acidification, in the response of cells expressing
zalpha11, relative to a control, are a direct measurement of
zalpha11-modulated cellular responses. Moreover, such
zalpha11-modulated responses can be assayed under a variety of
stimuli. Also, using the microphysiometer, there is provided a
method of identifying agonists and antagonists of zalpha11
polypeptide, comprising providing cells expressing a zalpha11
polypeptide, culturing a first portion of the cells in the absence
of a test compound, culturing a second portion of the cells in the
presence of a test compound, and detecting an increase or a
decrease in a cellular response of the second portion of the cells
as compared to the first portion of the cells. Antagonists and
agonists, including the natural ligand for zalpha11 polypeptide,
can be rapidly identified using this method.
[0119] Additional assays provided by the present invention include
the use of hybrid receptor polypeptides. These hybrid polypeptides
fall into two general classes. Within the first class, the
intracellular domain of zalpha11, comprising approximately residues
256 (Lys) to 528 (Ser) of SEQ ID NO:2, is joined to the
ligand-binding domain of a second receptor. It is preferred that
the second receptor be a hematopoietic cytokine receptor, such as
mpl receptor (Souyri et al., Cell 63:1137-1147, 1990). The hybrid
receptor will further comprise a transmembrane domain, which may be
derived from either receptor. A DNA construct encoding the hybrid
receptor is then inserted into a host cell. Cells expressing the
hybrid receptor are cultured in the presence of a ligand for the
binding domain and assayed for a response. This system provides a
means for analyzing signal transduction mediated by zalpha11 while
using readily available ligands. This system can also be used to
determine if particular cell lines are capable of responding to
signals transduced by zalpha11. A second class of hybrid receptor
polypeptides comprise the extracellular (ligand-binding) domain of
zalpha11 (approximately residues 20 (Cys) to 237 (His) of SEQ ID
NO:2) with a cytoplasmic domain of a second receptor, preferably a
cytokine receptor, and a transmembrane domain. The transmembrane
domain may be derived from either receptor. Hybrid receptors of
this second class are expressed in cells known to be capable of
responding to signals transduced by the second receptor. Together,
these two classes of hybrid receptors enable the use of a broad
spectrum of cell types within receptor-based assay systems.
[0120] Cells found to express a ligand for zalpha11 are then used
to prepare a cDNA library from which the ligand-encoding cDNA may
be isolated as disclosed above. The present invention thus
provides, in addition to novel receptor polypeptides, methods for
cloning polypeptide ligands for the receptors.
[0121] The tissue specificity of zalpha11 expression suggests a
role in early thymocyte development and immune response regulation.
These processes involve stimulation of cell proliferation and
differentiation in response to the binding of one or more cytokines
to their cognate receptors. In view of the tissue distribution
observed for this receptor, agonists (including the natural ligand)
and antagonists have enormous potential in both in vitro and in
vivo applications. Compounds identified as receptor agonists are
useful for stimulating proliferation and development of target
cells in vitro and in vivo. For example, agonist compounds are
useful as components of defined cell culture media, and may be used
alone or in combination with other cytokines and hormones to
replace serum that is commonly used in cell culture. Agonists are
thus useful in specifically promoting the growth and/or development
of T-cells, B-cells, and other cells of the lymphoid and myeloid
lineages, and hematopoietic cells in culture.
[0122] Agonist ligands for zalpha11 may be useful in stimulating
cell-mediated immunity and for stimulating lymphocyte
proliferation, such as in the treatment of infections involving
immunosuppression, including certain viral infections. Additional
uses include tumor suppression, where malignant transformation
results in tumor cells that are antigenic. Agonist ligands could be
used to induce cytotoxicity, which may be mediated through
activation of effector cells such as T-cells, NK (natural killer)
cells, or LAK (lymphoid activated killer) cells, or induced
directly through apoptotic pathways. Agonist ligands may also be
useful in treating leukopenias by increasing the levels of the
affected cell type, and for enhancing the regeneration of the
T-cell repertoire after bone marrow transplantation.
[0123] Antagonist ligands or compounds may find utility in the
suppression of the immune system, such as in the treatment of
autoimmune diseases, including rheumatoid arthritis, multiple
sclerosis, diabetes mellitis, inflammatory bowel disease, Crohn's
disease, etc. Immune suppression can also be used to reduce
rejection of tissue or organ transplants and grafts and to treat
T-cell specific leukemias or lymphomas by inhibiting proliferation
of the affected cell type.
[0124] Zalpha11 may also be used within diagnostic systems for the
detection of circulating levels of ligand. Within a related
embodiment, antibodies or other agents that specifically bind to
zalpha11 can be used to detect circulating receptor polypeptides.
Elevated or depressed levels of ligand or receptor polypeptides may
be indicative of pathological conditions, including cancer. Soluble
receptor polypeptides may contribute to pathologic processes and
can be an indirect marker of an underlying disease. For example,
elevated levels of soluble IL-2 receptor in human serum have been
associated with a wide variety of inflammatory and neoplastic
conditions, such as myocardial infarction, asthma, myasthenia
gravis, rheumatoid arthritis, acute T-cell leukemia, B-cell
lymphomas, chronic lymphocytic leukemia, colon cancer, breast
cancer, and ovarian cancer (Heaney et al., Blood 87:847-857,
1996).
[0125] A ligand-binding polypeptide of a zalpha11 receptor, or
"soluble receptor," can be prepared by expressing a truncated DNA
encoding the zalpha11 cytokine binding domain (approximately
residue 20 (Cys) through residue 237 (His) of the human receptor
(SEQ ID NO:2)) or the corresponding region of a non-human receptor.
It is preferred that the extracellular domain be prepared in a form
substantially free of transmembrane and intracellular polypeptide
segments. Moreover, ligand-binding polypeptide fragments within the
zalpha11 cytokine binding domain, described above, can also serve
as zalpha11 soluble receptors for uses described herein. To direct
the export of a receptor polypeptide from the host cell, the
receptor DNA is linked to a second DNA segment encoding a secretory
peptide, such as a t-PA secretory peptide or a zalpha11 secretory
peptide. To facilitate purification of the secreted receptor
polypeptide, a C-terminal extension, such as a poly-histidine tag,
substance P, Flag.TM. peptide (Hopp et al., Bio/Technology
6:1204-1210, 1988; available from Eastman Kodak Co., New Haven,
Conn.) or another polypeptide or protein for which an antibody or
other specific binding agent is available, can be fused to the
receptor polypeptide.
[0126] In an alternative approach, a receptor extracellular domain
can be expressed as a fusion with immunoglobulin heavy chain
constant regions, typically an Fc fragment, which contains two
constant region domains and lacks the variable region. Such fusions
are typically secreted as multimeric molecules wherein the Fc
portions are disulfide bonded to each other and two receptor
polypeptides are arrayed in close proximity to each other. Fusions
of this type can be used to affinity purify the cognate ligand from
solution, as an in vitro assay tool, to block signals in vitro by
specifically titrating out ligand, and as antagonists in vivo by
administering them parenterally to bind circulating ligand and
clear it from the circulation. To purify ligand, a zalpha11-Ig
chimera is added to a sample containing the ligand (e.g.,
cell-conditioned culture media or tissue extracts) under conditions
that facilitate receptor-ligand binding (typically
near-physiological temperature, pH, and ionic strength). The
chimera-ligand complex is then separated by the mixture using
protein A, which is immobilized on a solid support (e.g., insoluble
resin beads). The ligand is then eluted using conventional chemical
techniques, such as with a salt or pH gradient. In the alternative,
the chimera itself can be bound to a solid support, with binding
and elution carried out as above. Collected fractions can be
re-fractionated until the desired level of purity is reached.
[0127] Moreover, zalpha11 soluble receptors can be used as a
"ligand sink," i.e., antagonist, to bind ligand in vivo or in vitro
in therapeutic or other applications where the presence of the
ligand is not desired. For example, in cancers that are expressing
large amount of bioactive zalpha11 ligand, zalpha11 soluble
receptors can be used as a direct antagonist of the ligand in vivo,
and may aid in reducing progression and symptoms associated with
the disease. Moreover, zalpha11 soluble receptor can be used to
slow the progression of cancers that over-express zalkpha11
receptors, by binding ligand in vivo that would otherwise enhance
proliferation of those cancers. Similar in vitro applications for a
zalpha11 soluble receptor can be used, for instance, as a negative
selection to select cell lines that grow in the absence of zalpha11
ligand.
[0128] Moreover, zalpha11 soluble receptor can be used in vivo or
in diagnostic applications to detect zalpha11 ligand-expressing
cancers in vivo or in tissue samples. For example, the zalpha11
soluble receptor can be conjugated to a radio-label or fluorescent
label as described herein, and used to detect the presence of the
ligand in a tissue sample using an in vitro ligand-receptor type
binding assay, or fluorescent imaging assay. Moreover, a
radio-labeled zalpha11 soluble receptor could be administered in
vivo to detect ligand-expressing solid tumors through a
radio-imaging method known in the art.
[0129] Analysis of the tissue distribution of the mRNA
corresponding to this novel DNA showed expression in lymphoid
tissues, including thymus, spleen, lymph nodes, and peripheral
blood leukocytes. These data indicate a role for the zalpha11
receptor in proliferation, differentiation, and/or activation of
immune cells, and suggest a role in development and regulation of
immune responses. The data also suggest that the interaction of
zalpha11 with its ligand may stimulate proliferation and
development of myeloid cells and may, like IL-2, IL-6, LIF, IL-11
and OSM (Baumann et al., J. Biol. Chem. 268:8414-8417, 1993),
induce acute-phase protein synthesis in hepatocytes.
[0130] It is preferred to purify the polypeptides of the present
invention to >80% purity, more preferably to >90% purity,
even more preferably >95% purity, and particularly preferred is
a pharmaceutically pure state, that is greater than 99.9% pure with
respect to contaminating macromolecules, particularly other
proteins and nucleic acids, and free of infectious and pyrogenic
agents. Preferably, a purified polypeptide is substantially free of
other polypeptides, particularly other polypeptides of animal
origin.
[0131] Expressed recombinant zalpha11 polypeptides (or zalpha11
chimeric or fusion polypeptides) can be purified using
fractionation and/or conventional purification methods and media.
Ammonium sulfate precipitation and acid or chaotrope extraction may
be used for fractionation of samples. Exemplary purification steps
may include hydroxyapatite, size exclusion, FPLC and reverse-phase
high performance liquid chromatography. Suitable chromatographic
media include derivatized dextrans, agarose, cellulose,
polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and
Q derivatives are preferred. Exemplary chromatographic media
include those media derivatized with phenyl, butyl, or octyl
groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl
650 (Toso Haas, Montgomeryville, Pa.), Octyl-Sepharose (Pharmacia)
and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso
Haas) and the like. Suitable solid supports include glass beads,
silica-based resins, cellulosic resins, agarose beads, cross-linked
agarose beads, polystyrene beads, cross-linked polyacrylamide
resins and the like that are insoluble under the conditions in
which they are to be used. These supports may be modified with
reactive groups that allow attachment of proteins by amino groups,
carboxyl groups, sulfhydryl groups, hydroxyl groups and/or
carbohydrate moieties. Examples of coupling chemistries include
cyanogen bromide activation, N-hydroxysuccinimide activation,
epoxide activation, sulfhydryl activation, hydrazide activation,
and carboxyl and amino derivatives for carbodiimide coupling
chemistries. These and other solid media are well known and widely
used in the art, and are available from commercial suppliers.
Methods for binding receptor polypeptides to support media are well
known in the art. Selection of a particular method is a matter of
routine design and is determined in part by the properties of the
chosen support. See, for example, Affinity Chromatography:
Principles & Methods, Pharmacia LKB Biotechnology, Uppsala,
Sweden, 1988.
[0132] The polypeptides of the present invention can be isolated by
exploitation of their biochemical, structural, and biological
properties. For example, immobilized metal ion adsorption (IMAC)
chromatography can be used to purify histidine-rich proteins,
including those comprising polyhistidine tags. Briefly, a gel is
first charged with divalent metal ions to form a chelate
(Sulkowski, Trends in Biochem. 3:1-7, 1985). Histidine-rich
proteins will be adsorbed to this matrix with differing affinities,
depending upon the metal ion used, and will be eluted by
competitive elution, lowering the pH, or use of strong chelating
agents. Other methods of purification include purification of
glycosylated proteins by lectin affinity chromatography and ion
exchange chromatography (Methods in Enzymol., Vol. 182, "Guide to
Protein Purification", M. Deutscher, (ed.), Acad. Press, San Diego,
1990, pp. 529-39). Within additional embodiments of the invention,
a fusion of the polypeptide of interest and an affinity tag (e.g.,
maltose-binding protein, an immunoglobulin domain) may be
constructed to facilitate purification.
[0133] Moreover, using methods described in the art, polypeptide
fusions, or hybrid zalpha11 proteins, are constructed using regions
or domains of the inventive zalpha11 in combination with those of
other human cytokine receptor family proteins, or heterologous
proteins (Sambrook et al., ibid., Altschul et al., ibid., Picard,
Cur. Opin. Biology, 5:511-5, 1994, and references therein). These
methods allow the determination of the biological importance of
larger domains or regions in a polypeptide of interest. Such
hybrids may alter reaction kinetics, binding, constrict or expand
the substrate specificity, or alter tissue and cellular
localization of a polypeptide, and can be applied to polypeptides
of unknown structure.
[0134] Fusion polypeptides or proteins can be prepared by methods
known to those skilled in the art by preparing each component of
the fusion protein and chemically conjugating them. Alternatively,
a polynucleotide encoding one or more components of the fusion
protein in the proper reading frame can be generated using known
techniques and expressed by the methods described herein. For
example, part or all of a domain(s) conferring a biological
function may be swapped between zalpha11 of the present invention
with the functionally equivalent domain(s) from another cytokine
family member. Such domains include, but are not limited to, the
secretory signal sequence, extracellular cytokine binding domain,
transmembrane domain, and intracellular signaling domain, Box I and
Box II sites, as disclosed herein. Such fusion proteins would be
expected to have a biological functional profile that is the same
or similar to polypeptides of the present invention or other known
family proteins, depending on the fusion constructed. Moreover,
such fusion proteins may exhibit other properties as disclosed
herein.
[0135] Standard molecular biological and cloning techniques can be
used to swap the equivalent domains between the zalpha11
polypeptide and those polypeptides to which they are fused.
Generally, a DNA segment that encodes a domain of interest, e.g., a
zalpha11 domain described herein, is operably linked in frame to at
least one other DNA segment encoding an additional polypeptide (for
instance a domain or region from another cytokine receptor, such as
the IL-2 receptor), and inserted into an appropriate expression
vector, as described herein. Generally DNA constructs are made such
that the several DNA segments that encode the corresponding regions
of a polypeptide are operably linked in frame to make a single
construct that encodes the entire fusion protein, or a functional
portion thereof. For example, a DNA construct would encode from
N-terminus to C-terminus a fusion protein comprising a signal
polypeptide followed by a cytokine binding domain, followed by a
transmembrane domain, followed by an intracellular signaling
domain. Such fusion proteins can be expressed, isolated, and
assayed for activity as described herein.
[0136] Zalpha11 polypeptides or fragments thereof may also be
prepared through chemical synthesis. zalpha11 polypeptides may be
monomers or multimers; glycosylated or non-glycosylated; pegylated
or non-pegylated; and may or may not include an initial methionine
amino acid residue.
[0137] Polypeptides of the present invention can also be
synthesized by exclusive solid phase synthesis, partial solid phase
methods, fragment condensation or classical solution synthesis.
Methods for synthesizing polypeptides are well known in the art.
See, for example, Merrifield, J. Am. Chem. Soc. 85:2149, 1963;
Kaiser et al., Anal. Biochem. 34:595, 1970. After the entire
synthesis of the desired peptide on a solid support, the
peptide-resin is with a reagent which cleaves the polypeptide from
the resin and removes most of the side-chain protecting groups.
Such methods are well established in the art.
[0138] The activity of molecules of the present invention can be
measured using a variety of assays that measure cell
differentiation and proliferation. Such assays are well known in
the art.
[0139] Proteins of the present invention are useful for example, in
treating lymphoid, immune, inflammatory, spleenic, blood or bone
disorders, and can be measured in vitro using cultured cells or in
vivo by administering molecules of the claimed invention to the
appropriate animal model. For instance, host cells expressing a
zalpha11 soluble receptor polypeptide can be embedded in an
alginate environment and injected (implanted) into recipient
animals. Alginate-poly-L-lysine microencapsulation, permselective
membrane encapsulation and diffusion chambers are a means to entrap
transfected mammalian cells or primary mammalian cells. These types
of non-immunogenic "encapsulations" permit the diffusion of
proteins and other macromolecules secreted or released by the
captured cells to the recipient animal. Most importantly, the
capsules mask and shield the foreign, embedded cells from the
recipient animal's immune response. Such encapsulations can extend
the life of the injected cells from a few hours or days (naked
cells) to several weeks (embedded cells). Alginate threads provide
a simple and quick means for generating embedded cells.
[0140] The materials needed to generate the alginate threads are
known in the art. In an exemplary procedure, 3% alginate is
prepared in sterile H.sub.2O, and sterile filtered. Just prior to
preparation of alginate threads, the alginate solution is again
filtered. An approximately 50% cell suspension (containing about
5.times.10.sup.5 to about 5.times.10.sup.7 cells/ml) is mixed with
the 3% alginate solution. One ml of the alginate/cell suspension is
extruded into a 100 mM sterile filtered CaCl.sub.2 solution over a
time period of .about.15 min, forming a "thread". The extruded
thread is then transferred into a solution of 50 mM CaCl.sub.2, and
then into a solution of 25 mM CaCl.sub.2. The thread is then rinsed
with deionized water before coating the thread by incubating in a
0.01% solution of poly-L-lysine. Finally, the thread is rinsed with
Lactated Ringer's Solution and drawn from solution into a syringe
barrel (without needle). A large bore needle is then attached to
the syringe, and the thread is intraperitoneally injected into a
recipient in a minimal volume of the Lactated Ringer's
Solution.
[0141] An in vivo approach for assaying proteins of the present
invention involves viral delivery systems. Exemplary viruses for
this purpose include adenovirus, herpesvirus, retroviruses,
vaccinia virus, and adeno-associated virus (AAV). Adenovirus, a
double-stranded DNA virus, is currently the best studied gene
transfer vector for delivery of heterologous nucleic acid (for
review, see T. C. Becker et al., Meth. Cell Biol. 43:161-89, 1994;
and J. T. Douglas and D. T. Curiel, Science & Medicine 4:44-53,
1997). The adenovirus system offers several advantages: (i)
adenovirus can accommodate relatively large DNA inserts; (ii) can
be grown to high-titer; (iii) infect a broad range of mammalian
cell types; and (iv) can be used with a large number of different
promoters including ubiquitous, tissue specific, and regulatable
promoters. Also, because adenoviruses are stable in the
bloodstream, they can be administered by intravenous injection.
[0142] Using adenovirus vectors where portions of the adenovirus
genome are deleted, inserts are incorporated into the viral DNA by
direct ligation or by homologous recombination with a
co-transfected plasmid. In an exemplary system, the essential E1
gene has been deleted from the viral vector, and the virus will not
replicate unless the E1 gene is provided by the host cell (the
human 293 cell line is exemplary). When intravenously administered
to intact animals, adenovirus primarily targets the liver. If the
adenoviral delivery system has an E1 gene deletion, the virus
cannot replicate in the host cells. However, the host's tissue
(e.g., liver) will express and process (and, if a secretory signal
sequence is present, secrete) the heterologous protein. Secreted
proteins will enter the circulation in the highly vascularized
liver, and effects on the infected animal can be determined.
[0143] Moreover, adenoviral vectors containing various deletions of
viral genes can be used in an attempt to reduce or eliminate immune
responses to the vector. Such adenoviruses are E1 deleted, and in
addition contain deletions of E2A or E4 (Lusky, M. et al., J.
Virol. 72:2022-2032, 1998; Raper, S. E. et al., Human Gene Therapy
9:671-679, 1998). In addition, deletion of E2b is reported to
reduce immune responses (Amalfitano, A. et al., J. Virol.
72:926-933, 1998). Moreover, by deleting the entire adenovirus
genome, very large inserts of heterologous DNA can be accommodated.
Generation of so called "gutless" adenoviruses where all viral
genes are deleted are particularly advantageous for insertion of
large inserts of heterologous DNA. For review, see Yeh, P. and
Perricaudet, M., FASEB J. 11:615-623, 1997.
[0144] The adenovirus system can also be used for protein
production in vitro. By culturing adenovirus-infected non-293 cells
under conditions where the cells are not rapidly dividing, the
cells can produce proteins for extended periods of time. For
instance, BHK cells are grown to confluence in cell factories, then
exposed to the adenoviral vector encoding the secreted protein of
interest. The cells are then grown under serum-free conditions,
which allows infected cells to survive for several weeks without
significant cell division. Alternatively, adenovirus vector
infected 293 cells can be grown as adherent cells or in suspension
culture at relatively high cell density to produce significant
amounts of protein (See Garnier et al., Cytotechnol. 15:145-55,
1994). With either protocol, an expressed, secreted heterologous
protein can be repeatedly isolated from the cell culture
supernatant, lysate, or membrane fractions depending on the
disposition of the expressed protein in the cell. Within the
infected 293 cell production protocol, non-secreted proteins may
also be effectively obtained.
[0145] In view of the tissue distribution observed for zalpha11,
agonists (including the natural ligand/substrate/cofactor/etc.) and
antagonists have enormous potential in both in vitro and in vivo
applications. Compounds identified as zalpha11 agonists are useful
for stimulating growth of immune and hematopoietic cells in vitro
and in vivo. For example, zalpha11 and agonist compounds are useful
as components of defined cell culture media, and may be used alone
or in combination with other cytokines and hormones to replace
serum that is commonly used in cell culture. Agonists are thus
useful in specifically promoting the growth and/or development of
T-cells, B-cells, and other cells of the lymphoid and myeloid
lineages in culture. Moreover, zalpha11 soluble receptor, agonist,
or antagonist may be used in vitro in an assay to measure
stimulation of colony formation from isolated primary bone marrow
cultures. Such assays are well known in the art.
[0146] Antagonists are also useful as research reagents for
characterizing sites of ligand-receptor interaction. Inhibitors of
zalpha11 activity (zalpha11 antagonists) include anti-zalpha11
antibodies and soluble zalpha11 receptors, as well as other
peptidic and non-peptidic agents (including ribozymes).
[0147] Zalpha11 can also be used to identify modulators (e.g,
antagonists) of its activity. Test compounds are added to the
assays disclosed herein to identify compounds that inhibit the
activity of zalpha11. In addition to those assays disclosed herein,
samples can be tested for inhibition of zalpha11 activity within a
variety of assays designed to measure zalpha11 binding,
oligomerization, or the stimulation/inhibition of
zalpha11-dependent cellular responses. For example,
zalpha11-expressing cell lines can be transfected with a reporter
gene construct that is responsive to a zalpha11-stimulated cellular
pathway. Reporter gene constructs of this type are known in the
art, and will generally comprise a zalpha11-DNA response element
operably linked to a gene encoding an assay detectable protein,
such as luciferase. DNA response elements can include, but are not
limited to, cyclic AMP response elements (CRE), hormone response
elements (HRE) insulin response element (IRE) (Nasrin et al., Proc.
Natl. Acad. Sci. USA 87:5273-7, 1990) and serum response elements
(SRE) (Shaw et al. Cell 56: 563-72, 1989). Cyclic AMP response
elements are reviewed in Roestler et al., J. Biol. Chem. 263
(19):9063-6; 1988 and Habener, Molec. Endocrinol. 4 (8):1087-94;
1990. Hormone response elements are reviewed in Beato, Cell
56:335-44; 1989. Candidate compounds, solutions, mixtures or
extracts or conditioned media from various cell types are tested
for the ability to enhance the activity of zalpha11 receptor as
evidenced by a increase in zalpha11 stimulation of reporter gene
expression. Assays of this type will detect compounds that directly
stimulate zalpha11 signal transduction activity through binding the
receptor or by otherwise stimulating part of the signal cascade. As
such, there is provided a method of identifying agonists of
zalpha11 polypeptide, comprising providing cells responsive to a
zalpha11 polypeptide, culturing a first portion of the cells in the
absence of a test compound, culturing a second portion of the cells
in the presence of a test compound, and detecting a increase in a
cellular response of the second portion of the cells as compared to
the first portion of the cells. Moreover third cell, containing the
reporter gene construct described above, but not expressing
zaplpha11 receptor, can be used as a control cell to assess
non-specific, or non-zalpha11-mediated, stimulation of the
reporter. Agonists, including the natural ligand, are therefore
useful to stimulate or increase zalpha11 polypeptide function.
[0148] A zalpha11 ligand-binding polypeptide, such as the cytokine
binding domain disclosed herein, can also be used for purification
of ligand. The polypeptide is immobilized on a solid support, such
as beads of agarose, cross-linked agarose, glass, cellulosic
resins, silica-based resins, polystyrene, cross-linked
polyacrylamide, or like materials that are stable under the
conditions of use. Methods for linking polypeptides to solid
supports are known in the art, and include amine chemistry,
cyanogen bromide activation, N-hydroxysuccinimide activation,
epoxide activation, sulfhydryl activation, and hydrazide
activation. The resulting medium will generally be configured in
the form of a column, and fluids containing ligand are passed
through the column one or more times to allow ligand to bind to the
receptor polypeptide. The ligand is then eluted using changes in
salt concentration, chaotropic agents (guanidine HCl), or pH to
disrupt ligand-receptor binding.
[0149] An assay system that uses a ligand-binding receptor (or an
antibody, one member of a complement/anti-complement pair) or a
binding fragment thereof, and a commercially available biosensor
instrument may be advantageously employed (e.g., BIAcore.TM.,
Pharmacia Biosensor, Piscataway, N.J.; or SELDI.TM. technology,
Ciphergen, Inc., Palo Alto, Calif.). Such receptor, antibody,
member of a complement/anti-complement pair or fragment is
immobilized onto the surface of a receptor chip. Use of this
instrument is disclosed by Karlsson, J. Immunol. Methods
145:229-240, 1991 and Cunningham and Wells, J. Mol. Biol.
234:554-63, 1993. A receptor, antibody, member or fragment is
covalently attached, using amine or sulfhydryl chemistry, to
dextran fibers that are attached to gold film within the flow cell.
A test sample is passed through the cell. If a ligand, epitope, or
opposite member of the complement/anti-complement pair is present
in the sample, it will bind to the immobilized receptor, antibody
or member, respectively, causing a change in the refractive index
of the medium, which is detected as a change in surface plasmon
resonance of the gold film. This system allows the determination of
on- and off-rates, from which binding affinity can be calculated,
and assessment of stoichiometry of binding.
[0150] Ligand-binding receptor polypeptides can also be used within
other assay systems known in the art. Such systems include
Scatchard analysis for determination of binding affinity (see
Scatchard, Ann. NY Acad. Sci. 51: 660-672, 1949) and calorimetric
assays (Cunningham et al., Science 253:545-48, 1991; Cunningham et
al., Science 245:821-25, 1991).
[0151] Zalpha11 polypeptides can also be used to prepare antibodies
that bind to zalpha11 epitopes, peptides or polypeptides. The
zalpha11 polypeptide or a fragment thereof serves as an antigen
(immunogen) to inoculate an animal and elicit an immune response.
One of skill in the art would recognize that antigens or
immunogenic epitopes can consist of stretches of amino acids within
a longer polypeptide, from about 10 amino acids and up to about the
entire length of the polypeptide or longer depending on the
polypeptide. Suitable antigens include the zalpha11 polypeptide
encoded by SEQ ID NO:2 from amino acid number 20 (Cys) to amino
acid number 538 (Ser), or a contiguous 9 to 519 AA amino acid
fragment thereof. Preferred peptides to use as antigens are the
cytokine binding domain, intracellular signaling domain, Box I and
Box II sites, disclosed herein, and zalpha11 hydrophilic peptides
such as those predicted by one of skill in the art from a
hydrophobicity plot, determined for example, from a Hopp/Woods
hydrophilicity profile based on a sliding six-residue window, with
buried G, S, and T residues and exposed H, Y, and W residues
ignored (See, FIG. 1). Zalpha11 hydrophilic peptides include
peptides comprising amino acid sequences selected from the group
consisting of: (1) amino acid number 51 (Trp) to amino acid number
61 (Glu) of SEQ ID NO:2; (2) amino acid number 136 (Ile) to amino
acid number 143 (Glu) of SEQ ID NO:2; (3) amino acid number 187
(Pro) to amino acid number 195 (Ser) of SEQ ID NO:2; (4) amino acid
number 223 (Phe) to amino acid number 232 (Glu) of SEQ ID NO:2; and
(5) amino acid number 360 (Glu) to amino acid number 368 (Asp) of
SEQ ID NO:2. In addition, conserved motifs, and variable regions
between conserved motifs of zalpha11 are suitable antigens.
Moreover, corresponding regions of the mouse zalpha11 polypeptide
(SEQ ID NO:85) can be used to generate antibodies against the mouse
zalpha11. Antibodies generated from this immune response can be
isolated and purified as described herein. Methods for preparing
and isolating polyclonal and monoclonal antibodies are well known
in the art. See, for example, Current Protocols in Immunology,
Cooligan, et al. (eds.), National Institutes of Health, John Wiley
and Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A
Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989;
and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies:
Techniques and Applications, CRC Press, Inc., Boca Raton, Fla.,
1982.
[0152] As would be evident to one of ordinary skill in the art,
polyclonal antibodies can be generated from inoculating a variety
of warm-blooded animals such as horses, cows, goats, sheep, dogs,
chickens, rabbits, mice, and rats with a zalpha11 polypeptide or a
fragment thereof. The immunogenicity of a zalpha11 polypeptide may
be increased through the use of an adjuvant, such as alum (aluminum
hydroxide) or Freund's complete or incomplete adjuvant.
Polypeptides useful for immunization also include fusion
polypeptides, such as fusions of zalpha11 or a portion thereof with
an immunoglobulin polypeptide or with maltose binding protein. The
polypeptide immunogen may be a full-length molecule or a portion
thereof. If the polypeptide portion is "hapten-like", such portion
may be advantageously joined or linked to a macromolecular carrier
(such as keyhole limpet hemocyanin (KLH), bovine serum albumin
(BSA) or tetanus toxoid) for immunization.
[0153] As used herein, the term "antibodies" includes polyclonal
antibodies, affinity-purified polyclonal antibodies, monoclonal
antibodies, and antigen-binding fragments, such as F(ab').sub.2 and
Fab proteolytic fragments. Genetically engineered intact antibodies
or fragments, such as chimeric antibodies, Fv fragments, single
chain antibodies and the like, as well as synthetic antigen-binding
peptides and polypeptides, are also included. Non-human antibodies
may be humanized by grafting non-human CDRs onto human framework
and constant regions, or by incorporating the entire non-human
variable domains (optionally "cloaking" them with a human-like
surface by replacement of exposed residues, wherein the result is a
"veneered" antibody). In some instances, humanized antibodies may
retain non-human residues within the human variable region
framework domains to enhance proper binding characteristics.
Through humanizing antibodies, biological half-life may be
increased, and the potential for adverse immune reactions upon
administration to humans is reduced.
[0154] Alternative techniques for generating or selecting
antibodies useful herein include in vitro exposure of lymphocytes
to zalpha11 protein or peptide, and selection of antibody display
libraries in phage or similar vectors (for instance, through use of
immobilized or labeled zalpha11 protein or peptide). Genes encoding
polypeptides having potential zalpha11 polypeptide binding domains
can be obtained by screening random peptide libraries displayed on
phage (phage display) or on bacteria, such as E. coli. Nucleotide
sequences encoding the polypeptides can be obtained in a number of
ways, such as through random mutagenesis and random polynucleotide
synthesis. These random peptide display libraries can be used to
screen for peptides which interact with a known target which can be
a protein or polypeptide, such as a ligand or receptor, a
biological or synthetic macromolecule, or organic or inorganic
substances. Techniques for creating and screening such random
peptide display libraries are known in the art (Ladner et al., U.S.
Pat. No. 5,223,409; Ladner et al., U.S. Pat. No. 4,946,778; Ladner
et al., U.S. Pat. No. 5,403,484 and Ladner et al., U.S. Pat. No.
5,571,698) and random peptide display libraries and kits for
screening such libraries are available commercially, for instance
from Clontech (Palo Alto, Calif.), Invitrogen Inc. (San Diego,
Calif.), New England Biolabs, Inc. (Beverly, Mass.) and Pharmacia
LKB Biotechnology Inc. (Piscataway, N.J.). Random peptide display
libraries can be screened using the zalpha11 sequences disclosed
herein to identify proteins which bind to zalpha11. These "binding
peptides" which interact with zalpha11 polypeptides can be used for
tagging cells; for isolating homolog polypeptides by affinity
purification; they can be directly or indirectly conjugated to
drugs, toxins, radionuclides and the like. These binding peptides
can also be used in analytical methods such as for screening
expression libraries and neutralizing activity. The binding
peptides can also be used for diagnostic assays for determining
circulating levels of zalpha11 polypeptides; for detecting or
quantitating soluble zalpha11 polypeptides as marker of underlying
pathology or disease. These binding peptides can also act as
zalpha11 "antagonists" to block zalpha11 binding and signal
transduction in vitro and in vivo. These anti-zalpha11 binding
peptides would be useful for inhibiting the action of a ligand that
binds with zalpha11.
[0155] Antibodies are determined to be specifically binding if: 1)
they exhibit a threshold level of binding activity, and/or 2) they
do not significantly cross-react with related polypeptide
molecules. First, antibodies herein specifically bind if they bind
if they bind to a zalpha11 polypeptide, peptide or epitope with an
affinity at least 10-fold greater than the binding affinity to
control (non-zalpha11) polypeptide. It is preferred that the
antibodies exhibit a binding affinity (K.sub.a) of 10.sup.6
M.sup.-1 or greater, preferably 10.sup.7 M.sup.-1 or greater, more
preferably 10.sup.8 M.sup.-1 or greater, and most preferably
10.sup.9 M.sup.-1 or greater. The binding affinity of an antibody
can be readily determined by one of ordinary skill in the art, for
example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci.
51: 660-672, 1949).
[0156] Second, antibodies are determined to specifically bind if
they do not significantly cross-react with related polypeptides.
Antibodies do not significantly cross-react with related
polypeptide molecules, for example, if they detect zalpha11 but not
known related polypeptides using a standard Western blot analysis
(Ausubel et al., ibid.). Examples of known related polypeptides are
orthologs, proteins from the same species that are members of a
protein family (e.g. IL-6), zalpha11 polypeptides, and non-human
zalpha11. Moreover, antibodies may be "screened against" known
related polypeptides to isolate a population that specifically
binds to the inventive polypeptides. For example, antibodies raised
to zalpha11 are adsorbed to related polypeptides adhered to
insoluble matrix; antibodies specific to zalpha11 will flow through
the matrix under the proper buffer conditions. Such screening
allows isolation of polyclonal and monoclonal antibodies
non-crossreactive to closely related polypeptides (Antibodies: A
Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor
Laboratory Press, 1988; Current Protocols in Immunology, Cooligan,
et al. (eds.), National Institutes of Health, John Wiley and Sons,
Inc., 1995). Screening and isolation of specific antibodies is well
known in the art. See, Fundamental Immunology, Paul (eds.), Raven
Press, 1993; Getzoff et al., Adv. in Immunol 43: 1-98, 1988;
Monoclonal Antibodies: Principles and Practice, Goding, J. W.
(eds.), Academic Press Ltd., 1996; Benjamin et al., Ann. Rev.
Immunol. 2: 67-101, 1984.
[0157] A variety of assays known to those skilled in the art can be
utilized to detect antibodies which specifically bind to zalpha11
proteins or peptides. Exemplary assays are described in detail in
Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold
Spring Harbor Laboratory Press, 1988. Representative examples of
such assays include: concurrent immunoelectrophoresis,
radioimmunoassay, radioimmuno-precipitation, enzyme-linked
immunosorbent assay (ELISA), dot blot or Western blot assay,
inhibition or competition assay, and sandwich assay. In addition,
antibodies can be screened for binding to wild-type versus mutant
zalpha11 protein or polypeptide.
[0158] Antibodies to zalpha11 may be used for tagging cells that
express zalpha11; for isolating zalpha11 by affinity purification;
for diagnostic assays for determining circulating levels of
zalpha11 polypeptides; for detecting or quantitating soluble
zalpha11 as marker of underlying pathology or disease; in
analytical methods employing FACS; for screening expression
libraries; for generating anti-idiotypic antibodies; and as
neutralizing antibodies or as antagonists to block zalpha11
activity in vitro and in vivo. Suitable direct tags or labels
include radionuclides, enzymes, substrates, cofactors, inhibitors,
fluorescent markers, chemiluminescent markers, magnetic particles
and the like; indirect tags or labels may feature use of
biotin-avidin or other complement/anti-complement pairs as
intermediates. Antibodies herein may also be directly or indirectly
conjugated to drugs, toxins, radionuclides and the like, and these
conjugates used for in vivo diagnostic or therapeutic applications.
Moreover, antibodies to zalpha11 or fragments thereof may be used
in vitro to detect denatured zalpha11 or fragments thereof in
assays, for example, Western Blots or other assays known in the
art.
[0159] Antibodies to zalpha11 are useful for tagging cells that
express the receptor and assaying Zalpha11 expression levels, for
affinity purification, within diagnostic assays for determining
circulating levels of soluble receptor polypeptides, analytical
methods employing fluorescence-activated cell sorting. Divalent
antibodies may be used as agonists to mimic the effect of the
zalpha11 ligand.
[0160] Antibodies herein can also be directly or indirectly
conjugated to drugs, toxins, radionuclides and the like, and these
conjugates used for in vivo diagnostic or therapeutic applications.
For instance, antibodies or binding polypeptides which recognize
zalpha11 of the present invention can be used to identify or treat
tissues or organs that express a corresponding anti-complementary
molecule (i.e., a zalpha11 receptor). More specifically,
anti-zalpha11 antibodies, or bioactive fragments or portions
thereof, can be coupled to detectable or cytotoxic molecules and
delivered to a mammal having cells, tissues or organs that express
the zalpha11 molecule.
[0161] Suitable detectable molecules may be directly or indirectly
attached to polypeptides that bind zalpha11 ("binding
polypeptides," including binding peptides disclosed above),
antibodies, or bioactive fragments or portions thereof. Suitable
detectable molecules include radionuclides, enzymes, substrates,
cofactors, inhibitors, fluorescent markers, chemiluminescent
markers, magnetic particles and the like. Suitable cytotoxic
molecules may be directly or indirectly attached to the polypeptide
or antibody, and include bacterial or plant toxins (for instance,
diphtheria toxin, Pseudomonas exotoxin, ricin, abrin and the like),
as well as therapeutic radionuclides, such as iodine-131,
rhenium-188 or yttrium-90 (either directly attached to the
polypeptide or antibody, or indirectly attached through means of a
chelating moiety, for instance). Binding polypeptides or antibodies
may also be conjugated to cytotoxic drugs, such as adriamycin. For
indirect attachment of a detectable or cytotoxic molecule, the
detectable or cytotoxic molecule can be conjugated with a member of
a complementary/anticomplementary pair, where the other member is
bound to the binding polypeptide or antibody portion. For these
purposes, biotin/streptavidin is an exemplary
complementary/anticomplementary pair.
[0162] In another embodiment, binding polypeptide-toxin fusion
proteins or antibody-toxin fusion proteins can be used for targeted
cell or tissue inhibition or ablation (for instance, to treat
cancer cells or tissues). Alternatively, if the binding polypeptide
has multiple functional domains (i.e., an activation domain or a
ligand binding domain, plus a targeting domain), a fusion protein
including only the targeting domain may be suitable for directing a
detectable molecule, a cytotoxic molecule or a complementary
molecule to a cell or tissue type of interest. In instances where
the fusion protein including only a single domain includes a
complementary molecule, the anti-complementary molecule can be
conjugated to a detectable or cytotoxic molecule. Such
domain-complementary molecule fusion proteins thus represent a
generic targeting vehicle for cell/tissue-specific delivery of
generic anti-complementary-detectable/cytotoxic molecule
conjugates.
[0163] In another embodiment, zalpha11 binding polypeptide-cytokine
or antibody-cytokine fusion proteins can be used for enhancing in
vivo killing of target tissues (for example, blood, lymphoid,
colon, and bone marrow cancers), if the binding
polypeptide-cytokine or anti-zalpha11 antibody targets the
hyperproliferative cell (See, generally, Homick et al., Blood
89:4437-47, 1997). They described fusion proteins enable targeting
of a cytokine to a desired site of action, thereby providing an
elevated local concentration of cytokine. Suitable anti-zalpha11
antibodies target an undesirable cell or tissue (i.e., a tumor or a
leukemia), and the fused cytokine mediates improved target cell
lysis by effector cells. Suitable cytokines for this purpose
include interleukin 2 and granulocyte-macrophage colony-stimulating
factor (GM-CSF), for instance.
[0164] Alternatively, zalpha11 binding polypeptide or antibody
fusion proteins described herein can be used for enhancing in vivo
killing of target tissues by directly stimulating a
zalpha11-modulated apoptotic pathway, resulting in cell death of
hyperproliferative cells expressing zalpha11.
[0165] The bioactive binding polypeptide or antibody conjugates
described herein can be delivered orally, intravenously,
intraarterially or intraductally, or may be introduced locally at
the intended site of action.
[0166] Four-helix bundle cytokines that bind to cytokine receptors
as well as other proteins produced by activated lymphocytes play an
important biological role in cell differentiation, activation,
recruitment and homeostasis of cells throughout the body.
Therapeutic utility includes treatment of diseases which require
immune regulation including autoimmune diseases, such as,
rheumatoid arthritis, multiple sclerosis, myasthenia gravis,
systemic lupus erythomatosis and diabetes. Zalpha 11 antagonists or
agonists, including soluble receptors and the natural ligand, may
be important in the regulation of inflammation, and therefore would
be useful in treating rheumatoid arthritis, asthma, ulcerative
colitis, inflammatory bowel disease, Crohn's disease, and sepsis.
There may be a role of zalpha11 antagonists or agonists, including
soluble receptors and the natural ligand, in mediating
tumorgenesis, and therefore would be useful in the treatment of
cancer. Zalpha11 antagonists or agonists, including soluble
receptors and the natural ligand, may be a potential therapeutic in
suppressing the immune system which would be important for reducing
graft rejection. Zalpha11 Ligand may have usefulness in prevention
of graft vs. host disease.
[0167] Alternatively, zalpha11 antagonists or agonists, including
soluble receptors and the natural ligand may activate the immune
system which would be important in boosting immunity to infectious
diseases, treating immunocompromised patients, such as HIV+
patient, or in improving vaccines. In particular, zalpha11
antagonists or agonists, including soluble receptors and the
natural ligand can modulate, stimulate or expand NK cells, or their
progenitors, and would provide therapeutic value in treatment of
viral infection, and as an anti-neoplastic factor. NK cells are
thought to play a major role in elimination of metastatic tumor
cells and patients with both metastases and solid tumors have
decreased levels of NK cell activity (Whiteside et. al., Curr. Top.
Microbiol. Immunol. 230:221-244, 1998).
[0168] Polynucleotides encoding zalpha11 polypeptides are useful
within gene therapy applications where it is desired to increase or
inhibit zalpha11 activity. If a mammal has a mutated or absent
zalpha11 gene, the zalpha11 gene can be introduced into the cells
of the mammal. In one embodiment, a gene encoding a zalpha11
polypeptide is introduced in vivo in a viral vector. Such vectors
include an attenuated or defective DNA virus, such as, but not
limited to, herpes simplex virus (HSV), papillomavirus, Epstein
Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the
like. Defective viruses, which entirely or almost entirely lack
viral genes, are preferred. A defective virus is not infective
after introduction into a cell. Use of defective viral vectors
allows for administration to cells in a specific, localized area,
without concern that the vector can infect other cells. Examples of
particular vectors include, but are not limited to, a defective
herpes simplex virus 1 (HSV1) vector (Kaplitt et al., Molec. Cell.
Neurosci. 2:320-30, 1991); an attenuated adenovirus vector, such as
the vector described by Stratford-Perricaudet et al., J. Clin.
Invest. 90:626-30, 1992; and a defective adeno-associated virus
vector (Samulski et al., J. Virol. 61:3096-101, 1987; Samulski et
al., J. Virol. 63:3822-8, 1989).
[0169] In another embodiment, a zalpha11 gene can be introduced in
a retroviral vector, e.g., as described in Anderson et al., U.S.
Pat. No. 5,399,346; Mann et al. Cell 33:153, 1983; Temin et al.,
U.S. Pat. No. 4,650,764; Temin et al., U.S. Pat. No. 4,980,289;
Markowitz et al., J. Virol. 62:1120, 1988; Temin et al., U.S. Pat.
No. 5,124,263; International Patent Publication No. WO 95/07358,
published Mar. 16, 1995 by Dougherty et al.; and Kuo et al., Blood
82:845, 1993. Alternatively, the vector can be introduced by
lipofection in vivo using liposomes. Synthetic cationic lipids can
be used to prepare liposomes for in vivo transfection of a gene
encoding a marker (Felgner et al., Proc. Natl. Acad. Sci. USA
84:7413-7, 1987; Mackey et al., Proc. Natl. Acad. Sci. USA
85:8027-31, 1988). The use of lipofection to introduce exogenous
genes into specific organs in vivo has certain practical
advantages. Molecular targeting of liposomes to specific cells
represents one area of benefit. More particularly, directing
transfection to particular cells represents one area of benefit.
For instance, directing transfection to particular cell types would
be particularly advantageous in a tissue with cellular
heterogeneity, such as the pancreas, liver, kidney, and brain.
Lipids may be chemically coupled to other molecules for the purpose
of targeting. Targeted peptides (e.g., hormones or
neurotransmitters), proteins such as antibodies, or non-peptide
molecules can be coupled to liposomes chemically.
[0170] It is possible to remove the target cells from the body; to
introduce the vector as a naked DNA plasmid; and then to re-implant
the transformed cells into the body. Naked DNA vectors for gene
therapy can be introduced into the desired host cells by methods
known in the art, e.g., transfection, electroporation,
microinjection, transduction, cell fusion, DEAE dextran, calcium
phosphate precipitation, use of a gene gun or use of a DNA vector
transporter. See, e.g., Wu et al., J. Biol. Chem. 267:963-7, 1992;
Wu et al., J. Biol. Chem. 263:14621-4, 1988.
[0171] Antisense methodology can be used to inhibit zalpha11 gene
transcription, such as to inhibit cell proliferation in vivo.
Polynucleotides that are complementary to a segment of a
zalpha11-encoding polynucleotide (e.g., a polynucleotide as set
froth in SEQ ID NO:1) are designed to bind to zalpha11-encoding
mRNA and to inhibit translation of such mRNA. Such antisense
polynucleotides are used to inhibit expression of zalpha11
polypeptide-encoding genes in cell culture or in a subject.
[0172] In addition, as a cell surface molecule, zalpha11
polypeptide can be used as a target to introduce gene therapy into
a cell. This application would be particularly appropriate for
introducing therapeutic genes into cells in which zalpha11 is
normally expressed, such as lymphoid tissue and PBLs, or cancer
cells which express zalpha11 polypeptide. For example, viral gene
therapy, such as described above, can be targeted to specific cell
types in which express a cellular receptor, such as zalpha11
polypeptide, rather than the viral receptor. Antibodies, or other
molecules that recognize zalpha11 molecules on the target cell's
surface can be used to direct the virus to infect and administer
gene therapeutic material to that target cell. See, Woo, S. L. C,
Nature Biotech. 14:1538, 1996; Wickham, T. J. et al, Nature
Biotech. 14:1570-1573, 1996; Douglas, J. T et al., Nature Biotech.
14:1574-1578, 1996; Rihova, B., Crit. Rev. Biotechnol. 17:149-169,
1997; and Vile, R. G. et al., Mol. Med. Today 4:84-92, 1998. For
example, a bispecific antibody containing a virus-neutralizing Fab
fragment coupled to a zalpha11-specific antibody can be used to
direct the virus to cells expressing the zalpha11 receptor and
allow efficient entry of the virus containing a genetic element
into the cells. See, for example, Wickham, T. J., et al., J. Virol.
71:7663-7669, 1997; and Wickham, T. J., et al., J. Virol.
70:6831-6838, 1996.
[0173] The present invention also provides reagents which will find
use in diagnostic applications. For example, the zalpha11 gene, a
probe comprising zalpha11 DNA or RNA or a subsequence thereof can
be used to determine if the zalpha11 gene is present on chromosome
16 or if a mutation has occurred. Zalpha11 is located at the
16p11.1 region of chromosome 16 (See, Example 3). Detectable
chromosomal aberrations at the zalpha11 gene locus include, but are
not limited to, aneuploidy, gene copy number changes, insertions,
deletions, restriction site changes and rearrangements. Such
aberrations can be detected using polynucleotides of the present
invention by employing molecular genetic techniques, such as
restriction fragment length polymorphism (RFLP) analysis,
fluorescence in situ hybridization methods, short tandem repeat
(STR) analysis employing PCR techniques, and other genetic linkage
analysis techniques known in the art (Sambrook et al., ibid.;
Ausubel et. al., ibid.; Marian, Chest 108:255-65, 1995).
[0174] The precise knowledge of a gene's position can be useful for
a number of purposes, including: 1) determining if a sequence is
part of an existing contig and obtaining additional surrounding
genetic sequences in various forms, such as YACs, BACs or cDNA
clones; 2) providing a possible candidate gene for an inheritable
disease which shows linkage to the same chromosomal region; and 3)
cross-referencing model organisms, such as mouse, which may aid in
determining what function a particular gene might have.
[0175] The zalpha11 gene is located at the 16p11.1 region of
chromosome 16. Several genes of known function map to this region.
For example, the interleukin 4 (IL-4) cytokine receptor
alpha-subunit, a member of the hematopoietin receptor family, maps
to 16p12.1-p11.2. This subunit may form a heterodimer with
zalpha11. Moreover, zalpha11 polynucleotide probes can be used to
detect abnormalities or genotypes associated with defects in IL-4
receptor, such as those that are implicated in some allergic
inflammatory disorders and asthma (Deichman, K. A. et al., Exp.
Allergy 28:151-155; 1998; Mitsuyasu, H. et al., Nature Genet.
19:119-120, 1998). In addition, zalpha11 polynucleotide probes can
be used to detect abnormalities or genotypes associated with
inflammatory bowel disease, where a susceptibility marker maps to
16p12-q13 (Cho, J. H. et al, Proc. Nat. Acad. Sci. 95:7502-7507,
1998). Further, zalpha11 polynucleotide probes can be used to
detect abnormalities or genotypes associated with hemoglobin loci
located at 16pter-p13.3, and particularly hemoglobin-alpha defects
associated with alpha-thalassemia syndromes, such as hydrops
fetalis (for review, see Chui, M. P., and Waye, J. S. Blood
91:2213-2222, 1998). Moreover, amongst other genetic loci, those
for Wilms tumor, type III (16q), Rubenstein-Taybi syndrome
(16p13.3), severe infantile polycystic kidney disease (16p13.3),
all manifest themselves in human disease states as well as map to
this region of the human genome. See the Online Mendellian
Inheritance of Man (OMIM) gene map, and references therein, for
this region of chromosome 16 on a publicly available WWW server
(http://www3.ncbi.nlm.nih.gov/htbin-post/Omim/getmap?chromosome=16p11.1).
All of these serve as possible candidate genes for an inheritable
disease which show linkage to the same chromosomal region as the
zalpha11 gene.
[0176] Similarly, defects in the zalpha11 locus itself may result
in a heritable human disease state. Molecules of the present
invention, such as the polypeptides, antagonists, agonists,
polynucleotides and antibodies of the present invention would aid
in the detection, diagnosis prevention, and treatment associated
with a zalpha11 genetic defect.
[0177] Mice engineered to express the zalpha11 gene, referred to as
"transgenic mice," and mice that exhibit a complete absence of
zalpha11 gene function, referred to as "knockout mice," may also be
generated (Snouwaert et al., Science 257:1083, 1992; Lowell et al.,
Nature 366:740-42, 1993; Capecchi, M. R., Science 244: 1288-1292,
1989; Palmiter, R. D. et al. Annu Rev Genet. 20: 465-499, 1986).
For example, transgenic mice that over-express zalpha11, either
ubiquitously or under a tissue-specific or tissue-restricted
promoter can be used to ask whether over-expression causes a
phenotype. For example, over-expression of a wild-type zalpha11
polypeptide, polypeptide fragment or a mutant thereof may alter
normal cellular processes, resulting in a phenotype that identifies
a tissue in which zalpha11 expression is functionally relevant and
may indicate a therapeutic target for the zalpha11, its agonists or
antagonists. For example, a preferred transgenic mouse to engineer
is one that expresses a "dominant-negative" phenotype, such as one
that over-expresses the zalpha11 extracellular cytokine binding
domain with the transmembrane domain attached (approximately amino
acids 20 (Cys) to 255 (Leu) of SEQ ID NO:2). Moreover, such
over-expression may result in a phenotype that shows similarity
with human diseases. Similarly, knockout zalpha11 mice can be used
to determine where zalpha11 is absolutely required in vivo. The
phenotype of knockout mice is predictive of the in vivo effects of
that a zalpha11 antagonist, such as those described herein, may
have. The mouse or the human zalpha11 cDNA can be used to isolate
murine zalpha11 mRNA, cDNA and genomic DNA, which are subsequently
used to generate knockout mice. These mice may be employed to study
the zalpha11 gene and the protein encoded thereby in an in vivo
system, and can be used as in vivo models for corresponding human
diseases. Moreover, transgenic mice expression of zalpha11
antisense polynucleotides or ribozymes directed against zalpha11,
described herein, can be used analogously to transgenic mice
described above.
[0178] For pharmaceutical use, the soluble receptor polypeptides of
the present invention are formulated for parenteral, particularly
intravenous or subcutaneous, delivery according to conventional
methods. Intravenous administration will be by bolus injection or
infusion over a typical period of one to several hours. In general,
pharmaceutical formulations will include a zalpha11 soluble
receptor polypeptide in combination with a pharmaceutically
acceptable vehicle, such as saline, buffered saline, 5% dextrose in
water or the like. Formulations may further include one or more
excipients, preservatives, solubilizers, buffering agents, albumin
to prevent protein loss on vial surfaces, etc. Methods of
formulation are well known in the art and are disclosed, for
example, in Remington: The Science and Practice of Pharmacy,
Gennaro, ed., Mack Publishing Co., Easton, Pa., 19th ed., 1995.
Therapeutic doses will generally be in the range of 0.1 to 100
.mu.g/kg of patient weight per day, preferably 0.5-20 mg/kg per
day, with the exact dose determined by the clinician according to
accepted standards, taking into account the nature and severity of
the condition to be treated, patient traits, etc. Determination of
dose is within the level of ordinary skill in the art. The proteins
may be administered for acute treatment, over one week or less,
often over a period of one to three days or may be used in chronic
treatment, over several months or years. In general, a
therapeutically effective amount of zalpha11 soluble receptor
polypeptide is an amount sufficient to produce a clinically
significant effect.
[0179] The invention is further illustrated by the following
non-limiting examples.
EXAMPLES
Example 1
Identification of Human Zalpha11 Using an EST Sequence to Obtain
Full-length Zalpha11
[0180] Scanning of a translated DNA database resulted in
identification of an expressed sequence tag (EST) sequence found to
be a member of the Class I Cytokine Receptor family and designated
zalpha11.
[0181] Confirmation of the EST sequence was made by sequence
analyses of the cDNA from which the EST originated. This cDNA clone
was obtained and sequenced using the following primers: ZC 447 (SEQ
ID NO:5), ZC 976 (SEQ ID NO:6), ZC 19345 (SEQ ID NO:7), ZC 19346
(SEQ ID NO:8), ZC 19349 (SEQ ID NO:9), and ZC 19350 (SEQ ID NO:10),
ZC 19458 (SEQ ID NO:11), ZC 19459 (SEQ ID NO:12), ZC 19460 (SEQ ID
NO:13), ZC 19461 (SEQ ID NO:14), ZC 19572 (SEQ ID NO:15), ZC 19573
(SEQ ID NO:16), ZC 19657 (SEQ ID NO:17). The insert was 2945 bp,
and was full-length.
Example 2
Tissue Distribution
[0182] Northern blot analysis was performed using Human Multiple
Tissue Northern.TM. Blots (MTN I, MTN II, and MTN III) (Clontech).
The cDNA described in Example 1 was used in a PCR reaction using
oligos ZC 19,181 (SEQ ID NO:18) and ZC 19,182 (SEQ ID NO:19) as
primers. PCR conditions were as follows: 94.degree. C. for 1.5
minutes; 35 cycles at 94.degree. C. for 15 seconds then 68.degree.
C. for 30 seconds; 72.degree. C. for 10 minutes; 4.degree. C.
overnight. A sample of the PCR reaction product was run on a 1.5%
agarose gel. A band of the expected size of 175 bp was seen. The
175 bp PCR fragment, was gel purified using a commercially
available kit (QiaexII.TM.; Qiagen) and then radioactively labeled
with .sup.32P-dCTP using Rediprime II.TM. (Amersham), a random
prime labeling system, according to the manufacturer's
specifications. The probe was then purified using a Nuc-Trap.TM.
column (Stratagene) according to the manufacturer's instructions.
ExpressHyb.TM. (Clontech) solution was used for prehybridization
and as a hybridizing solution for the Northern blots. Hybridization
took place overnight at 65.degree. C. using 1-2.times.10.sup.6
cpm/ml of labeled probe. The blots were then washed 4 times for 15
minutes in 2.times.SSC/1% SDS at 25.degree. C., followed by a wash
in 0.1.times.SSC/0.1% SDS at 50.degree. C. Transcripts of
approximately 3 kb and 5 kb were detected in lymph node, peripheral
blood leukocytes, and thymus.
[0183] Dot Blots were also performed using Human RNA Master
Blots.TM. (Clontech). The methods and conditions for the Dot Blots
are the same as for the Multiple Tissue Blots described above. Dot
blot had strongest signals in thymus, lymph node, and spleen.
[0184] Northern analysis was also performed using Human Cancer Cell
Line MTN.TM. (Clontech). The cDNA described in Example 1 was used
in a PCR reaction using oligos ZC19,907 (SEQ ID NO:20) and ZC19,908
(SEQ ID NO:21) as primers. PCR conditions were as follows: 35
cycles at 95.degree. C. for 1 minute, then 60.degree. C. for 1
minute; 72.degree. C. for 1.5 minutes; 72.degree. C. for 10
minutes; 4.degree. C. overnight. A sample of the PCR reaction
product was run on a 1.5% agarose gel. A band of the expected size
of 1.2 kb was seen. The 1.2 kb PCR fragment, was gel purified using
a commercially available kit (QiaQuick.TM. Gel Extraction Kit;
Qiagen) and then radioactively labeled with .sup.32P-dCTP using
Prime-It II.TM. (Stratagene), a random prime labeling system,
according to the manufacturer's specifications. The probe was then
purified using a Nuc-Trap.TM. column (Stratagene) according to the
manufacturer's instructions. ExpressHyb.TM. (Clontech) solution was
used for prehybridization and as a hybridizing solution for the
Northern blots. Hybridization took place for 2 hours at 65.degree.
C. using 1-2.times.10.sup.6 cpm/ml of labeled probe. The blots were
then washed 4 times for 15 minutes in 2.times.SSC/1% SDS at
25.degree. C., followed by two 30 minute washes in
0.1.times.SSC/0.1% SDS at 50.degree. C. A strong signal was seen in
the Raji cell line derived from Burkitt's lymphoma.
Example 3
PCR-Based Chromosomal Mapping of the Zalpha11 Gene
[0185] Zalpha11 was mapped to chromosome 16 using the commercially
available "GeneBridge 4 Radiation Hybrid Panel" (Research Genetics,
Inc., Huntsville, Ala.). The GeneBridge 4 Radiation Hybrid Panel
contains PCRable DNAs from each of 93 radiation hybrid clones, plus
two control DNAs (the HFL donor and the A23 recipient). A publicly
available WWW server
(http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl) allows
mapping relative to the Whitehead Institute/MIT Center for Genome
Research's radiation hybrid map of the human genome (the "WICGR"
radiation hybrid map) which was constructed with the GeneBridge 4
Radiation Hybrid Panel.
[0186] For the mapping of Zalpha11 with the "GeneBridge 4 RH
Panel", 20 .mu.l reactions were set up in a 96-well microtiter
plate (Stratagene, La Jolla, Calif.) and used in a "RoboCycler
Gradient 96" thermal cycler (Stratagene). Each of the 95 PCR
reactions consisted of 2 .mu.l 10.times.PCR reaction buffer
(Clontech Laboratories, Inc., Palo Alto, Calif.), 1.6 .mu.l dNTPs
mix (2.5 mM each, Perkin-Elmer, Foster City, Calif.), 1 .mu.l sense
primer, ZC 19,954, (SEQ ID NO:22), 1 .mu.l antisense primer, ZC
19,955 (SEQ ID NO:23), 2 .mu.l "RediLoad" (Research Genetics, Inc.,
Huntsville, Ala.), 0.4 .mu.l 50.times. Advantage KlenTaq Polymerase
Mix (Clontech), 25 ng of DNA from an individual hybrid clone or
control and ddH2O for a total volume of 20 .mu.l. The reactions
were overlaid with an equal amount of mineral oil and sealed. The
PCR cycler conditions were as follows: an initial 1 cycle 4 minute
denaturation at 94.degree. C.; 35 cycles of a 45 seconds at
94.degree. C., 45 seconds at 68.degree. C., and 1 minute at
72.degree. C.; followed by 7 minutes at 72.degree. C. The reactions
were separated by electrophoresis on a 2% agarose gel (Life
Technologies).
[0187] The results showed that zalpha11 maps 9.54 cR.sub.--3000
from the framework marker WI-3768 on the chromosome 16 WICGR
radiation hybrid map. Proximal and distal framework markers were
WI-3768 and TIGR-A002K05, respectively. The use of surrounding
markers positions Zalpha11 in the 16p11.1 region on the integrated
LDB chromosome 16 map (The Genetic Location Database, University of
Southhampton, WWW server:
http://cedar.genetics.soton.ac.uk/public_html/).
Example 4
Construction of Human MPL-Zalpha11 Polypeptide Chimera: MPL
Extracellular and TM Domain Fused to the Zalpha11 Intracellular
Signaling Domain
[0188] The extracellular and transmembrane domains of the MPL
receptor were isolated from a plasmid containing the MPL receptor
(PHZ1/MPL plasmid) using PCR with primers ZC17,212 (SEQ ID NO:24)
and ZC19,914 (SEQ ID NO:25). The reaction conditions were as
follows: 95.degree. C. for 1 min.; 35 cycles at 95.degree. C. for 1
min., 45.degree. C. for 1 min., 72.degree. C. for 2 min.; followed
by 72.degree. C. at 10 min.; then a 10.degree. C. soak. The PCR
product was run on a 1% low melting point agarose (Boerhinger
Mannheim, Indianapolis, Ind.) and the approximately 1.5 kb MPL
receptor fragment isolated using Qiaquick.TM. gel extraction kit
(Qiagen) as per manufacturer's instructions.
[0189] The intracellular domains of zalpha11 were isolated from a
plasmid containing zalpha11 receptor cDNA using PCR with primers
ZC19,913 (SEQ ID NO:26) and ZC20,097 (SEQ ID NO:27). The
polynucleotide sequence corresponding to the zalpha11 receptor
coding sequence is shown in SEQ ID NO:1 from nucleotide 69 to 1682.
The reaction conditions were as per above. The PCR product was run
on a 1% low melting point agarose (Boerhinger Mannheim) and the
approximately 900 bp zalpha11 fragment isolated using Qiaquick gel
extraction kit as per manufacturer's instructions.
[0190] Each of the isolated fragments described above were mixed at
a 1:1 volumetric ratio and used in a PCR reaction using ZC17,212
(SEQ ID NO:24) and ZC20,097 (SEQ ID NO:27) to create the
MPL-zalpha11 chimera. The reaction conditions were as follows:
95.degree. C. for 1 min.; 35 cycles at 95.degree. C. for 1 min.,
55.degree. C. for 1 min., 72.degree. C. for 2 min.; followed by
72.degree. C. at 10 min.; then a 10.degree. C. soak. The entire PCR
product was run on a 1% low melting point agarose (Boehringer
Mannheim) and the approximately 2.4 kb MPL-zalpha11 chimera
fragment isolated using Qiaquick gel extraction kit (Qiagen) as per
manufacturer's instructions. The MPL-zalpha11 chimera fragment was
digested with EcoRI (BRL) and XbaI (Boerhinger Mannheim) as per
manufacturer's instructions. The entire digest was run on a 1% low
melting point agarose (Boehringer Mannheim) and the cleaved
MPL-zalpha11 chimera isolated using Qiaquick.TM. gel extraction kit
(Qiagen) as per manufacturer's instructions. The resultant cleaved
MPL-zalpha11 chimera was inserted into an expression vector as
described below.
[0191] Recipient expression vector pZP-5N was digested with EcoRI
(BRL) and HindIII (BRL) as per manufacturer's instructions, and gel
purified as described above. This vector fragment was combined with
the EcoRI and XbaI cleaved MPL-zalpha11 chimera isolated above and
a XbaI/HindIII linker fragment in a ligation reaction. The ligation
was run using T4 Ligase (BRL), at 15.degree. C. overnight. A sample
of the ligation was electroporated in to DH10B ElectroMAX.TM.
electrocompetent E. coli cells (25 .mu.F, 200.OMEGA., 2.3V).
Transformants were plated on LB+Ampicillin plates and single
colonies screened by PCR to check for the MPL-zalpha11 chimera
using ZC17,212 (SEQ ID NO:24) and ZC20,097 (SEQ ID NO:27) using the
PCR conditions as described above.
[0192] Confirmation of the MPL-zalpha11 chimera sequence was made
by sequence analyses using the following primers: ZC12,700 (SEQ ID
NO:28), ZC5,020 (SEQ ID NO:29), ZC6,675 (SEQ ID NO:30), ZC7,727
(SEQ ID NO:31), ZC8,290 (SEQ ID NO:32), ZC19,572 (SEQ ID NO:15),
ZC6,622 (SEQ ID NO:33), ZC7,736 (SEQ ID NO:34), and ZC9,273 (SEQ ID
NO:35). The insert was approximately 2.4 bp, and was
full-length.
Example 5
MPL-Zalpha11 Chimera Based Proliferation in BAF3 Assay Using Alamar
Blue
A. Construction of BaF3 Cells Expressing MPL-Zalpha11 Chimera
[0193] BaF3, an interleukin-3 (IL-3) dependent pre-lymphoid cell
line derived from murine bone marrow (Palacios and Steinmetz, Cell
41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6:
4133-4135, 1986), was maintained in complete media (RPMI medium
(JRH Bioscience Inc., Lenexa, Kans.) supplemented with 10%
heat-inactivated fetal calf serum, 2 ng/ml murine IL-3 (m/L-3) (R
& D, Minneapolis, Minn.), 2 mM L-glutaMax-1.TM. (Gibco BRL), 1
mM Sodium Pyruvate (Gibco BRL), and PSN antibiotics (GIBCO BRL)).
Prior to electroporation, pZP-5N/MPL-zalpha11 DNA (Example 4) was
prepared and purified using a Qiagen Maxi Prep kit (Qiagen) as per
manufacturer's instructions. BaF3 cells for electroporation were
washed once in RPMI media and then resuspended in RPMI media at a
cell density of 10.sup.7 cells/ml. One ml of resuspended BaF3 cells
was mixed with 30 .mu.g of the pZP-5N/MPL-zalpha11 plasmid DNA and
transferred to separate disposable electroporation chambers (GIBCO
BRL). Following a 15 minute incubation at room temperature the
cells were given two serial shocks (800 lFad/300 V.; 1180 lFad/300
V.) delivered by an electroporation apparatus (CELL-PORATOR.TM.;
GIBCO BRL). After a 5 minute recovery time, the electroporated
cells were transferred to 50 ml of complete media and placed in an
incubator for 15-24 hours (37.degree. C., 5% CO.sub.2). The cells
were then spun down and resuspended in 50 ml of complete media
containing Geneticin.TM. (Gibco) selection (500 .mu.g/ml G418) in a
T-162 flask to isolate the G418-resistant pool. Pools of the
transfected BaF3 cells, hereinafter called BaF3/MPL-zalpha11 cells,
were assayed for signaling capability as described below.
B. Testing the Signaling Capability of the BaF3/MPL-Zalpha11 Cells
Using an Alamar Blue Proliferation Assay
[0194] BaF3/MPL-zalpha11 cells were spun down and washed in the
complete media, described above, but without mIL-3 (hereinafter
referred to as "mIL-3 free media"). The cells were spun and washed
3 times to ensure the removal of the mIL-3. Cells were then counted
in a hemacytometer. Cells were plated in a 96-well format at 5000
cells per well in a volume of 100 .mu.l per well using the mIL-3
free media.
[0195] Proliferation of the BaF3/MPL-zalpha11 cells was assessed
using thrombopoietin (TPO) diluted with mIL-3 free media to 500
ng/ml, 250 ng/ml, 125 ng/ml, 62 ng/ml, 30 ng/ml, 15 ng/ml, 7.5
ng/ml, 3.75 ng/ml, 1.8 ng/ml, 0.9 ng/ml, 0.5 ng/ml and 0.25 ng/ml
concentrations. 100 .mu.l of the diluted TPO was added to the
BaF3/MPL-zalpha11 cells. The total assay volume is 200 .mu.l.
Negative controls were run in parallel using mIL-3 free media only,
without the addition of TPO. The assay plates were incubated at
37.degree. C., 5% CO.sub.2 for 3 days at which time Alamar Blue
(Accumed, Chicago, Ill.) was added at 20 .mu.l/well. Alamar Blue
gives a fluourometric readout based on number of live cells, and is
thus a direct measurement of cell proliferation in comparison to a
negative control. Plates were again incubated at 37.degree. C., 5%
CO.sub.2 for 24 hours. Plates were read on the Fmax.TM. plate
reader (Molecular Devices Sunnyvale, Calif.) using the SoftMax.TM.
Pro program, at wavelengths 544 (Excitation) and 590
(Emmission).
[0196] Results confirmed the signaling capability of the
intracellular portion of the zalpha11 receptor as the
thrombopoietin induced proliferation at approximately 10 fold over
back ground at 62 ng/ml and greater.
Example 6
Construction of Expression Vector Expressing Full-length
Zalpha11
[0197] The entire zalpha11 receptor was isolated from a plasmid
containing zalpha11 receptor cDNA using PCR with primers ZC19,905
(SEQ ID NO:36) and ZC19,906 (SEQ ID NO:37). The reaction conditions
were as follows: 95.degree. C. for 1 min; 35 cycles at 95.degree.
C. for 1 min, 55.degree. C. for 1 min, 72.degree. C. for 2 min;
followed by 72.degree. C. at 10 min; then a 10.degree. C. soak. The
PCR product was run on a 1% low melting point agarose (Boerhinger
Mannheim) and the approximately 1.5 kb zalpha11 cDNA isolated using
Qiaquick.TM. gel extraction kit (Qiagen) as per manufacturer's
instructions.
[0198] The purified zalpha11 cDNA was digested with BamHI
(Boerhinger Mannheim) and EcoRI (BRL) as per manufacturer's
instructions. The entire digest was run on a 1% low melting point
agarose (Boerhinger Mannheim) and purified the cleaved zalpha11
fragment using Qiaquick gel extraction kit as per manufacturer's
instructions. The resultant cleaved zalpha11 chimera was inserted
into an expression vector as described below.
[0199] Recipient expression vector pZP-5N was digested with BamHI
(Boerhinger Mannheim) and EcoRI (BRL) as per manufacturer's
instructions, and gel purified as described above. This vector
fragment was combined with the BamHI and EcoRI cleaved zalpha11
fragment isolated above in a ligation reaction. The ligation was
run using T4 Ligase (BRL), at 15.degree. C. overnight. A sample of
the ligation was electroporated in to DH10B electroMAX.TM.
electrocompetent E. coli cells (25 .mu.F, 200.OMEGA., 2.3V).
Transformants were plated on LB+Ampicillin plates and single
colonies screened by PCR to check for the zalpha11 sequence using
ZC19,905 (SEQ ID NO:36) and ZC19,906 (SEQ ID NO:37) using the PCR
conditions as described above.
[0200] Confirmation of the MPL-zalpha11 sequence was made by
sequence analyses using the following primers: ZC12,700 (SEQ ID
NO:28), ZC5,020 (SEQ ID NO:29), ZC20,114 (SEQ ID NO:38), ZC19,459
(SEQ ID NO:12), ZC19,954 (SEQ ID NO:39), and ZC20,116 (SEQ ID
NO:40). The insert was approximately 1.6 kb, and was
full-length.
Example 7
Zalpha11 Based Proliferation in BAF3 Assay Using Alamar Blue
A. Construction of BaF3 Cells Expressing Zalpha11 Receptor
[0201] BaF3 cells expressing the full-length zalpha11 receptor were
constructed as per Example 5A above, using 30 .mu.g of the zalpha11
expression vector, described in Example 6 above. The BaF3 cells
expressing the zalpha11 receptor mRNA were designated as
BaF3/zalpha11. These cells were used to screen for a zalpha11
activity as described below in Examples 8 and 12.
Example 8
Screening for zalpha11 Activity Using BaF3/Zalpha11 Cells Using an
Alamar Blue Proliferation Assay
A. Monkey Primary Source Used to Test for Presence of Zalpha11
Activity
[0202] Conditioned media from primary monkey spleen cells was used
to test for the presence of activity as described below. Monkey
spleen cells were activated with 5 ng/ml
Phorbol-12-myristate-13-acetate (PMA) (Calbiochem, San Diego,
Calif.), and 0.5 .mu.g/ml Ionomycin.TM. (Calbiochem) for 72 h. The
supernatant from the stimulated monkey spleen cells was used to
assay proliferation of the BaF3/zalpha11 cells as described
below.
B. Screening for Zalpha11 Activity Using BaF3/Zalpha11 Cells Using
an Alamar Blue Proliferation Assay
[0203] BaF3/Zalpha11 cells were spun down and washed in mIL-3 free
media. The cells were spun and washed 3 times to ensure the removal
of the mIL-3. Cells were then counted in a hemacytometer. Cells
were plated in a 96-well format at 5000 cells per well in a volume
of 100 .mu.l per well using the mIL-3 free media.
[0204] Proliferation of the BaF3/Zalpha11 cells was assessed using
conditioned media from activated monkey spleen (see Example 8A,
above) was diluted with mIL-3 free media to 50%, 25%, 12.5%, 6.25%,
3.125%, 1.5%, 0.75% and 0.375% concentrations. 100 .mu.l of the
diluted conditioned media was added to the BaF3/Zalpha11 cells. The
total assay volume is 200 .mu.l. The assay plates were incubated at
37.degree. C., 5% CO.sub.2 for 3 days at which time Alamar Blue
(Accumed, Chicago, Ill.) was added at 20 .mu.l/well. Plates were
again incubated at 37.degree. C., 5% CO.sub.2 for 24 hours. Plates
were read on the Fmax.TM. plate reader (Molecular devices) as
described above (Example 5).
[0205] Results confirmed the proliferative response of the
BaF3/Zalpha11 cells to a factor present in the activate monkey
spleen conditioned media. The response, as measured, was
approximately 4-fold over background at the 50% concentration. The
BaF3 wild type cells did not proliferate in response to this
factor, showing that this factor is specific for the Zalpha11
receptor.
C. Human Primary Source Used to Isolate Zalpha11 Activity
[0206] 100 ml blood draws were taken from each of six donors. The
blood was drawn using 10.times.10 ml vacutainer tubes containing
heparin. Blood was pooled from six donors (600 ml), diluted 1:1 in
PBS, and separated using a Ficoll-Paque.RTM. PLUS (Pharmacia
Biotech, Uppsala, Sweden). The isolated primary human cell yield
after separation on the ficoll gradient was 1.2.times.10.sup.9
cells.
[0207] Cells were suspended in 9.6 ml MACS buffer (PBS, 0.5% EDTA,
2 mM EDTA). 1.6 ml of cell suspension was removed and 0.4 ml CD3
microbeads (Miltenyi Biotec, Auburn, Calif.) added. The mixture was
incubated for 15 min. at 4.degree. C. These cells labeled with CD3
beads were washed with 30 ml MACS buffer, and then resuspended in 2
ml MACS buffer.
[0208] A VS+ column (Miltenyi) was prepared according to the
manufacturer's instructions. The VS+ column was then placed in a
VarioMACS.TM. magnetic field (Miltenyi). The column was
equilibrated with 5 ml MACS buffer. The isolated primary human
cells were then applied to the column. The CD3 negative cells were
allowed to pass through. The column was rinsed with 9 ml (3.times.3
ml) MACS buffer. The column was then removed from the magnet and
placed over a 15 ml falcon tube. CD3+ cells were eluted by adding 5
ml MACS buffer to the column and bound cells flushed out using the
plunger provided by the manufacturer. The incubation of the cells
with the CD3 magnetic beads, washes, and VS+ column steps
(incubation through elution) above were repeated five more times.
The resulting CD3+ fractions from the six column separations were
pooled. The yield of CD3+ selected human T-cells were
3.times.10.sup.8 total cells.
[0209] A sample of the pooled CD3+ selected human T-cells was
removed for staining and sorting on a fluorescent antibody cell
sorter (FACS) to assess their purity. The CD3+ selected human
T-cells were 91% CD3+ cells.
[0210] The CD3+ selected human T-cells were activated by incubating
in RPMI+5% FBS+PMA 10 ng/ml and Ionomycin 0.5 .mu.g/ml (Calbiochem)
for 13 hours 37.degree. C. The supernatant from these activated
CD3+ selected human T-cells was tested for zalpha11 activity as
described below.
D. Testing Supernatant from Activated CD3+ Selected Human T-Cells
for Zalpha11 Activity Using BaF3/Zalpha11 Cells and an Alamar Blue
Proliferation Assay
[0211] BaF3/Zalpha11 cells were spun down and washed in mIL-3 free
media. The cells were spun and washed 3 times to ensure the removal
of the mIL-3. Cells were then counted in a hemacytometer. Cells
were plated in a 96-well format at 5000 cells per well in a volume
of 100 .mu.l per well using the mIL-3 free media.
[0212] Proliferation of the BaF3/Zalpha11 cells was assessed using
conditioned media from activated CD3+ selected human T-cells (see
Example 8C, above) diluted with mIL-3 free media to 50%, 25%,
12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. 100
.mu.l of the diluted conditioned media was added to the
BaF3/Zalpha11 cells. The total assay volume is 200 .mu.l. The assay
plates were incubated and assayed as described in Example 8B
above.
[0213] Results confirmed the proliferative response of the
BaF3/Zalpha11 cells to a factor present in the activated CD3+
selected human T-cell conditioned media. The response, as measured,
was approximately 10-fold over background at the 50% concentration.
The BaF3 wild type cells did not proliferate in response to this
factor, showing that this factor is specific for the Zalpha11
receptor.
Example 9
Construction of Mammalian Expression Vectors T that Express
Zalpha11 Soluble Receptors: Zalpha11CEE, Zalpha11CFLG, Zalpha11CHIS
and Zalph11-Fc4
A. Construction of Zalpha11 Mammalian Expression Vector Containing
Zalph11CEE, Zalph11CFLG and Zalph11CHIS
[0214] An expression vector was prepared for the expression of the
soluble, extracellular domain of the zalpha11 polypeptide,
pC4zalph11CEE, wherein the construct is designed to express a
zalpha11 polypeptide comprised of the predicted initiating
methionine and truncated adjacent to the predicted transmembrane
domain, and with a C-terminal Glu-Glu tag (SEQ ID NO:41).
[0215] A 700 bp PCR generated zalpha11 DNA fragment was created
using ZC19,931 (SEQ ID NO:42) and ZC19,932 (SEQ ID NO:43) as PCR
primers to add Asp718 and BamHI restriction sites. A plasmid
containing the zalpha11 receptor cDNA was used as a template. PCR
amplification of the zalpha11 fragment was performed as follows:
Twenty five cycles at 94C for 0.5 minutes; five cycles at
94.degree. C. for 10 seconds, 50.degree. C. for 30 seconds,
68.degree. C. for 45 seconds, followed by a 4.degree. C. hold. The
reaction was purified by chloroform/phenol extraction and
isopropanol precipitation, and digested with Asp718 and BamHI
(Gibco BRL) following manufacturer's protocol. A band of the
predicted size, 700 bp, was visualized by 1% agarose gel
electrophoresis, excised and the DNA was purified using a
QiaexII.TM. purification system (Qiagen) according the
manufacturer's instructions.
[0216] The excised DNA was subcloned into plasmid pC4EE which had
been cut with BamHI and Asp718. The pC4zalph11CEE expression vector
uses the native zalpha11 signal peptide and attaches the Glu-Glu
tag (SEQ ID NO:41) to the C-terminus of the zalpha11
polypeptide-encoding polynucleotide sequence. Plasmid pC4EE, is a
mammalian expression vector containing an expression cassette
having the mouse metallothionein-1 promoter, multiple restriction
sites for insertion of coding sequences, a stop codon and a human
growth hormone terminator. The plasmid also has an E. coli origin
of replication, a mammalian selectable marker expression unit
having an SV40 promoter, enhancer and origin of replication, a DHFR
gene and the SV40 terminator.
[0217] About 30 ng of the restriction digested zalpha11 insert and
about 12 ng of the digested vector were ligated overnight at
16.degree. C. One microliter of each ligation reaction was
independently electroporated into DH10B competent cells (GIBCO BRL,
Gaithersburg, Md.) according to manufacturer's direction and plated
onto LB plates containing 50 mg/ml ampicillin, and incubated
overnight. Colonies were screened by restriction analysis of DNA
prepared from 2 ml liquid cultures of individual colonies. The
insert sequence of positive clones was verified by sequence
analysis. A large scale plasmid preparation was done using a
QIAGEN.RTM. Maxi prep kit (Qiagen) according to manufacturer's
instructions.
[0218] The same process was used to prepare the zalpha11 soluble
receptors with a C-terminal his tag, composed of 6 His residues in
a row; and a C-terminal flag (SEQ ID NO:49) tag, zalpha11CFLAG. To
construct these constructs, the aforementioned vector has either
the HIS or the FLAG.RTM. tag in place of the glu-glu tag (SEQ ID
NO:41).
B. Mammalian Expression Construction of Soluble Zalpha11 Receptor
Zalpha11-Fc4
[0219] An expression plasmid containing all or part of a
polynucleotide encoding zalpha11 was constructed via homologous
recombination. A fragment of zalpha11 cDNA was isolated using PCR
that includes the polynucleotide sequence from extracellular domain
of the zalha11 receptor. The two primers used in the production of
the zalpha11 fragment were: (1) The primers for PCR each include
from 5' to 3' end: 40 bp of the vector flanking sequence (5' of the
insert) and 17 bp corresponding to the 5' end of the zalpha11
extracellular domain (SEQ ID NO:44); and (2) 40 bp of the 5' end of
the Fc4 polynucleotide sequence (SEQ ID NO:45) and 17 bp
corresponding to the 3' end of the zalpha11 extracellular domain
(SEQ ID NO:46). The fragment of Fc-4 for fusion with the zalpha11
was generated by PCR in a similar fashion. The two primers used in
the production of the Fc4 fragment were: (1) a 5' primer consisting
of 40 bp of sequence from the 3' end of zalpha11 extracellular
domain and 17 bp of the 5' end of Fc4 (SEQ ID NO:47); and (2) a 3'
primer consisting of 40 bp of vector sequence (3' of the insert)
and 17 bp of the 3' end of Fc4 (SEQ ID NO:48).
[0220] PCR amplification of the each of the reactions described
above was performed as follows: one cycle at 94.degree. C. for 2
minutes; twenty-five cycles at 94.degree. C. for 30 seconds,
60.degree. C. for 30 seconds, 72.degree. C. for 1 minute; one cycle
at 72.degree. C. for 5 minutes; followed by a 4.degree. C. hold.
Ten .mu.I of the 100 .mu.l PCR reaction was run on a 0.8% LMP
agarose gel (Seaplaque GTG) with 1.times.TBE buffer for analysis.
The remaining 90 .mu.l of PCR reaction is precipitated with the
addition of 5 .mu.l 1 M NaCl and 250 .mu.l of absolute ethanol. The
expression vector used was derived from the plasmid pCZR199
(deposited at the American Type Culture Collection, 10801
University Boulevard, Manassas, Va. 20110-2209, and is designated
No. 98668), and was cut with Sma1 (BRL). The expression vector was
derived from the plasmid pCZR199, and is a mammalian expression
vector containing an expression cassette having the CMV immediate
early promoter, a consensus intron from the variable region of
mouse immunoglobulin heavy chain locus, multiple restriction sites
for insertion of coding sequences, a stop codon and a human growth
hormone terminator. The expression vector also has an E. coli
origin of replication, a mammalian selectable marker expression
unit having an SV40 promoter, enhancer and origin of replication, a
DHFR gene and the SV40 terminator. The expression vector used was
constructed from pCZR199 by the replacement of the metallothionein
promoter with the CMV immediate early promoter.
[0221] One hundred microliters of competent yeast cells (S.
cerevisiae) were combined with 10 .mu.l containing approximately 1
.mu.g each of the zalpha11 and Fc4 inserts, and 100 ng of Sma1
(BRL) digested expression vector and transferred to a 0.2 cm
electroporation cuvette. The yeast/DNA mixtures were electropulsed
at 0.75 kV (5 kV/cm), "infinite" ohms, 25 .mu.F. To each cuvette is
added 600 .mu.l of 1.2 M sorbitol and the yeast was plated in two
300 .mu.l aliquots onto two URA-D plates and incubated at
30.degree. C.
[0222] After about 48 hours, the Ura+ yeast transformants from a
single plate were resuspended in 1 ml H.sub.2O and spun briefly to
pellet the yeast cells. The cell pellet was resuspended in 1 ml of
lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH
8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was
added to an Eppendorf tube containing 300 .mu.l acid washed glass
beads and 200 .mu.l phenol-chloroform, vortexed for 1 minute
intervals two or three times, followed by a 5 minute spin in a
Eppendorf centrifuge at maximum speed. Three hundred microliters of
the aqueous phase was transferred to a fresh tube, and the DNA
precipitated with 600 .mu.l ethanol (EtOH), followed by
centrifugation for 10 minutes at 4.degree. C. The DNA pellet was
resuspended in 100 .mu.l H.sub.2O.
[0223] Transformation of electrocompetent E. coli cells (DH10B,
GibcoBRL) is done with 0.5-2 ml yeast DNA prep and 40 .mu.l of
DH10B cells. The cells were electropulsed at 2.0 kV, 25 mF and 400
ohms. Following electroporation, 1 ml SOC (2% Bactoe Tryptone
(Difco, Detroit, Mich.), 0.5% yeast extract (Difco), 10 mM NaCl,
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was plated in
250 .mu.l aliquots on four LB AMP plates (LB broth (Lennox), 1.8%
Bacto Agar (Difco), 100 mg/L Ampicillin).
[0224] Individual clones harboring the correct expression construct
for zalpha11-Fc4 were identified by restriction digest to verify
the presence of the zalpha11-Fc4 insert and to confirm that the
various DNA sequences have been joined correctly to one another.
The insert of positive clones were subjected to sequence analysis.
Larger scale plasmid DNA is isolated using the Qiagen Maxi kit
(Qiagen) according to manufacturer's instructions.
Example 10
Transfection and Expression of Zalpha11 Soluble Receptor
Polypeptides
[0225] BHK 570 cells (ATCC No. CRL-10314), passage 27, were plated
at 1.2.times.10.sup.6 cells/well (6-well plate) in 800 .mu.l of
serum free (SF) DMEM media (DMEM, Gibco/BRL High Glucose) (Gibco
BRL, Gaithersburg, Md.). The cells were transfected with expression
plasmids containing zalpha11CEE/CFLG/CHIS described above (see,
Example 9), using Lipofectin.TM. (Gibco BRL), in serum free (SF)
DMEM. Three micrograms of zalpha11CEE/CFLG/CHIS each were
separately diluted into 1.5 ml tubes to a total final volume of 100
.mu.l SF DMEM. In separate tubes, 15 .mu.l of Lipofectin.TM. (Gibco
BRL) was mixed with 100 .mu.l of SF DMEM. The Lipofectin.TM. mix
was incubated at room temperature for 30-45 minutes then the DNA
mix was added and allowed to incubate approximately 10-15 minutes
at room temperature.
[0226] The entire DNA: Lipofectin.TM. mixture was added to the
plated cells and distributed evenly over them. The cells were
incubated at 37.degree. C. for approximately five hours, then
transferred to separate 150 mm MAXI plates in a final volume of 30
ml DMEM/5% fetal bovine serum (FBS) (Hyclone, Logan, Utah). The
plates were incubated at 37.degree. C., 5% CO.sub.2, overnight and
the DNA: Lipofectin.TM. mixture was replaced with selection media
(5% FBS/DMEM with 1 .mu.M methotrexate (MTX)) the next day.
[0227] Approximately 10-12 days post-transfection, the plates were
washed with 10 ml SF DMEM. The wash media was aspirated and
replaced with 7.25 ml serum-free DMEM. Sterile Teflon meshes
(Spectrum Medical Industries, Los Angeles, Calif.) pre-soaked in SF
DMEM were then placed over the clonal cell colonies. A sterile
nitrocellulose filter pre-soaked in SF DMEM was then placed over
the mesh. Orientation marks on the nitrocellulose were transferred
to the culture dish. The plates were then incubated for 5-6 hours
in a 37.degree. C., 5% CO.sub.2 incubator.
[0228] Following incubation, the filters/meshes were removed, and
the media aspirated and replaced with 5% FBS/DMEM with 1 .mu.M MTX.
The filters were then blocked in 10% nonfat dry milk/Western A
buffer (Western A: 50 mM Tris pH 7.4, 5 mM EDTA, 0.05% NP-40, 150
mM NaCl and 0.25% gelatin) for 15 minutes at room temperature on a
rotating shaker. The filters were then incubated with an
anti-Glu-Glu, anti-FLAG.RTM., or anti-HIS antibody-HRP conjugates,
respectively, in 2.5% nonfat dry milk/Western A buffer for one hour
at room temperature on a rotating shaker. The filters were then
washed three times at room temperature with Western A for 5-10
minutes per wash. The filters were developed with ultra ECL reagent
(Amersham Corp., Arlington Heights, Ill.) according the
manufacturer's directions and visualized on the Lumi-Imager (Roche
Corp.)
[0229] Positive expressing clonal colonies were mechanically picked
to 12-well plates in one ml of 5% FCS/DMEM with 5 .mu.M MTX, then
grown to confluence. Conditioned media samples were then tested for
expression levels via SDS-PAGE and Western anlaysis. The three
highest expressing clones for each construct were picked; two out
of three were frozen down as back up and one was expanded for
mycoplasma testing and large-scale factory seeding.
B. Mammalian Expression of Soluble Zalpha11 Receptor
Zalpha11-Fc4
[0230] BHK 570 cells (ATCC NO: CRL-10314) were plated in 10 cm
tissue culture dishes and allowed to grow to approximately 50 to
70% confluency overnight at 37_C, 5% CO.sub.2, in DMEM/FBS media
(DMEM, Gibco/BRL High Glucose, (Gibco BRL, Gaithersburg, Md.), 5%
fetal bovine serum (Hyclone, Logan, Utah), 1 mM L-glutamine (JRH
Biosciences, Lenexa, Kans.), 1 mM sodium pyruvate (Gibco BRL)). The
cells were then transfected with the plasmid containing
zalpha11-Fc4 (see, Example 9), using Lipofectamine.TM. (Gibco BRL),
in serum free (SF) media formulation (DMEM, 10 mg/ml transferrin, 5
mg/ml insulin, 2 mg/ml fetuin, 1% L-glutamine and 1% sodium
pyruvate). The plasmid containing zalpha11-Fc4 was diluted into 15
ml tubes to a total final volume of 640 ml with SF media. 35 ml of
Lipofectamine.TM. (Gibco BRL) was mixed with 605 ml of SF medium.
The Lipofectamine.TM. mix was added to the DNA mix and allowed to
incubate approximately 30 minutes at room temperature. Five
milliliters of SF media was added to the DNA:Lipofectamine.TM.
mixture. The cells were rinsed once with 5 ml of SF media,
aspirated, and the DNA:Lipofectamine.TM. mixture is added. The
cells were incubated at 37.degree. C. for five hours, then 6.4 ml
of DMEM/10% FBS, 1% PSN media was added to each plate. The plates
were incubated at 37.degree. C. overnight and the
DNA:Lipofectamine.TM. mixture was replaced with fresh 5% FBS/DMEM
media the next day. On day 2 post-transfection, the cells were
split into the selection media (DMEM/FBS media from above with the
addition of 1 mM methotrexate (Sigma Chemical Co., St. Louis, Mo.))
in 150 mm plates at 1:10, 1:20 and 1:50. The media on the cells was
replaced with fresh selection media at day 5 post-transfection.
Approximately 10 days post-transfection, two 150 mm culture dishes
of methotrexate resistant colonies from each transfection were
trypsinized and the cells are pooled and plated into a T-162 flask
and transferred to large scale culture.
Example 11
Purification of Zalpha11 Soluble Receptors From BHK 570 Cells
A. Purification of Zalpha11CEE polypeptide from BHK 570
[0231] Unless otherwise noted, all operations were carried out at
4.degree. C. The following procedure was used for purifying
zalpha11 polypeptide containing C-terminal GluGlu (EE) tags. Thirty
liters of cell factory conditioned media was concentrated to 1.6
liters with an Amicon S10Y3 spiral cartridge on a ProFlux A30. A
Protease inhibitor solution was added to the concentrated 1.6
liters of cell factory conditioned media from transfected BHK 570
cells (see, Example 10) to final concentrations of 2.5 mM
ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co. St.
Louis, Mo.), 0.003 mM leupeptin (Boehringer-Mannheim, Indianapolis,
Ind.), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc
(Boehringer-Mannheim). Samples were removed for analysis and the
bulk volume was frozen at -80.degree. C. until the purification was
started. Total target protein concentrations of the concentrated
cell factory conditioned media was determined via SDS-PAGE and
Western blot analysis with the anti-EE HRP conjugated antibody.
[0232] A 100 ml column of anti-EE G-Sepharose (prepared as
described below) was poured in a Waters AP-5, 5 cm.times.10 cm
glass column. The column was flow packed and equilibrated on a
BioCad Sprint (PerSeptive BioSystems, Framingham, Mass.) with
phosphate buffered saline (PBS) pH 7.4. The concentrated cell
factory conditioned media was thawed, 0.2 micron sterile filtered,
pH adjusted to 7.4, then loaded on the column overnight with 1
ml/minute flow rate. The column was washed with 10 column volumes
(CVs) of phosphate buffered saline (PBS, pH 7.4), then plug eluted
with 200 ml of PBS (pH 6.0) containing 0.5 mg/ml EE peptide
(Anaspec, San Jose, Calif.) at 5 ml/minute. The EE peptide used has
the sequence EYMPME (SEQ ID NO:41). The column was washed for 10
CVs with PBS, then eluted with 5 CVs of 0.2M glycine, pH 3.0. The
pH of the glycine-eluted column was adjusted to 7.0 with 2 CVs of
5.times.PBS, then equilibrated in PBS (pH 7.4). Five ml fractions
were collected over the entire elution chromatography and
absorbance at 280 and 215 nM were monitored; the pass through and
wash pools were also saved and analyzed. The EE-polypeptide elution
peak fractions were analyzed for the target protein via SDS-PAGE
Silver staining and Western Blotting with the anti-EE HRP
conjugated antibody. The polypeptide elution fractions of interest
were pooled and concentrated from 60 ml to 5.0 ml using a 10,000
Dalton molecular weight cutoff membrane spin concentrator
(Millipore, Bedford, Mass.) according to the manufacturer's
instructions.
[0233] To separate zalpha11CEE from other co-purifying proteins,
the concentrated polypeptide elution pooled fractions were
subjected to a POROS HQ-50 (strong anion exchange resin from
PerSeptive BioSystems, Framingham, Mass.) at pH 8.0. A
1.0.times.6.0 cm column was poured and flow packed on a BioCad
Sprint. The column was counter ion charged then equibrated in 20 mM
TRIS pH 8.0 (Tris (Hydroxymethyl Aminomethane)). The sample was
diluted 1:13 (to reduce the ionic strength of PBS) then loaded on
the Poros HQ column at 5 ml/minute. The column was washed for 10
CVs with 20 mM Tris pH 8.0 then eluted with a 40 CV gradient of 20
mM Tris/1 M sodium chloride (NaCl) at 10 ml/minute. 1.5 ml
fractions were collected over the entire chromatography and
absorbance at 280 and 215 nM were monitored. The elution peak
fractions were analyzed via SDS-PAGE Silver staining. Fractions of
interest were pooled and concentrated to 1.5-2 ml using a 10,000
Dalton molecular weight cutoff membrane spin concentrator
(Millipore, Bedford, Mass.) according to the manufacturer's
instructions.
[0234] To separate zalpha11CEE polypeptide from free EE peptide and
any contaminating co-purifying proteins, the pooled concentrated
fractions were subjected to chromatography on a 1.5.times.90 cm
Sephadex S200 (Pharmacia, Piscataway, N.J.) column equilibrated and
loaded in PBS at a flow rate of 1.0 ml/min using a BioCad Sprint.
1.5 ml fractions were collected across the entire chromatography
and the absorbance at 280 and 215 nM were monitored. The peak
fractions were characterized via SDS-PAGE Silver staining, and only
the most pure fractions were pooled. This material represented
purified zalpha11CEE polypeptide.
[0235] This purified material was finally subjected to a 4 ml
ActiClean Etox (Sterogene) column to remove any remaining
endotoxins. The sample was passed over the PBS equilibrated gravity
column four times then the column was washed with a single 3 ml
volume of PBS, which was pooled with the "cleaned" sample. The
material was then 0.2 micron sterile filtered and stored at
-80.degree. C. until it was aliquoted.
[0236] On Western blotted, Coomassie Blue and Silver stained
SDS-PAGE gels, the zalpha11CEE polypeptide was one major band of an
apparent molecular weight of 50,000 Daltons. The mobility of this
band was the same on reducing and non-reducing gels.
[0237] The protein concentration of the purified material was
performed by BCA analysis (Pierce, Rockford, Ill.) and the protein
was aliquoted, and stored at -80.degree. C. according to our
standard procedures. On IEF (isoelectric focusing) gels the protein
runs with a PI of less than 4.5. The concentration of zalpha11CEE
polypeptide was 1.0 mg/ml.
[0238] Purified zalpha11CEE polypeptide was prepared for injection
into rabbits and sent to R & R Research and Development
(Stanwood, Wash.) for antibody production. Rabbits were injected to
produce anti-huzalpha11-CEE-BHK serum (Example 15, below).
[0239] To prepare anti-EE Sepharose, a 100 ml bed volume of protein
G-Sepharose (Pharmacia, Piscataway, N.J.) was washed 3 times with
100 ml of PBS containing 0.02% sodium azide using a 500 ml Nalgene
0.45 micron filter unit. The gel was washed with 6.0 volumes of 200
mM triethanolamine, pH 8.2 (TEA, Sigma, St. Louis, Mo.), and an
equal volume of EE antibody solution containing 900 mg of antibody
was added. After an overnight incubation at 4.degree. C., unbound
antibody was removed by washing the resin with 5 volumes of 200 mM
TEA as described above. The resin was resuspended in 2 volumes of
TEA, transferred to a suitable container, and
dimethylpimilimidate-2HCl (Pierce, Rockford, Ill.) dissolved in
TEA, was added to a final concentration of 36 mg/ml of protein
G-Sepharose gel. The gel was rocked at room temperature for 45 min
and the liquid was removed using the filter unit as described
above. Nonspecific sites on the gel were then blocked by incubating
for 10 min. at room temperature with 5 volumes of 20 mM
ethanolamine in 200 mM TEA. The gel was then washed with 5 volumes
of PBS containing 0.02% sodium azide and stored in this solution at
4.degree. C.
B. Purification of Zalpha11CFLAG Polypeptide from BHK 570
[0240] Unless otherwise noted, all operations were carried out at
4.degree. C. The following procedure was used for purifying
zalpha11 polypeptide containing C-terminal FLAG.TM. (FLG)
(Sigma-Aldrich Co.) tags. Thirty liters of cell factory conditioned
media was concentrated to 1.7 liters with an Amicon S10Y3 spiral
catridge on a ProFlux A30. A Protease inhibitor solution was added
to the 1.7 liters of concentrated cell factory conditioned media
from transfected BHK 570 cells (see, Example 10) to final
concentrations of 2.5 mM ethylenediaminetetraacetic acid (EDTA,
Sigma Chemical Co. St. Louis, Mo.), 0.003 mM leupeptin
(Boehringer-Mannheim, Indianapolis, Ind.), 0.001 mM pepstatin
(Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim).
Samples were removed for analysis and the bulk volume was frozen at
-80.degree. C. until the purification was started. Total target
protein concentrations of the cell factory conditioned media was
determined via SDS-PAGE and Western blot analysis with the
anti-FLAG.RTM. (Kodak) HRP conjugated antibody. A 125 ml column of
anti-FLAG.RTM. M2-Agarose affinity gel (Sigma-Aldrich Co.) was
poured in a Waters AP-5, 5 cm.times.10 cm glass column. The column
was flow packed and equilibrated on a BioCad Sprint (PerSeptive
BioSystems, Framingham, Mass.) with phosphate buffered saline (PBS)
pH 7.4. The concentrated cell factory conditioned media was thawed,
0.2 micron sterile filtered, pH adjusted to 7.4, then loaded on the
column overnight with 1 ml/minute flow rate. The column was washed
with 10 column volumes (CVs) of phosphate buffered saline (PBS, pH
7.4), then plug eluted with 250 ml of PBS (pH 6.0) containing 0.5
mg/ml FLAG.RTM. (Sigma-Aldrich Co.) peptide at 5 ml/minute. The
FLAG.RTM. peptide used has the sequence DYKDDDDK (SEQ ID NO:49).
The column was washed for 10 CVs with PBS, then eluted with 5 CVs
of 0.2M glycine, pH 3.0. The pH of the glycine-eluted column was
adjusted to 7.0 with 2 CVs of 5.times.PBS, then equilibrated in PBS
(pH 7.4). Five ml fractions were collected over the entire elution
chromatography and absorbence at 280 and 215 nM were monitored; the
pass through and wash pools were also saved and analyzed. The
FLAG.RTM.-polypeptide elution peak fractions were analyzed for the
target protein via SDS-PAGE Silver staining and Western Blotting
with the anti-FLAG HRP conjugated antibody. The polypeptide elution
fractions of interest were pooled and concentrated from 80 ml to 12
ml using a 10,000 Dalton molecular weight cutoff membrane spin
concentrator (Millipore, Bedford, Mass.) according to the
manufacturer's instructions.
[0241] To separate zalpha11 CFLG from other co-purifying proteins,
the polypeptide elution pooled fractions were subjected to a POROS
HQ-50 (strong anion exchange resin from PerSeptive BioSystems,
Framingham, Mass.) at pH 8.0. A 1.0.times.6.0 cm column was poured
and flow packed on a BioCad Sprint. The column was counter ion
charged then equilibrated in 20 mM TRIS pH 8.0 (Tris (Hydroxymethyl
Aminomethane)). The sample was diluted 1:13 (to reduce the ionic
strength of PBS) then loaded on the Poros HQ-50 column at 5
ml/minute. The column was washed for 10 column volumes (CVs) with
20 mM Tris pH 8.0 then eluted with a 40 CV gradient of 20 mM Tris/1
M sodium chloride (NaCl) at 10 ml/minute. 1.5 ml fractions were
collected over the entire chromatography and absorbance at 280 and
215 nM were monitored. The elution peak fractions were analyzed via
SDS-PAGE Silver staining. Fractions of interest were pooled and
concentrated to 1.5-2 ml using a 10,000 Dalton molecular weight
cutoff membrane spin concentrator (Millipore, Bedford, Mass.)
according to the manufacturer's instructions.
[0242] To separate zalpha11CFLG polypeptide from free FLAG.RTM.
peptide and any contaminating co-purifying proteins, the pooled
concentrated fractions were subjected to chromatography on a
1.5.times.90 cm Sephacryl S200 (Pharmacia, Piscataway, N.J.) column
equilibrated and loaded in PBS at a flow rate of 1.0 ml/min using a
BioCad Sprint. 1.5 ml fractions were collected across the entire
chromatograohy and the absorbance at 280 and 215 nM were monitored.
The peak fractions were characterized via SDS-PAGE Silver staining,
and only the most pure fractions were pooled. This material
represented purified zalpha11CFLG polypeptide.
[0243] This purified material was finally subjected to a 4 ml
ActiClean Etox (Sterogene) column to remove any remaining
endotoxins. The sample was passed over the PBS equilibrated gravity
column four times then the column was washed with a single 3 ml
volume of PBS, which was pooled with the "cleaned" sample. The
material was then 0.2 micron sterile filtered and stored at
-80.degree. C. until it was aliquoted.
[0244] On Western blotted, Coomassie Blue and Silver stained
SDS-PAGE gels, the zalpha11CFLG polypeptide was one major band of
an apparent molecular weight of 50,000 Daltons. The mobility of
this band was the same on reducing and non-reducing gels.
[0245] The protein concentration of the purified material was
performed by BCA analysis (Pierce, Rockford, Ill.) and the protein
was aliquoted, and stored at -80.degree. C. according to our
standard procedures. On IEF (isoelectric focusing) gels the protein
runs with a PI of less than 4.5. The concentration of zalpha11CFLG
polypeptide was 1.2 mg/ml.
C. Purification of Zalpha11-Fc4 Polypeptide from Transfected BHK
570 Cells
[0246] Unless otherwise noted, all operations were carried out at
4.degree. C. The following procedure was used for purifying
zalpha11 polypeptide containing C-terminal fusion to human IgG/Fc
(zalpha11-Fc4; Examples 8 and 9). 12,000 ml of conditioned media
from BHK 570 cells transfected with zalpha11-Fc4 (Example 10) was
filtered through a 0.2 mm sterilizing filter and then supplemented
with a solution of protease inhibitors, to final concentrations of,
0.001 mM leupeptin (Boerhinger-Mannheim, Indianapolis, Ind.), 0.001
mM pepstatin (Boerhinger-Mannheim) and 0.4 mM Pefabloc
(Boerhinger-Mannheim). A protein G sepharose (6 ml bed volume,
Pharmacia Biotech) was packed and washed with 500 ml PBS
(Gibco/BRL) The supplemented conditioned media was passed over the
column with a flow rate of 10 ml/minute, followed by washing with
1000 ml PBS (BRL/Gibco). zalpha11-Fc4 was eluted from the column
with 0.1 M Glycine pH 3.5 and 2 ml fractions were collected
directly into 0.2 ml 2M Tris pH 8.0, to adjust the final pH to 7.0
in the fractions.
[0247] The eluted fractions were characterized by SDS-PAGE and
western blotting with anti-human Fc (Amersham) antibodies. Western
blot analysis of reducing SDS-PAGE gels reveal an immunoreactive
protein of 80,000 KDa in fractions 2-10. Silver stained SDS-PAGE
gels also revealed an 80,000 KDa zalpa11:Fc polypeptide in
fractions 2-10. Fractions 2-10 were pooled.
[0248] The protein concentration of the pooled fractions was
performed by BCA analysis (Pierce, Rockford, Ill.) and the material
was aliquoted, and stored at -80.degree. C. according to our
standard procedures. The concentration of the pooled fractions was
0.26 mg/ml.
Example 12
Assay Using zalpha11 Soluble Receptor Zalpha11CEE, Zalpha11CFLG and
Zalpha11-Fc4 (Mutant) Soluble Receptors in Competitive Inhibition
Assay
[0249] BaF3/Zalpha11 cells were spun down and washed in mIL-3 free
media. The cells were spun and washed 3 times to ensure the removal
of the mIL-3. Cells were then counted in a hemacytometer. Cells
were plated in a 96-well format at 5000 cells per well in a volume
of 100 .mu.l per well using the mIL-3 free media.
[0250] Both media from the monkey spleen cell activation and the
CD3+ selected cells, described in Example 8 above, were added in
separate experiments at 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75%
and 0.375% concentrations, with or without zalpha11 soluble
receptors (CEE, C-flag, and Fc4 constructs; See, Example 10 and 11)
at 10 .mu.g/ml. The total assay volume was 200 .mu.l.
[0251] The assay plates were incubated 37.degree. C., 5% CO.sub.2
for 3 days at which time Alamar Blue (Accumed) was added at 20
.mu.l/well. Plates were again incubated at 37.degree. C., 5%
CO.sub.2 for 24 hours. Plates were read on the Fmax.TM. plate
reader (Molecular Devices) as described above (Example 5). Results
demonstrated complete inhibition of cell growth from each of the
different zalpha11 soluble receptor constructs at 10 .mu.g/ml,
confirming that the factor in each sample was specific for the
zalpha11 receptor.
[0252] Titration curves, diluting out the soluble receptors, were
also run using the above stated assay. Both the zalpha11CEE and
zalpha11CFLG soluble zalpha11 receptors were able to completely
inhibit growth as low as 20 ng/ml. The mutant zalpha11-Fc4 soluble
zalpha11 receptor was only as effective at 1.5 .mu.g/ml.
Example 13
Expression of Human Zalpha11 in E. Coli
A. Construction of Expression Vector pCZR225 that Expresses
Huzalpha11/MBP-6H Fusion Polypeptide
[0253] An expression plasmid containing a polynucleotide encoding a
human zalpha11 soluble receptor fused C-terminally to maltose
binding protein (MBP) was constructed via homologous recombination.
The polynucleotide sequence for the MBP-zalpha11 soluble receptor
fusion polypeptide is shown in SEQ ID NO:50, with the corresponding
protein sequence shown in SEQ ID NO:51. The fusion polypeptide,
designated huzalpha11/MBP-6H, in Example 14, contains an MBP
portion (amino acid 1 (Met) to amino acid 388 (Ser) of SEQ ID
NO:51) fused to the human zalpha11 soluble receptor (amino acid 389
(Cys) to amino acid 606 (His) of SEQ ID NO:51). A fragment of human
zalpha11 cDNA (SEQ ID NO:52) was isolated using PCR. Two primers
were used in the production of the human zalpha11 fragment in a PCR
reaction: (1) Primer ZC20,187 (SEQ ID NO:53), containing 40 bp of
the vector flanking sequence and 25 bp corresponding to the amino
terminus of the human zalpha11, and (2) primer ZC20,185 (SEQ ID
NO:54), containing 40 bp of the 3' end corresponding to the
flanking vector sequence and 25 bp corresponding to the carboxyl
terminus of the human zalpha11. The PCR Reaction conditions were as
follows: 25 cycles of 94.degree. C. for 30 seconds, 50.degree. C.
for 30 seconds, and 72.degree. C. for 1 minute; followed by
4.degree. C. soak, run in duplicate. Two .mu.l of the 100 .mu.l PCR
reaction was run on a 1.0% agarose gel with 1.times.TBE buffer for
analysis, and the expected approximately 660 bp fragment was seen.
The remaining 90 .mu.l of PCR reaction was combined with the second
PCR tube precipitated with 400 .mu.l of absolute ethanol. The
precipitated DNA used for recombining into the Sma1 cut recipient
vector pTAP98 to produce the construct encoding the MBP-zalpha11
fusion, as described below.
[0254] Plasmid pTAP98 was derived from the plasmids pRS316 and
pMAL-c2. The plasmid pRS316 is a Saccharomyces cerevisiae shuttle
vector (Hieter P. and Sikorski, R., Genetics 122:19-27, 1989).
pMAL-C2 (NEB) is an E. coli expression plasmid. It carries the tac
promoter driving MalE (gene encoding MBP) followed by a His tag, a
thrombin cleavage site, a cloning site, and the rrnB terminator.
The vector pTAP98 was constructed using yeast homologous
recombination. 100 ng of EcoR1 cut pMAL-c2 was recombined with 1
.mu.g Pvul cut pRS316, 1 .mu.g linker, and 1 g Sca1/EcoR1 cut
pRS316. The linker consisted of oligos ZC19,372 (SEQ ID NO:55) (100
pmol): ZC19,351 (SEQ ID NO:56) (1 pmol): ZC19,352 (SEQ ID NO:57) (1
pmol), and ZC19,371 (SEQ ID NO:58) (100 pmol) combined in a PCR
reaction. PCR reaction conditions were as follows: 10 cycles of
94.degree. C. for 30 seconds, 50.degree. C. for 30 seconds, and
72.degree. C. for 30 seconds; followed by 4.degree. C. soak. PCR
products were concentrated via 100% ethanol precipitation.
[0255] One hundred microliters of competent yeast cells (S.
cerevisiae) were combined with 10 .mu.l of a mixture containing
approximately 1 .mu.g of the human zalpha11 receptor PCR product
above, and 100 ng of SmaI digested pTAP98 vector, and transferred
to a 0.2 cm electroporation cuvette. The yeast/DNA mixture was
electropulsed at 0.75 kV (5 kV/cm), infinite ohms, 25 .mu.F. To
each cuvette was added 600 .mu.l of 1.2 M sorbitol and the yeast
was then plated in two 300 .mu.l aliquots onto two-URA D plates and
incubated at 30.degree. C.
[0256] After about 48 hours, the Ura+ yeast transformants from a
single plate were resuspended in 1 ml H.sub.2O and spun briefly to
pellet the yeast cells. The cell pellet was resuspended in 1 ml of
lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH
8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was
added to an Eppendorf tube containing 300 .mu.l acid washed glass
beads and 200 .mu.l phenol-chloroform, vortexed for 1 minute
intervals two or three times, followed by a 5 minute spin in a
Eppendorf centrifuge at maximum speed. Three hundred microliters of
the aqueous phase was transferred to a fresh tube, and the DNA
precipitated with 600 .mu.l ethanol (EtOH), followed by
centrifugation for 10 minutes at 4.degree. C. The DNA pellet was
resuspended in 100 .mu.l H.sub.2O.
[0257] Transformation of electrocompetent E. coli cells (MC1061,
Casadaban et. al. J. Mol. Biol. 138, 179-207) was done with 1 .mu.l
yeast DNA prep and 40 .mu.l of MC1061 cells. The cells were
electropulsed at 2.0 kV, 25 .mu.F and 400 ohms. Following
electroporation, 0.6 ml SOC (2% Bacto.TM. Tryptone (Difco, Detroit,
Mich.), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM
MgCl2, 10 mM MgSO4, 20 mM glucose) was plated in one aliquot on
MM/CA +AMP 100 mg/L plates (Pryor and Leiting, Protein Expression
and Purification 10:309-319, 1997).
[0258] Cells harboring the correct expression construct for human
zalpha11 receptor were identified by expression. Cells were grown
in MM/CA with 100 .mu.g/ml Ampicillin for two hours, shaking, at
37.degree. C. 1 ml of the culture was induced with 1 mM IPTG. 2-4
hours later the 250 .mu.l of each culture was mixed with 250 .mu.l
acid washed glass beads and 250 .mu.l Thorner buffer with 5%
.beta.ME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2 mM
EDTA, 5% SDS). Samples were vortexed for one minute and heated to
65.degree. C. for 10 minutes. 20 .mu.l were loaded per lane on a
4%-12% PAGE gel (NOVEX). Gels were run in 1.times.MES buffer. The
positive clones were designated pCZR225 and subjected to sequence
analysis. The polynucleotide sequence of MBP-zalpha11 fusion is
shown in SEQ ID NO:50.
B. Bacterial Expression of Human Huzalpha11/MBP-6H Fusion
Polypeptide
[0259] One microliter of sequencing DNA was used to transform
strain BL21. The cells were electropulsed at 2.0 kV, 25.degree. F.
and 400 ohms. Following electroporation, 0.6 ml MM/CA with 100 mg/L
Ampicillin.
[0260] Cells were grown in MM/CA with 100 .mu.g/ml Ampicillin for
two hours, shaking, at 37.degree. C. 1 ml of the culture was
induced with 1 mM IPTG. 2-4 hours later the 250 .mu.l of each
culture was mixed with 250 .mu.l acid washed glass beads and 250
.mu.l Thorner buffer with 5% .beta.ME and dye (8M urea, 100 mM Tris
pH7.0, 10% glycerol, 2 mM EDTA, 5% SDS). Samples were vortexed for
one minute and heated to 65.degree. C. for 10 minutes. 20 .mu.l
were loaded per lane on a 4%-12% PAGE gel (NOVEX). Gels were run in
1.times.MES buffer. The positive clones were used to grow up for
protein purification of the huzalpha11/MBP-6H fusion protein
(Example 14, below).
Example 14
Purification of Huzalpha11/MBP-6H Soluble Receptor from E. Coli
Fermentation
[0261] Unless otherwise noted, all operations were carried out at
4.degree. C. The following procedure was used for purifying
huzalpha11/MBP-6H soluble receptor polypeptide. E. Coli cells
containing the pCZR225 construct and expressing huzalpha11/MBP-6H
soluble receptor (Example 13) were grown up in SuperBroth 11 (12
g/L Casien, 24 g/L Yeast Extract, 11.4 g/L di-potassium phosphate,
1.7 g/L Mono-potassium phosphate; Becton Dickenson, Cockeysville,
Md.), and frozen in 0.5% glycerol. Twenty grams of the frozen cells
in SuperBroth II+Glycerol were used to purify the protein. The
frozen cells were thawed and diluted 1:10 in a protease inhibitor
solution (Extraction buffer) prior to lysing the cells and
releasing the huzalpha11/MBP-6H soluble receptor protein. The
diluted cells contained final concentrations of 20 mM Tris (JT
Baker, Philipsburg, N.J.) 100 mM Sodium Chloride (NaCl,
Mallinkrodt, Paris, Ky.), 0.5 mM pheynlmethylsulfonyl fluoride
(PMSF, Sigma Chemical Co., St. Louis, Mo.), 2 .mu.g/ml Leupeptin
(Fluka, Switzerland), and 2 .mu.g/ml Aprotinin (Sigma). A French
Press cell breaking system (Constant Systems Ltd., Warwick, UK)
with temperature of -7 to -10.degree. C. and 30K PSI was used to
lyse the cells. The diluted cells were checked for breakage by
A.sub.600 readings before and after the French Press. The lysed
cells were centrifuged @ 18,000G for 45 minutes to remove the
broken cell debris, and the supernatant used to purify the protein.
Total target protein concentrations of the supernatant was
determined via BCA Protein Assay (Pierce, Rockford, Ill.),
according to manufacturer's instructions.
[0262] A 25 ml column of Talon Metal Affinity resin (Clontech, Palo
Alto, Calif.) (prepared as described below) was poured in a
Bio-Rad, 2.5 cm D.times.10 cm H glass column. The column was packed
and equilibrated by gravity with 10 column volumes (CVs) of Talon
Equilibration buffer (20 mM Tris, 100 mM NaCl, pH 8.0). The
supernatant was batch loaded to Talon metal affinity resin and was
rocked overnight. The resin was poured back into the column and was
washed with 10 CV's of Talon Equilibration buffer by gravity, then
gravity eluted with 140 ml of Elution buffer (Talon Equilibration
buffer+200 mM Imidazole-Fluka Chemical). The talon column was
cleaned with 5 CVs of 20 mM 2-(N-Morhpholino) ethanesulfonic acid
pH 5.0 (MES, Sigma), 5 CVs of distilled H.sub.2O, then stored in
20% Ethanol/0.1% Sodium Azide. Fourteen ml fractions were collected
over the entire elution chromatography and the fractions were read
with absorbance at 280 and 320 nM and BCA protein assay; the pass
through and wash pools were also saved and analyzed. The protein
elution fractions of interest were pooled and loaded straight to
Amylose resin (New England Biolabs, Beverly, Mass.).
[0263] To obtain more pure huzalpha11/MBP-6H polypeptide, the talon
affinity elution pooled fractions were subjected to Amylose resin
(22 mls) at pH 7.4. A 2.5 cm D.times.10 cm H Bio-Rad column was
poured, packed and equilibrated in 10 CVs of Amylose equilibration
buffer-20 mM Tris (JT Baker), 100 mM NaCl (Mallinkrodt), 1 mM PMSF
(Sigma), 10 mM beta-Mercaptoethanol (BME, ICN Biomedicals Inc.,
Aurora, Ohio) pH 7.4. The sample was loaded by gravity flow rate of
0.5 ml/min. The column was washed for 10 CVs with Amylose
equilibration buffer, then eluted with .about.2 CV of Amylose
equilibration buffer+10 mM Maltose (Fluka Biochemical, Switzerland)
by gravity. 5 ml fractions were collected over the entire
chromatography and absorbance at 280 and 320 nM were read. The
Amylose column was regenerated with 1 CV of distilled H.sub.2O, 5
CVs of 0.1% (w/v) SDS (Sigma), 5 CVs of distilled H.sub.2O, and
then 5 CVs of Amylose equilibration buffer.
[0264] Fractions of interest were pooled and dialyzed in a
Slide-A-Lyzer (Pierce) with 4.times.4L PBS pH 7.4 (Sigma) to remove
low molecular weight contaminants, buffer exchange and desalt.
After the changes of PBS, the material harvested represented the
purified huzalpha11/MBP-6H polypeptide. The purified
huzalpha11/MBP-6H polypeptide was analyzed via SDS-PAGE Coomassie
staining and Western blot analysis with the anti-rabbit HRP
conjugated antibody (Rockland, Gilbertsville, Pa.). The
concentration of the huzalpha11/MBP-6H polypeptide was 1.92 mg/ml
as determined by BCA analysis.
[0265] Purified huzalpha11/MBP-6H polypeptide was prepared for
injection into rabbits and sent to R & R Research and
Development (Stanwood, Wash.) for antibody production. Rabbits were
injected to produce anti anti-huzalpha11/MBP-6H serum (Example 15,
below).
Example 15
Zalpha11 Polyclonal Antibodies
[0266] Polyclonal antibodies were prepared by immunizing two female
New Zealand white rabbits with the purified huzalpha11/MBP-6H
polypeptide (Example 14), or the purified recombinant zalphal iCEE
soluble receptor (Example 11A). Corresponding polyclonal antibodies
were designated rabbit anti-huzalpha11/MBP-6H and rabbit
anti-huzalpha11-CEE-BHK respectively. The rabbits were each given
an initial intraperitoneal (IP) injection of 200 mg of purified
protein in Complete Freund's Adjuvant (Pierce, Rockford, Ill.)
followed by booster IP injections of 100 mg purified protein in
Incomplete Freund's Adjuvant every three weeks. Seven to ten days
after the administration of the third booster injection, the
animals were bled and the serum was collected. The rabbits were
then boosted and bled every three weeks.
[0267] The zalpha11-specific polyclonal antibodies were affinity
purified from the rabbit serum using an CNBr--SEPHAROSE 4B protein
column (Pharmacia LKB) that was prepared using 10 mg of the
purified huzalpha11/MBP-6H polypeptide (Example 14) per gram
CNBr--SEPHAROSE, followed by 20.times. dialysis in PBS overnight.
Zalpha11-specific antibodies were characterized by an ELISA titer
check using 1 mg/ml of the appropriate protein antigen as an
antibody target. The lower limit of detection (LLD) of the rabbit
anti-huzalpha11/MBP-6H affinity purified antibody is a dilution of
500 .mu.g/ml. The LLD of the rabbit anti-huzalpha11-CEE-BHK
affinity purified antibody is a dilution of 50 pg/ml.
Example 16
Identification of Cells Expressing Zalpha11 Receptor Using
RT-PCR
[0268] Specific human cell types were isolated and screened for
zalpha11 expression by RT-PCR. B-cells were isolated from fresh
human tonsils by mechanical disruption through 100 .mu.m nylon cell
strainers (Falcon.TM.; Bectin Dickenson, Franklin Lakes, N.J.). The
B-cell suspensions were enriched for CD19+B-cells by positive
selection with VarioMACS VS+magnetic column and CD19 microbeads
(Miltenyi Biotec, Auburn, Calif.) as per manufacturer's
instructions. T-cells and monocytes were isolated from human
apheresed blood samples. CD3+ T-cells were purified by CD3
microbead VarioMACS positive selection and monocytes were purified
by VarioMACS negative selection columns (Miltenyi) as per
manufacturer's instructions. Samples from each population were
stained and analyzed by fluorescent antibody cell sorting (FACS)
(Bectin Dickinson, San Jose, Calif.) analysis to determine the
percent enrichment and resulting yields. CD19+B-cells were
approximately 96% purified CD3+ T-cells were approximately 95%
purified, and monocytes were approximately 96% purified.
[0269] RNA was prepared, using a standard method in the art, from
all three cell types that were either resting or activated. RNA was
isolated from resting cells directly from the column preparations
above. The CD19+ and CD3+ cells were activated by culturing at
500,000 cells/ml in RPMI+10% FBS containing PMA 5 ng/ml
(Calbiochem, La Jolla, Calif.) and Ionomycin 0.5 ug/ml (Calbiochem)
for 4 and 24 hours. The monocytes were activated by culturing in
RPMI+10% FBS containing LPS 10 ng/ml (Sigma St. Louis Mo.) and
rhIFN-g 10 ng/ml (R&D, Minneapolis, Minn.) for 24 hours. Cells
were harvested and washed in PBS. RNA was prepared from the cell
pellets using RNeasy Midiprep.TM. Kit (Qiagen, Valencia, Calif.) as
per manufacturer's instructions and first strand cDNA synthesis was
generated with Superscript II.TM. Kit (GIBCO BRL, Grand Island,
N.Y.) as per manufacturers protocol.
[0270] Oligos ZC19907 (SEQ ID NO:20) and ZC19908 (SEQ ID NO:21)
were used in a PCR reaction to screen the above described samples
for a 1.2 kb fragment corresponding to zalpha11 message. PCR
amplification was performed with Taq Polymerase (BRL Grand Island
N.Y.), and conditions as follows: 35 cycles of 95.degree. C. for 1
min., 60.degree. C. for 1 min., 72.degree. C. for 30 sec.; 1 cycle
at 72.degree. C. for 10 min.; and 4.degree. C. soak. 10 ul of each
50 .mu.l reaction volume was run on a 2% agarose 1.times.TAE gel to
identify resultant products. PCR products were scored as (-) for no
product, (+) for band visible, (++) increased presence of band and
(+++) being the most predominant band, with results shown in Table
5 below. TABLE-US-00005 TABLE 5 cDNA Source Activation PCR Product
CD19+ cells 0 hr resting + 4 hr activated ++ 24 hr activated +++
CD3+ cells 0 hr resting - 4 hr activated ++ 24 hr activated -
monocytes 0 hr resting - 24 hr activated -
[0271] These results indicated that zalpha11 message is present in
resting human CD19+B-cells and increases with mitogenic activation.
It also appears to be expressed by human CD3+ T-cells only after 4
hour activation. There was no apparent message in either resting or
activated human monocytes.
Example 17
Zalpha11 Immunohistochemistry
A. Cell and Tissue Preparations
[0272] Positive control tissues consisted of BaF3 cells transfected
with zalpha11 (Example 7) and lymphoid tissues known to express
zalpha11 including mouse lymph node, spleen and thymus received
from HSD (Harlan Sprague Dawley, Indianapolis, Ind.), monkey lymph
node and spleen received from Regional Primate Research Center
(University of Washington, Seattle, Wash.), human lymph node and
spleen received from CHTN (Cleveland, Ohio). Negative controls
performed on each tissue sample included: (1) untransfected BaF3
cells, (2) liver and brain from mouse and human known not to
express zalpha11, (3) staining with antibody dilution buffer
(Ventann Bioteck Systems, Tucson Ariz.) in the absence of primary
antibody, and (4) using zalpha11 soluble protein in competition
experiments.
[0273] Other cell samples were examined. Both non-stimulated and
stimulated HL60 cells were assayed. HL60 cells are a promyelocytic
cell line, which can be differentiated into myeloid or granulocyte
lineages with different reagents. Stimulated HL60 samples were
prepared as follows: (1) HL60 cells were treated with 10 ng/ml of
phorbol-myristate-acetate (PMA) (Sigma, St. Louis, Mo.) for 48
hours to differentiate into monocyte lineage cells; and (2) HL60
cells treated with 1.25% DMSO (Sigma) for 4 days to differentiate
into neutrophil-like cells. In addition, human polymorphonuclear
(PMN) cells, human granulocytes, human peripheral blood lymphocytes
(PBL) and human monocytes from fresh human blood were examined
(prepared in house using routine methods in the art). The cells and
tissues described above were fixed overnight in 10% NBF (Surgipath,
Richmond, Ill.), and embedded in parapalst X-tra (Oxford
Scientific, St. Louis, Mo.), and sectioned at 5 .mu.m with a
Reichart-Jung 2050 microme (Leica Instruments GmbH, Nussloch,
Germany).
B. Immunohistochemistry
[0274] Tissue slides were deparaffinized, hydrated to buffer
(water), and subjected to steam HIER treatment in Antigen Retrieval
Citra buffer (BioGenex, San Roman, Calif.) for 20 minutes. 5%
normal goat serum (Vector, Burlingame, Calif.) was used to block
non-specific binding for 10 minutes. Immunocytochemical screening
analyses were performed using polyclonal antibodies to zalpha11
soluble receptor protein (rabbit anti-huzalpha11-MBP-6H and rabbit
anti-huzalpha11-CEE-BHK; see, Example 15) as the primary
antibodies, at dilutions of 1:200 and 1:400 respectively. Biotin
conjugated goat anti-rabbit IgG (Vector; Cat. No. BA-1000, 1.5
mg/ml) was used as the secondary antibody at dilution of 1:200. In
separate samples, protein competition was performed by using
additional zalpha11 CEE soluble receptor protein (in 10.times. fold
excess) (Example 11A) to the primary antibody to pre-block primary
antibody immunoreaction. This competition was used as a control for
the rabbit polyclonal antibody specificity to zalpha11. Detection
was performed on the Ventana ChemMate 500 instrument using a
ChemMate DAB Kit (labeled Streptavidin-Biotin Kit with application
of a streptavidin-horseradish peroxidase conjugate, and DAB
substrate) according to manufacturer's instruction and using the
manufacturer's hematoxylin counterstain for 30 seconds (Ventana
Biotek Systems, Tucson, Ariz.).
[0275] High expression of zalpha11 was observed in the
PMA-activated HL60 cells. Low level expression was observed in PBL
and HL60 cells without stimulation. A subset of cells in the
spleen, thymus and lymph node of mouse showed positive staining.
Lymph node and spleen of both human and monkey, and HL60 cells with
DMSO stimulation showed minimal or no staining. The signal seen in
the cells and tissues was mostly competed out by using the excess
zalpha11 soluble receptor protein. The negative control tissues of
brain and liver showed no staining.
Example 18
Identifying Peripheral Blood Mononuclear Cells (PBMNC's) that
Express Zalpha11 Receptor Using Polyclonal Rabbit Anti-sera to
Zalpha11 Soluble Receptor
[0276] 200 ml fresh heparinized blood was obtained from a normal
donor. Blood was diluted 1:1 in PBS, and separated using a
Ficoll-Paque PLUS gradient (Pharmacia Biotech, Uppsala, Sweden),
and the lymphocyte interface collected. Cells were washed 2.times.
in PBS and resuspended in RPMI+5% FBS media at a concentration of
2.times.10.sup.6 cells/ml.
[0277] In order to determine whether expression of zalpha11
receptor is affected by the activation state of the lymphocyte
cells, i.e., between resting and activated cells several
stimulation conditions were used: 1) un-stimulated, i.e., media
alone (RPMI+5% FBS media); 2) stimulated with PMA 10
ng/ml+Ionomycin 0.5 .mu.g/ml (both from Calbiochem); and 3) PHA
activation (phytohemagglutinin-P, Difco/VWR). The cells were
incubated at 37.degree. C. for 17 hours then collected for staining
to detect expression of zalpha11 receptor.
[0278] An indirect staining protocol was used. Briefly, the human
lymphocyte cells were suspended in staining buffer (PBS+0.02%
NaN3+BSA 1% normal human serum 2%) and plated at 2.times.10.sup.5
cells in 50 .mu.l/well in a 96 well plate. Antibodies to the
zalpha11CEE soluble receptor (Example 15) were used to determine
whether they co-stained with a B-cell (CD-19), T-cell (CD-3) or
monocyte marker (CD-14) on the isolated human lymphocytes. A rabbit
polyclonal sera to zalpha11 soluble receptor (Rb
anti-huzalpha11-CEE-BHK) (Example 15) at 10 .mu.g/ml was used as
the antibody to identify zalpha11 on the lymphocytes. A secondary
antibody, goat anti-rabbit Ig-FITC (Biosource, Camarillo, Calif.),
was used to visualize the Rb anti-huzalpha11-CEE-BHK antibody
binding to the zalpha11 receptors. Other antibodies were
simultaneously used to stain T cells (CD3-PE; PharMingen, San
Diego, Calif.), B cells (CD19-PE) (PharMingen), and monocytes
(CD-14-PE) (PharMingen) in order to identify co-staining of the
anti-zalpha11 receptor antibody on these cell types. Various
controls were used to determine non-specific binding and background
levels of staining: (1) an irrelevant rabbit polyclonal sera was
used as a non-specific control; and (2) secondary antibody alone
was used to determine background binding of that reagent. Purified,
zalpha11CEE soluble receptor (Example 11) was used in about a
10-fold excess as a competitive inhibitor to verify the specificity
of the rabbit anti-huzalpha11-CEE-BHK antibody to zalpha11 soluble
receptor.
[0279] After plating the cells and adding the primary and
co-staining antibodies, the cells were incubated on ice for 30
minutes, washed 2.times. with staining buffer, and stained with the
secondary antibody, goat anti-rabbit Ig-FITC (Biosource), for 30
minutes on ice. Cells were washed 2.times. staining buffer, and
resuspended at 200 .mu.l per well in staining buffer containing the
viability stain 7AAD at about 1 .mu.g/ml final concentration
(Sigma, St. Louis, Mo.). Samples were read on the FACS-Caliber
(Becton-Dickinson, San Jose, Calif.) and viable cells analyzed.
[0280] The rabbit polyclonal to zalpha11 receptor stained resting B
cells. The signal on resting B cells was brighter than the signal
achieved using the irrelevant rabbit sera, and the signal was
diminished to a greater extent on B cells than on T cells with the
addition of excess zalpha11-CEE soluble receptor. This experiment
was repeated using separated B and T cells, and the results were
very similar. Again the staining with the polyclonal rabbit
anti-huzalpha11-CEE-BHK antibody to zalpha11 receptor was highest
on resting B cells.
Example 19
Zalpha11 Receptor Expression in Various Tissues Using Real-Time
Quantitative RT/PCR
A. Primers and Probes for Quantitative RT-PCR-
[0281] Real-time quantitative RT-PCR using the ABI PRISM 7700
Sequence Detection System (PE Applied Biosystems, Inc., Foster
City, Calif.) has been previously described (See, Heid, C. A. et
al., Genome Research 6:986-994, 1996; Gibson, U. E. M. et al.,
Genome Research 6:995-1001, 1996; Sundaresan, S. et al.,
Endocrinology 139:4756-4764, 1998. This method incorporates use of
a gene specific probe containing both reporter and quencher
fluorescent dyes. When the probe is intact the reporter dye
emission is negated due to the close proximity of the quencher dye.
During PCR extension using additional gene-specific forward and
reverse primers, the probe is cleaved by 5' nuclease activity of
Taq polymerase which releases the reporter dye from the probe
resulting in an increase in fluorescent emission.
[0282] The primers and probes used for real-time quantitative
RT-PCR analyses of zalpha11 expression were designed using the
primer design software Primer Express.TM. (PE Applied Biosystems,
Foster City, Calif.). Primers for human zalpha11 were designed
spanning an intron-exon junction to eliminate amplification of
genomic DNA. The forward primer, ZC22,277 (SEQ ID NO:59) and the
reverse primer, ZC22,276 (SEQ ID NO:60) were used in a PCR reaction
(below) at about 300 nM concentration to synthesize a 143 bp
product. The corresponding zalpha11 TaqMan.RTM. probe, designated
ZG31 (SEQ ID NO:61) was synthesized and labeled by PE Applied
Biosystems. The ZG31 probe was labeled at the 5'end with a reporter
fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied
Biosystems) and at the 3' end with a quencher fluorescent dye
(6-carboxy-tetramethyl-rhodamine) (TAMRA) (PE Applied
Biosystems).
[0283] As a control to test the integrity and quality of RNA
samples tested, all RNA samples (below) were screened for rRNA
using a primer and probe set ordered from PE Applied Biosystems
(cat No. 4304483). The kit contains an rRNA forward primer (SEQ ID
NO:66) and the rRNA reverse primer (SEQ ID NO:67), rRNA TaqMan.RTM.
probe (SEQ ID NO:68) The rRNA probe was labeled at the 5'end with a
reporter fluorescent dye VIC (PE Applied Biosystems) and at the 3'
end with the quencher fluorescent dye TAMRA (PE Applied
Biosystems). The rRNA results also serve as an endogenous control
and allow for the normalization of the zalpha11 mRNA expression
results seen in the test samples.
[0284] RNA samples from human CD3, CD19 and monocyte cell types
were prepared and described as per Example 16 above. Control RNA
was prepared, using RNeasy Miniprep.TM. Kit (Qiagen, Valencia,
Calif.) as per manufacturer's instructions, from approximately 10
million BaF3 cells expressing human zalpha11 receptor (Example
7).
B. Real-time quantitative RT-PCR-
[0285] Relative levels of zalpha11 mRNA were determined by
analyzing total RNA samples using the one-step RT-PCR method (PE
Applied Biosystems). Total RNA from BaF3 cells expressing human
zalpha11 receptor was isolated by standard methods and used to
generate a standard curve used for quantitation. The curve
consisted of 10-fold serial dilutions ranging from
2.5-2.5.times.10.sup.-4 ng/.mu.l for the rRNA screen and 250-0.025
ng/.mu.l for the zalpha11 screen with each standard curve point
analyzed in triplicate. The total RNA samples from the human CD3,
CD19 and monocyte cells were also analyzed in triplicate for human
zalpha11 transcript levels and for levels of rRNA as an endogenous
control. In a total volume of 25 .mu.l, each RNA sample was
subjected to a One-Step RT-PCR reaction containing: approximately
25 ng of total RNA in buffer A (50 mM KCL, 10 mM Tris-HCL); the
internal standard dye, carboxy-x-rhodamine (ROX)); appropriate
primers (approximately 50 nM rRNA primers (SEQ ID NO:66 and SEQ ID
NO:67) for the rRNA samples; and approximately 300 nM ZC22,277 (SEQ
ID NO:59) and ZC22,276 (SEQ ID NO:60) primers for zalpha11
samples); the appropriate probe (approximately 50 nM rRNA
TaqMan.RTM. probe (SEQ ID NO:68) for rRNA samples, approximately
100 nM ZG31 (SEQ ID NO:61) probe for zalpha11 samples); 5.5 mM
MgCl.sub.2; 300 .mu.M each d-CTP, d-ATP, and d-GTP and 600 .mu.M of
d-UTP; MuLV reverse transcriptase (0.25 U/.mu.l); AmpliTaq.TM. Gold
DNA polymerase (0.025 U/.mu.l) (PE Applied Biosystems); and RNase
Inhibitor (0.4 U/.mu.l) (PE Applied Biosystems). PCR thermal
cycling conditions were as follows: an initial reverse
transcription (RT) step of one cycle at 48.degree. C. for 30
minutes; followed by an AmpliTaq Gold.TM. (PE Applied Biosystems)
activation step of one cycle at 95.degree. C. for 10 minutes;
followed by 40 cycles of amplification at 95.degree. C. for 15
seconds and 60.degree. C. for 1 minute.
[0286] Relative zalpha11 RNA levels were determined by using the
Standard Curve Method as described by the manufacturer, PE
Biosystems (User Bulletin No. 2: ABI Prism 7700 Sequence Detection
System, Relative Quantitation of Gene Expression, Dec. 11,
1997).
[0287] The rRNA measurements were used to normalize the zalpha11
levels and the resting CD3+ RNA sample was used as a calibrator.
Resting CD3 was arbitrarily chosen as the calibrator and given a
value of 1.00. The rest of the samples were compared relative to
the calibrator. Data are shown in Table 6 below. TABLE-US-00006
TABLE 6 Sample Resting 4 hr Stimulation 24 hr Stimulation CD3 1.00
15.27 16.70 CD19 20.14 65.08 25.42 Monocytes 0.05 no data 0.26
[0288] There was a 15-fold increase in zalpha11 receptor expression
in CD3+ at 4 and 24 hrs. Resting CD19 had 20 fold increase in
receptor expression relative to resting CD3+. There was a 3 fold
increase with 4 hr stimulation that fell back to resting levels by
24 hrs. Monocytes showed no detectable zalpha11 receptor expression
in this assay.
Example 20
Identification of Cells Expressing Zalpha11 Receptor Using In Situ
Hybridization
[0289] Specific human tissues were isolated and screened for
zalpha11 expression by in situ hybridization. Various human tissues
prepared, sectioned and subjected to in situ hybridization included
thymus, spleen, tonsil, lymph node and lung. The tissues were fixed
in 10% buffered formalin and blocked in paraffin using standard
techniques (Example 17). Tissues were sectioned at 4 to 8 microns.
Tissues were prepared using a standard protocol ("Development of
non-isotopic in situ hybridization" at
http://dir.niehs.nih.gov/dirlep/ish.html). Briefly, tissue sections
were deparaffinized with HistoClear (National Diagnostics, Atlanta,
Ga.) and then dehydrated with ethanol. Next they were digested with
Proteinase K (50 .mu.g/ml) (Boehringer Diagnostics, Indianapolis,
Ind.) at 37.degree. C. for 2 to 20 minutes. This step was followed
by acetylation and re-hydration of the tissues.
[0290] Two in situ probes generated by PCR were designed against
the human zalpha11 sequence. Two sets of oligos were designed to
generate probes for separate regions of the zalpha11 cDNA: (1)
Oligos ZC23,684 (SEQ ID NO:62) and ZC23,656 (SEQ ID NO:63) were
used to generate a 413 bp probe for zalpha11; and (2) Oligos
ZC23,685 (SEQ ID NO:64) and ZC23,657 (SEQ ID NO:65) were used to
generate a 430 bp probe for zalpha11. The second probe is 1500 bp
3' of the first zalpha11 probe. The antisense oligo from each set
also contained the working sequence for the T7 RNA polymerase
promoter to allow for easy transcription of antisense RNA probes
from these PCR products. The PCR reaction conditions were as
follows: 30 cycles at 94.degree. C. for 30 sec, 60.degree. C. for 1
min., 72.degree. C. for 1.5 min. The PCR products were purified by
Qiagen spin columns followed by phenol/chloroform extraction and
ethanol precipitation. Probes were subsequently labeled with
digoxigenin (Boehringer) or biotin (Boehringer) using an In Vitro
transcription System (Promega, Madison, Wis.) as per manufacturer's
instruction.
[0291] In situ hybridization was performed with a digoxigenin- or
biotin-labeled zalpha11 probe (above). The probe was added to the
slides at a concentration of 1 to 5 pmol/ml for 12 to 16 hours at
55-60.degree. C. Slides were subsequently washed in 2.times.SSC and
0.1.times.SSC at 50.degree. C. The signals were amplified using
tyramide signal amplification (TSA) (TSA, in situ indirect kit;
NEN) and visualized with Vector Red substrate kit (Vector Lab) as
per manufacturer's instructions. The slides were then
counter-stained with hematoxylin (Vector Laboratories, Burlingame,
Calif.).
[0292] A signal was seen in the thymus, tonsil, lung, and lymph
node. The positive-staining cells appeared to be lymphocytes and
related cells.
Example 21
Isolation of the Mouse Zalpha11 Receptor
A. Mouse Genomic Library Screen
[0293] An initial partial mouse zalpha11 sequence was obtained by
probing a mouse genomic library with a human zalpha11 receptor
polynucleotide probe containing the entire cDNA. The human zalpha11
cDNA was generated by PCR with ZC19,905 (SEQ ID NO:36) and ZC19,906
(SEQ ID NO:37) primers and a plasmid containing full length human
zalpha11 (e.g., Example 1) was used for the template. The PCR
reaction conditions were as follows: 35 cycles at 98.degree. C. for
1 min., 68.degree. C. for 1 min., and 72.degree. C. for 2 min.;
followed by one cycle at 72.degree. C. for 10 min. The PCR product
was run on a 1% low melting point agarose (Boerhinger Mannheim) and
the approximately 1.5 kb human zalpha11 cDNA isolated using
Qiaquick.TM. gel extraction kit (Qiagen) as per manufacturer's
instructions. This human zalpha11 cDNA was used to screen a mouse
genomic DNA library (below).
[0294] The mouse genomic DNA library used was emb13 SP6/T7 lambda
BamHI cloned library (Clontech, Palo Alto, Calif.). This library
representing 7.2.times.10.sup.5 pfu was plated onto an E. Coli K802
host lawn on 24 NZY plates. Plaque lifts were performed using
Hybond-N filters (Amersham Pharmacia, Buckinghamshire, England, UK)
as per manufacturer's instructions. The filters were denatured in
1.5 M NaCl and 0.5 M NaOH for 10 min. and then neutralized in 1.5 M
NaCl and 0.5 M Tris-HCL (pH 7.2) for 10 min. The DNA was affixed to
the filter using a STRATALINKER UV crosslinker (Stratagene) at 1200
joules. The filters were pre-washed to remove cell debris at
65.degree. C. in pre-wash buffer (0.25.times.SSC, 0.25% SDS and 1
mM EDTA), changing solution three times for a total of 45 min. The
filters were prehybridized overnight at 50.degree. C. in
Expresshyb.TM. solution (Clontech) containing 0.1 mg/ml denatured
salmon sperm DNA. Approximately 50 ng of the purified human
zalpha11 cDNA (above) was labeled with .sup.32P using the Rediprime
II Random Prime Labeling System (Amersham Pharmacia) as per
manufacturers instructions. Unincorporated radioactivity was
removed from the zaplha11 cDNA probe using a NucTrap.TM. push
column (Stratagene, La Jolla, Calif.). Filters were hybridized in
Expresshyb.TM. solution (Clontech) containing about 0.5 to about
1.times.10.sup.6 cpm/ml zalpha11 cDNA probe, about 0.1 mg/ml
denatured salmon sperm DNA and denatured 0.5 .mu.g/ml cot-1 DNA.
Hybridization took place overnight at 50.degree. C. Filters were
washed in 2.times.SSC, 0.1% SDS at room temperature for 2 hours
(changing wash several times) then the temperature was raised to
60.degree. C. for one hour (changing buffer once). Overnight
exposure at -80.degree. C. showed 6 plaques representing primary
isolates.
[0295] To obtain secondary plaque isolates, the 6 plaques
representing primary isolates were picked with a Pasteur pipette
and eluted overnight at 4.degree. C. in 1 ml SM (0.1 M NaCl, 50 mM
Tris pH 7.5, 10 mM MgSO.sub.4, 0.02% gelatin) containing a few
drops of chloroform. After determining phage titers, about
12.5.times. the estimated amount of phage in the original plug
(12.5.times. coverage) of 6 primary isolates was plated on a lawn
of E. Coli K802 cells embedded in 10 mM MgSO.sub.4/NZY top agarose
on NZY maxi plates, and grown overnight at 37.degree. C. Plaque
lifts were done using Hybond-N filters (Amersham Pharmacia) as per
manufacturer's instructions. Filters were fixed as per above. The
second round filters were pre-washed to remove cell debris at
65.degree. C. in pre-wash buffer (2.times.SSC, 0.1% SDS and 1 mM
EDTA), changing solution three times for a total of 45 min. The
second round filter lifts were then prehybridized, and the zalpha11
cDNA probe prepared as described above.
[0296] The second round filters were hybridized as above in
Expresshyb.TM. solution (Clontech) containing about 10.sup.6 cpm/ml
zalpha11 cDNA probe containing about 0.1 mg/ml denatured salmon
sperm DNA. Hybridization took place overnight at 50.degree. C. Wash
conditions described above for the primary screen were repeated for
this secondary screen. After an overnight exposure at -80.degree.
C., two of the 6 original primary plaques isolates were verified as
positive in the secondary screen. Positive plaques hybridizing to
human zalpha11 cDNA in the secondary screen were picked with a
Pasteur pipette and designated 7b1 and 20b1.
[0297] The isolated plaques No. 7b1 and 20b1 were eluted in 200
.mu.l SM overnight at 4.degree. C. Serial 10-fold serial dilutions
ranging from 10.sup.-2 to 10.sup.-6 of each isolate were plated on
host E. Coli K802 cells to determine the titer. Isolate 20b1 had a
titer of 4.times.10.sup.3 pfu/.mu.l and was further pursued. 4
plates were prepared by plating 10.sup.5 pfu/plate on confluent
host E. Coli K802 cells in order to make a phage DNA prep. Plates
were grown at 37.degree. C. for about 6.5 hours until phage lysis
was starting to get confluent. The phage was then eluted overnight
at 4.degree. C. in 12 ml of SM per plate. Plates were then shaken
at room temperature one hour, the supernatant was removed; 1%
chloroform was added and supernatant was shaken again for 15 min.
The 20b1 phage DNA was prepped using the Wizard Lambda Preps DNA
Purification System (Promega, Madison, Wis.; sections IV and
VI).
[0298] Samples of 20b1 phage DNA were cut with several restriction
enzymes to generate DNA fragments for Southern blotting. The
digests were run on a 1% TBE agarose gel. The gel was soaked in
0.25 M HCl for 30 min.; rinsed in distilled H20; soaked in 0.5M
NaOH and 1.5 M NaCl for 40 min. with one solution change and
neutralized in 1.5 NaCl and 0.5 Tris-HCL (pH 7.2) for 40 min. with
one solution change. A TURBOBLOTTER.TM. Rapid Downward Transfer
System (Schleicher & Schuell, Keene, N.H.) was set up to
transfer the DNA onto a Nytran/BA-S membrane (Schleicher &
Schuell) overnight. The DNA was affixed to the Nytran using a
STRATALINKER UV crosslinker (Stratagene, La Jolla, Calif.) at 1200
joules. The blot was prehybridized as described above. About 50 ng
of the human zalpha11 cDNA was labeled and purified for a probe, as
described above. Filters were hybridized as above in Expresshyb.TM.
solution (Clontech) containing about 10.sup.6 cpm/ml zalpha11 cDNA
probe and about 0.1 mg/ml denatured salmon sperm DNA. Hybridization
took place overnight at 50.degree. C. The blot was washed as
described above and exposed to film overnight at -80.degree. C.
[0299] The Southern showed a DNA fragment generated from a
BamHI/StuI digest which hybridized to the human zalpha11 cDNA probe
in the expected size range of 1.3 to 1.6 kb. This fragment was
pursued. Approximately 3 .mu.g of 20b1 lambda DNA was cut with 20
units of BamHI (Boehringer Mannheim, Indianapolis, Ind.) and 20
Units StuI (NEB, Beverly, Mass.) for 2 hours at 37.degree. C. The
digest was run on a 1% TBE gel and a 1.3 kb doublet and 1.6 kb
doublet bands were excised from the gel and the DNA was extracted
from the agarose using the Qiaquick Gel Extraction Kit (Qiagen,
Valencia, Calif.). Due to the low yield of DNA from the prep, it
was not possible to determine by additional restriction digest
analysis whether fragments which hybridized to the human zalpha11
cDNA probe were BamHI/StuI or StuI/StuI fragments. Thus, blunt
ligations using 5 .mu.l of the 1.3 kb doublet fragment and 5 .mu.l
of the 1.6 kb doublet fragment were done using the Zero Blunt PCR
Cloning Kit (Invitrogen, Carlsbad, Calif.). The blunt ligation
yielded positive clones with both of the 1.6 kb fragments and one
of the 1.3 kb fragments. These clones were digested with EcoRI
(Life Technologies) which flanks the T-overhang site where the 1.6
and 1.3 kb fragments were inserted. Another Southern blot was
performed to determine which was the original fragment hybridizing
to the human zalpha11 cDNA probe. The 1% TBE gel was treated and
the DNA was transferred to the Nytran blot as described above.
[0300] The blot was prehybridized as above in 10 ml of
hybridization solution. A different human zalpha11 polynucleotide
probe was prepared. Another full length zalpha11 cDNA human
zalpha11 fragment was generated for use as a probe by PCR with the
oligos ZC19,905 (SEQ ID NO: 36) and ZC20,097 (SEQ ID NO: 27). The
PCR reaction conditions were as follows: 95.degree. C. for 1 min.;
35 cycles of 95.degree. C. for 1 min., 55.degree. C. for 1 min.,
and 72.degree. C. for 2 min.; followed by one cycle at 72.degree.
C. for 10 min. The PCR product was run on a 1% low melting point
agarose (Boerhinger Mannheim) and the approximately 1.5 kb human
zalpha11 cDNA isolated using Qiaquick.TM. gel extraction kit
(Qiagen) as per manufacturer's instructions. About 50 ng of this
isolated human zalpha11 cDNA fragment was labeled with .sup.32P and
purified as described above. Filters were hybridized as above in
Expresshyb.TM. solution (Clontech) containing about 10.sup.6 cpm/ml
zalpha11 cDNA probe, about 0.1 mg/ml denatured salmon sperm, and
denatured 0.5 .mu.g/ml cot-1 DNA. Hybridization and washing was as
described above. The blot was exposed to film 1.5 hours at
-80.degree. C. and the 1.3 kb insert was strongly hybridizing to
the human zalpha11 probe.
[0301] This clone was sequenced and found to contain a mouse
zalpha11 3' coding exon with a termination codon and upstream
intron sequence. Sequencing primers used were: ZC3,424 (SEQ ID
NO:86), ZC694 (SEQ ID NO:87), ZC24,399 (SEQ ID NO:88), and ZC24,400
(SEQ ID NO:89). The genomic sequence of mouse zalpha11 including
the 3' exon is shown in SEQ ID NO:69. The 3' exon coding sequence
starts at nucleotide 543 and ends at nucleotide 1262 in SEQ ID
NO:69, encoding a 240 amino acid exon (SEQ ID NO:70).
B. PCR Screen of Mouse cDNA Panel
[0302] A panel of available in-house and commercial mouse cDNAs
(Clontech; Life technologies, Gaithersburg, Md.) was screened by
PCR using ZC24,432 (SEQ ID NO:71) and ZC24,433 (SEQ ID NO:72) as
primers (about 20 pmol each). The PCR reaction conditions were as
follows: 94.degree. C., 2 min.; 32 cycles of 94.degree. C. for 20
sec., 64.degree. C. for 30 sec., and 72.degree. C. for 30 sec.;
followed by one cycle at 72.degree. C. for 5 min. Mouse spleen,
dendritic cells, neonatal skin, bone marrow, wild type BaF3 cells,
EL4 cells, and lung showed strong PCR products of the predicted 450
bp size.
[0303] C. 5' nested RACE 5' RACE reactions were performed using 20
pmol each of primers ZC9,739 (SEQ ID NO:73) and ZC24,434 (SEQ ID
NO:74) and CD90+ selected mouse spleen marathon cDNA as a template.
The marathon cDNA was prepared using a Marathon cDNA Amplification
Kit (Clontech) according to the manufacturer's instructions. The
PCR reaction conditions were as follows: 94.degree. C. for 1 min.;
5 cycles of 94.degree. C. for 20 sec., and 70.degree. C. for 1.5
min.; followed by 25 cycles of 94.degree. C. for 20 sec.,
64.degree. C. for 20 sec., and 70.degree. C. for 1.5 min.; followed
by one cycle at 72.degree. C. for 5 min.
[0304] To enrich for mouse zalpha11 5' RACE product, a nested 5'
RACE reaction was performed using PCR reaction conditions as
described above for the initial 5'RACE, except using nested primers
ZC24,431 (SEQ ID NO:75) and ZC9,719 (SEQ ID NO:76), and one .mu.l
of a 1/20 dilution of the initial 5' RACE reaction (above) as a
template. The products were purified by gel electrophoresis, the
DNA was eluted using the Qiaex II Agarose Gel Extraction Kit
(Qiagen) and subcloned using the TOPO TA Cloning Kit (Invitrogen).
Positive clones were identified by colony PCR using 10 pmol each of
ZC24,431 (SEQ ID NO:75) and ZC24,511 (SEQ ID NO:77). The PCR
reaction conditions were as follows: 94.degree. C., 2 min.; 35
cycles of 94.degree. C. for 20 sec., 64.degree. C. for 20 sec., and
72.degree. C. for 30 sec.; followed by one cycle at 72.degree. C.
for 5 min. Two subclones from each of the nested 5'RACE reactions
were sequenced. All the clones contained some zalpha11 sequence but
none were complete. A compiled sequence was generated from the
incomplete 5'RACE clones and the 3' exon sequence (SEQ ID NO:70)
representing a preliminary partial sequence of the mouse zalpha11
polynucleotide and corresponding polypeptide. The preliminary
sequence of the partial mouse zalpha11 cDNA is show in SEQ ID NO:78
(5'end) and SEQ ID NO:80 (3'end); there was approximately 330
nucleotides of yet unknown sequence between SEQ ID NO:78 (5'end)
and SEQ ID NO:80 (3'end) to comprise the entire mouse zalpha11 cDNA
(see below). The corresponding amino acid sequences for SEQ ID
NO:78 and SEQ ID NO:80 are shown in SEQ ID NO:79 (N-terminus) and
SEQ ID NO:81 (C-terminus) respectively.
D. Full Length PCR
[0305] Primers were designed from the mouse upstream UTR of the
initiation Met and downstream of the termination codon for full
length PCR. 20 pmol each of primers ZC24,616 (SEQ ID NO:82) and
ZC24,615 (SEQ ID NO:83) were used in PCR reactions using a mouse
dendritic cell marathon cDNA or a neonatal mouse skin in-house cDNA
library as a template.
[0306] PCR reaction conditions were as follows: 94.degree. C., 1
min.; 30 cycles of 94.degree. C. for 20 sec., and 66.degree. C. for
2 min.; followed by one cycle at 72.degree. C. for 5 min. The PCR
products were purified by gel electrophoresis, and the cDNA was
eluted using the Qiaquick Gel Extraction Kit and subcloned using
the TA Cloning Kit (Invitrogen). 2 subclones from each PCR reaction
were sequenced. Sequencing primers used were: ZC694 (SEQ ID NO:87),
ZC3,424 (SEQ ID NO:86), ZC24,431 (SEQ ID NO:75), ZC24,511 (SEQ ID
NO:77), ZC24,806 (SEQ ID NO:90), and ZC24,807 (SEQ ID NO:91). The
sequence of the full length mouse zalpha11 cDNA is show in SEQ ID
NO:84. The corresponding amino acid sequence is shown in SEQ ID
NO:85.
Example 22
Post-Translational Mannosylation of Zalpha11 Receptor Polypeptide
on a Highly Conserved Trp Residue
[0307] Mannosylation of the human zalpha11 receptor was assessed
using the method for C-2 mannosylation of Tryptophan as described
in Hofsteenge, J et al., Biochemistry 33:13524-13530, 1994, and
Loeffler, A et al., Biochemistry 35:12005-14, 1996. Moreover, these
investigators showed that in a motif of amino acids, WXXW (SEQ ID
NO:92), that Trp can be mannosylated.
[0308] A soluble zalpha11 receptor bearing a C-terminal Glu-Glu
(CEE) (SEQ ID NO:41) or FLAG (SEQ ID NO:49) tag was expressed in
BHK cells and purified by anti-Flag or anti-EE affinity
chromatography (Example 11A and 11B). A soluble zalpha11 receptor
C-terminally tagged with an Fc4 tag (SEQ ID NO:45) and expressed in
CHO cells was affinity purified by anti-Fc4 affinity chromatography
(Example 1.degree. C.). These polypeptides were enzymatically
cleaved to generate peptide fragments for the study.
[0309] All enzymatic digestions were performed overnight at a
protein concentration of 1.0 mg/ml. PNGaseF (Oxford GlycoSciences,
Abingdon, Oxford UK) digestion was performed by diluting each
soluble zalpha11 receptor polypeptide into a 50 mM EDTA, 20 mM
Na-Phosphate pH 7.5 buffer and incubating it with 0.4 U of enzyme
per .mu.g of protein. Glu-C (Roche Molecular Biochemicals,
Indianapolis, Ind.) digestion was performed at a 1:50 ratio of
enzyme to protein by buffer exchanging the sample into 25 mM
NH.sub.4HCO.sub.3 pH 7.8 and incubating it at 25.degree. C., except
for the Fc4 tagged material, which was digested in 50 mM
Na-Phosphate pH 7.8+5% Acetonitrile (EM Science, Darmstadt,
Germany) at 37.degree. C. The Glu-C digestion generated a zalpha11
WSXWS-containing peptide as shown from amino acid 197 (Leu) to
amino acid 218 (Ser) of SEQ ID NO:2. Asp-N (Roche Molecular
Biochemicals, Indianapolis, Ind.) digestion was performed by buffer
exchanging the protein into 50 mM Na-Phosphate pH 7.7 and
incubating it at 37.degree. C. with enzyme at a 1:50 ratio to
zalpha11 receptor polypeptide. The Asp-N digestion generated a
zalpha11 WSXWS-containing peptide as shown from amino acid 198
(Leu) to amino acid 229 (Glu) of SEQ ID NO:2.
[0310] LCMS and LCMS-MS analyses were performed on a Magic HPLC
(Michrom Bioresources, Auburn, Calif.) connected in-line to a
Finnigan LCQ mass spectrometer (Finnigan MAT, San Jose, Calif.). LC
separation was done on a Vydac C4 5.mu. 300A column (Michrom
Bioresources) with an elution gradient of 20%-80% solvent B over 80
minutes where solvent A was 2% Acetonitrile+0.1% TFA and solvent B
was 90% Acetonitrile+0.095% TFA (EM Science; Sigma, St. Louis,
Mo.). The LCQ mass spectrometer was set to collect MS spectra for
the duration of the run. LCMS-MS analysis of polypeptide digests
was performed on the same instrument system using a Vydac C18 5.mu.
300A column (Michrom Bioresources) with an elution gradient of
5-65% solvent B over 80 minutes with the same solvent system
described for LCMS analysis above. The LCQ mass spectrometer was
configured to collect MS, zoom-scan and MS-MS spectra for each ion
over a minimum threshold.
[0311] The extent of tryptophan mannosylation was estimated by
comparing ion intensities for the 2+ and 3+ ions of the peptides
containing the WSXWS motif (SEQ ID NO:3) from both Glu-C and Asp-N
digestion described above. Peak composition was first determined
utilizing the MS data and a peptide map was generated. Next, an
average spectrum was created starting approximately 1 minute before
the early eluting mannosylated WSXWS (SEQ ID NO:3) containing
peptide and ending approximately 1 minute after its later eluting
non-mannosylated companion peptide. The normalized intensities of
the ions corresponding to mannosylated and non-mannosylated peptide
were compared and used to generate a percentage occupancy number.
Values generated for both 2+ and 3+charge states were averaged to
generate a percent occupancy value for each digest. This value was
then averaged with the value from the companion digest for each lot
of protein to generate a final value.
[0312] Table 7 below summarizes the data that were calculated for
each Peptide-tag and host cell used for zalpha11 soluble receptor
expression. TABLE-US-00007 TABLE 7 C-terminal-Tag Expression Host %
WSXWS Mannosylated Glu--Glu BHK .about.46% FLAG BHK .about.35% Fc4
CHO .about.11%
[0313] One of skill in the art would appreciate that mannosylation
or non-mannosylation of the zalpha11 receptor WSXWS motif (SEQ ID
NO:3) can affect the ability of the zalpha11 receptor or zalpha11
soluble receptor to homodimerize, heterodimerize, and/or it's
ability to bind the zalpha11 Ligand. As the mannosylation on
zalpha11 receptor appears to differ depending on the cell type in
which the receptor so expressed, optimization of the expression and
production of zalpha11 receptor and soluble receptor polypeptides
may take into consideration whether the zalpha11 receptor produced
by the cell is mannosylated or non-mannosylated. As such, one of
skill in the art would appreciate that the polypeptides of the
present invention can be either mannosylated or
non-mannosylated.
[0314] As the mannosylation event is within the WSXWS motif (SEQ ID
NO:3) of the zalpha11 class I cytokine receptor, the mannosylation
of the Trp or the lack thereof can affect the polypeptide
functionally. For example, insertions or deletions in the WSXWS
motif (SEQ ID NO:3) of the EPOR can abrogate cell surface
expression, destroy or reduce proliferative response, decrease
receptor internalization, and affect EPO binding (Yoshimura, A et
al., J. Biol. Chem. 267:11619-11625, 1992; Quelle, D E et al., Mol.
Cell. Biol. 12:4553-4561, 1992; Hilton, D J et al., Proc. Natl.
Acad. Sci. USA 92:190-194, 1995). However, mutation in the WSXWS
motif (SEQ ID NO:3) can also result in more efficient export from
the ER and greater expression of the receptor on the cell surface
(Hilton, D J et al., supra.). Effects on cell surface expression,
ligand binding and stimulatory response have also been seen with
studies on WSXWS motif (SEQ ID NO:3) and related motifs in
mutational analysis on IL-2R.beta., GM-CSFR, and GHR (Miyazaki, et
al., EMBO J. 10:3191-3197, 1991; Ronco, L. V. et al., J. Biol.
Chem. 269:277-283, 1994; Baumgartner, J W et al., J. Biol. Chem.
269:29094-29101, 1994).
[0315] Similarly, mannosylation of the first Trp residue in the
WSXWS motif (SEQ ID NO:3) of zalpha11 receptor polypeptides,
including full-length and soluble receptors described herein, can
have important structural and functional implications such as
having affects on the overall stability of the receptor, rate of
proteolysis, intracellular processing, antigenicity, cell surface
expression, dimerization or multimerization, co-receptor binding,
signaling or internalization, affects on zalpha11 Ligand binding
and stability of receptor-ligand interaction. Comparison of
mannosylated and non-mannosylated zalpha11 receptors can be made
using X-ray crystallography or NMR on purified zalpha11
polypeptides (e.g., soluble receptors), or functional studies
comparing zalpha11 expressed in cell lines that either mannosylated
(e.g., BHK or other cell line) or are defective or reduced in
mannosylation (e.g., CHO or other cell line) and comparing the
receptors in the various assays described herein.
[0316] From the foregoing, it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended
claims.
Sequence CWU 1
1
92 1 2887 DNA Homo sapiens CDS (69)...(1682) 1 gaagcagcag
gtaccccctc cacatcccta gggctctgtg atgtaggcag aggcccgtgg 60 gagtcagc
atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc 110 Met Pro
Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu 1 5 10 cag gga ggc
tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc 158 Gln Gly Gly
Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu 15 20 25 30 cag
acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg 206 Gln
Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr 35 40
45 ctc acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc
254 Leu Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala
50 55 60 acc tcc tgc agc ctc cac agg tcg gcc cac aat gcc acg cat
gcc acc 302 Thr Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His
Ala Thr 65 70 75 tac acc tgc cac atg gat gta ttc cac ttc atg gcc
gac gac att ttc 350 Tyr Thr Cys His Met Asp Val Phe His Phe Met Ala
Asp Asp Ile Phe 80 85 90 agt gtc aac atc aca gac cag tct ggc aac
tac tcc cag gag tgt ggc 398 Ser Val Asn Ile Thr Asp Gln Ser Gly Asn
Tyr Ser Gln Glu Cys Gly 95 100 105 110 agc ttt ctc ctg gct gag agc
atc aag ccg gct ccc cct ttc aac gtg 446 Ser Phe Leu Leu Ala Glu Ser
Ile Lys Pro Ala Pro Pro Phe Asn Val 115 120 125 act gtg acc ttc tca
gga cag tat aat atc tcc tgg cgc tca gat tac 494 Thr Val Thr Phe Ser
Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr 130 135 140 gaa gac cct
gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg 542 Glu Asp Pro
Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu 145 150 155 cag
tac agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag 590 Gln
Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys 160 165
170 ctg atc tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc
638 Leu Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe
175 180 185 190 cgc aaa gac tcg agc tat gag ctg cag gtg cgg gca ggg
ccc atg cct 686 Arg Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly
Pro Met Pro 195 200 205 ggc tcc tcc tac cag ggg acc tgg agt gaa tgg
agt gac ccg gtc atc 734 Gly Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp
Ser Asp Pro Val Ile 210 215 220 ttt cag acc cag tca gag gag tta aag
gaa ggc tgg aac cct cac ctg 782 Phe Gln Thr Gln Ser Glu Glu Leu Lys
Glu Gly Trp Asn Pro His Leu 225 230 235 ctg ctt ctc ctc ctg ctt gtc
ata gtc ttc att cct gcc ttc tgg agc 830 Leu Leu Leu Leu Leu Leu Val
Ile Val Phe Ile Pro Ala Phe Trp Ser 240 245 250 ctg aag acc cat cca
ttg tgg agg cta tgg aag aag ata tgg gcc gtc 878 Leu Lys Thr His Pro
Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val 255 260 265 270 ccc agc
cct gag cgg ttc ttc atg ccc ctg tac aag ggc tgc agc gga 926 Pro Ser
Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly 275 280 285
gac ttc aag aaa tgg gtg ggt gca ccc ttc act ggc tcc agc ctg gag 974
Asp Phe Lys Lys Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu 290
295 300 ctg gga ccc tgg agc cca gag gtg ccc tcc acc ctg gag gtg tac
agc 1022 Leu Gly Pro Trp Ser Pro Glu Val Pro Ser Thr Leu Glu Val
Tyr Ser 305 310 315 tgc cac cca cca cgg agc ccg gcc aag agg ctg cag
ctc acg gag cta 1070 Cys His Pro Pro Arg Ser Pro Ala Lys Arg Leu
Gln Leu Thr Glu Leu 320 325 330 caa gaa cca gca gag ctg gtg gag tct
gac ggt gtg ccc aag ccc agc 1118 Gln Glu Pro Ala Glu Leu Val Glu
Ser Asp Gly Val Pro Lys Pro Ser 335 340 345 350 ttc tgg ccg aca gcc
cag aac tcg ggg ggc tca gct tac agt gag gag 1166 Phe Trp Pro Thr
Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu 355 360 365 agg gat
cgg cca tac ggc ctg gtg tcc att gac aca gtg act gtg cta 1214 Arg
Asp Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu 370 375
380 gat gca gag ggg cca tgc acc tgg ccc tgc agc tgt gag gat gac ggc
1262 Asp Ala Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp
Gly 385 390 395 tac cca gcc ctg gac ctg gat gct ggc ctg gag ccc agc
cca ggc cta 1310 Tyr Pro Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro
Ser Pro Gly Leu 400 405 410 gag gac cca ctc ttg gat gca ggg acc aca
gtc ctg tcc tgt ggc tgt 1358 Glu Asp Pro Leu Leu Asp Ala Gly Thr
Thr Val Leu Ser Cys Gly Cys 415 420 425 430 gtc tca gct ggc agc cct
ggg cta gga ggg ccc ctg gga agc ctc ctg 1406 Val Ser Ala Gly Ser
Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu 435 440 445 gac aga cta
aag cca ccc ctt gca gat ggg gag gac tgg gct ggg gga 1454 Asp Arg
Leu Lys Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly 450 455 460
ctg ccc tgg ggt ggc cgg tca cct gga ggg gtc tca gag agt gag gcg
1502 Leu Pro Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu
Ala 465 470 475 ggc tca ccc ctg gcc ggc ctg gat atg gac acg ttt gac
agt ggc ttt 1550 Gly Ser Pro Leu Ala Gly Leu Asp Met Asp Thr Phe
Asp Ser Gly Phe 480 485 490 gtg ggc tct gac tgc agc agc cct gtg gag
tgt gac ttc acc agc ccc 1598 Val Gly Ser Asp Cys Ser Ser Pro Val
Glu Cys Asp Phe Thr Ser Pro 495 500 505 510 ggg gac gaa gga ccc ccc
cgg agc tac ctc cgc cag tgg gtg gtc att 1646 Gly Asp Glu Gly Pro
Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile 515 520 525 cct ccg cca
ctt tcg agc cct gga ccc cag gcc agc taatgaggct 1692 Pro Pro Pro Leu
Ser Ser Pro Gly Pro Gln Ala Ser 530 535 gactggatgt ccagagctgg
ccaggccact gggccctgag ccagagacaa ggtcacctgg 1752 gctgtgatgt
gaagacacct gcagcctttg gtctcctgga tgggcctttg agcctgatgt 1812
ttacagtgtc tgtgtgtgtg tgtgcatatg tgtgtgtgtg catatgcatg tgtgtgtgtg
1872 tgtgtgtctt aggtgcgcag tggcatgtcc acgtgtgtgt gtgattgcac
gtgcctgtgg 1932 gcctgggata atgcccatgg tactccatgc attcacctgc
cctgtgcatg tctggactca 1992 cggagctcac ccatgtgcac aagtgtgcac
agtaaacgtg tttgtggtca acagatgaca 2052 acagccgtcc tccctcctag
ggtcttgtgt tgcaagttgg tccacagcat ctccggggct 2112 ttgtgggatc
agggcattgc ctgtgactga ggcggagccc agccctccag cgtctgcctc 2172
caggagctgc aagaagtcca tattgttcct tatcacctgc caacaggaag cgaaagggga
2232 tggagtgagc ccatggtgac ctcgggaatg gcaatttttt gggcggcccc
tggacgaagg 2292 tctgaatccc gactctgata ccttctggct gtgctacctg
agccaagtcg cctcccctct 2352 ctgggctaga gtttccttat ccagacagtg
gggaaggcat gacacacctg ggggaaattg 2412 gcgatgtcac ccgtgtacgg
tacgcagccc agagcagacc ctcaataaac gtcagcttcc 2472 ttccttctgc
ggccagagcc gaggcgggcg ggggtgagaa catcaatcgt cagcgacagc 2532
ctgggcaccc gcggggccgt cccgcctgca gagggccact cgggggggtt tccaggctta
2592 aaatcagtcc gtttcgtctc ttggaaacag ctccccacca accaagattt
ctttttctaa 2652 cttctgctac taagttttta aaaattccct ttatgcaccc
aagagatatt tattaaacac 2712 caattacgta gcaggccatg gctcatggga
cccacccccc gtggcactca tggagggggc 2772 tgcaggttgg aactatgcag
tgtgctccgg ccacacatcc tgctgggccc cctaccctgc 2832 cccaattcaa
tcctgccaat aaatcctgtc ttatttgttc atcctggaga attga 2887 2 538 PRT
Homo sapiens 2 Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu
Leu Gln Gly 1 5 10 15 Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr
Asp Tyr Leu Gln Thr 20 25 30 Val Ile Cys Ile Leu Glu Met Trp Asn
Leu His Pro Ser Thr Leu Thr 35 40 45 Leu Thr Trp Gln Asp Gln Tyr
Glu Glu Leu Lys Asp Glu Ala Thr Ser 50 55 60 Cys Ser Leu His Arg
Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr 65 70 75 80 Cys His Met
Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val 85 90 95 Asn
Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe 100 105
110 Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
115 120 125 Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr
Glu Asp 130 135 140 Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr
Glu Leu Gln Tyr 145 150 155 160 Arg Asn Arg Gly Asp Pro Trp Ala Val
Ser Pro Arg Arg Lys Leu Ile 165 170 175 Ser Val Asp Ser Arg Ser Val
Ser Leu Leu Pro Leu Glu Phe Arg Lys 180 185 190 Asp Ser Ser Tyr Glu
Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser 195 200 205 Ser Tyr Gln
Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln 210 215 220 Thr
Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu 225 230
235 240 Leu Leu Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu
Lys 245 250 255 Thr His Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala
Val Pro Ser 260 265 270 Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly
Cys Ser Gly Asp Phe 275 280 285 Lys Lys Trp Val Gly Ala Pro Phe Thr
Gly Ser Ser Leu Glu Leu Gly 290 295 300 Pro Trp Ser Pro Glu Val Pro
Ser Thr Leu Glu Val Tyr Ser Cys His 305 310 315 320 Pro Pro Arg Ser
Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu 325 330 335 Pro Ala
Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp 340 345 350
Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp 355
360 365 Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp
Ala 370 375 380 Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp
Gly Tyr Pro 385 390 395 400 Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro
Ser Pro Gly Leu Glu Asp 405 410 415 Pro Leu Leu Asp Ala Gly Thr Thr
Val Leu Ser Cys Gly Cys Val Ser 420 425 430 Ala Gly Ser Pro Gly Leu
Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg 435 440 445 Leu Lys Pro Pro
Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro 450 455 460 Trp Gly
Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser 465 470 475
480 Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly
485 490 495 Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro
Gly Asp 500 505 510 Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val
Val Ile Pro Pro 515 520 525 Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser
530 535 3 5 PRT Artificial Sequence consensus amino acid motif
VARIANT (1)...(5) Xaa = Any Amino Acid VARIANT (1)...(5) Xaa = Any
Amino Acid 3 Trp Ser Xaa Trp Ser 1 5 4 1614 DNA Artificial Sequence
degenerate nucleotide sequence of zalpha11 misc_feature
(1)...(1614) n = A,T,C or G misc_feature (1)...(1614) n = A,T,C or
G 4 atgccnmgng gntgggcngc nccnytnytn ytnytnytny tncarggngg
ntggggntgy 60 ccngayytng tntgytayac ngaytayytn caracngtna
thtgyathyt ngaratgtgg 120 aayytncayc cnwsnacnyt nacnytnacn
tggcargayc artaygarga rytnaargay 180 gargcnacnw sntgywsnyt
ncaymgnwsn gcncayaayg cnacncaygc nacntayacn 240 tgycayatgg
aygtnttyca yttyatggcn gaygayatht tywsngtnaa yathacngay 300
carwsnggna aytaywsnca rgartgyggn wsnttyytny tngcngarws nathaarccn
360 gcnccnccnt tyaaygtnac ngtnacntty wsnggncart ayaayathws
ntggmgnwsn 420 gaytaygarg ayccngcntt ytayatgytn aarggnaary
tncartayga rytncartay 480 mgnaaymgng gngayccntg ggcngtnwsn
ccnmgnmgna arytnathws ngtngaywsn 540 mgnwsngtnw snytnytncc
nytngartty mgnaargayw snwsntayga rytncargtn 600 mgngcnggnc
cnatgccngg nwsnwsntay carggnacnt ggwsngartg gwsngayccn 660
gtnathttyc aracncarws ngargarytn aargarggnt ggaayccnca yytnytnytn
720 ytnytnytny tngtnathgt nttyathccn gcnttytggw snytnaarac
ncayccnytn 780 tggmgnytnt ggaaraarat htgggcngtn ccnwsnccng
armgnttytt yatgccnytn 840 tayaarggnt gywsnggnga yttyaaraar
tgggtnggng cnccnttyac nggnwsnwsn 900 ytngarytng gnccntggws
nccngargtn ccnwsnacny tngargtnta ywsntgycay 960 ccnccnmgnw
snccngcnaa rmgnytncar ytnacngary tncargarcc ngcngarytn 1020
gtngarwsng ayggngtncc naarccnwsn ttytggccna cngcncaraa ywsnggnggn
1080 wsngcntayw sngargarmg ngaymgnccn tayggnytng tnwsnathga
yacngtnacn 1140 gtnytngayg cngarggncc ntgyacntgg ccntgywsnt
gygargayga yggntayccn 1200 gcnytngayy tngaygcngg nytngarccn
wsnccnggny tngargaycc nytnytngay 1260 gcnggnacna cngtnytnws
ntgyggntgy gtnwsngcng gnwsnccngg nytnggnggn 1320 ccnytnggnw
snytnytnga ymgnytnaar ccnccnytng cngayggnga rgaytgggcn 1380
ggnggnytnc cntggggngg nmgnwsnccn ggnggngtnw sngarwsnga rgcnggnwsn
1440 ccnytngcng gnytngayat ggayacntty gaywsnggnt tygtnggnws
ngaytgywsn 1500 wsnccngtng artgygaytt yacnwsnccn ggngaygarg
gnccnccnmg nwsntayytn 1560 mgncartggg tngtnathcc nccnccnytn
wsnwsnccng gnccncargc nwsn 1614 5 17 DNA Artificial Sequence
Oligonucleotide primer ZC447 5 taacaatttc acacagg 17 6 18 DNA
Artificial Sequence Oligonucleotide primer ZC976 6 cgttgtaaaa
cgacggcc 18 7 21 DNA Artificial Sequence Oligonucleotide primer
ZC19345 7 gaccagtctg gcaactactc c 21 8 20 DNA Artificial Sequence
Oligonucleotide primer ZC19346 8 gctctcagcc aggagaaagc 20 9 20 DNA
Artificial Sequence Oligonucleotide primer ZC19349 9 ggttggtggg
gagctgtttc 20 10 20 DNA Artificial Sequence Oligonucleotide primer
ZC19350 10 gggtgagaac atcaatcgtc 20 11 21 DNA Artificial Sequence
Oligonucleotide primer ZC19458 11 catatcttct tccatagcct c 21 12 21
DNA Artificial Sequence Oligonucleotide primer ZC19459 12
ctcctcctgc ttgtcatagt c 21 13 21 DNA Artificial Sequence
Oligonucleotide primer ZC19460 13 gtaaacgtgt ttgtggtcaa c 21 14 20
DNA Artificial Sequence Oligonucleotide primer ZC19461 14
tgccctgatc ccacaaagcc 20 15 20 DNA Artificial Sequence
Oligonucleotide primer ZC19572 15 gtcctgtggc tgtgtctcag 20 16 20
DNA Artificial Sequence Oligonucleotide primer ZC19573 16
cagtcagagc ccacaaagcc 20 17 20 DNA Artificial Sequence
Oligonucleotide primer ZC19657 17 ctgagacaca gccacaggac 20 18 24
DNA Artificial Sequence Oligonucleotide primer ZC19181 18
tccacatccc tagggctctg tgat 24 19 25 DNA Artificial Sequence
Oligonucleotide primer ZC19182 19 gaggttccac atttccagga tgcag 25 20
24 DNA Artificial Sequence Oligonucleotide primer ZC19907 20
atggatgtat tccacttcat ggcc 24 21 24 DNA Artificial Sequence
Oligonucleotide primer ZC19908 21 actgtcaaac gtgtccatat ccag 24 22
18 DNA Artificial Sequence Oligonucleotide primer ZC19954 22
actgggctgg gggactgc 18 23 18 DNA Artificial Sequence
Oligonucleotide primer ZC19955 23 ccccggggct ggtgaagt 18 24 33 DNA
Artificial Sequence Oligonucleotide primer ZC17212 24 ggggaattcg
aagccatgcc ctcttgggcc ctc 33 25 30 DNA Artificial Sequence
Oligonucleotide primer ZC19914 25 caatggatgg gtctttagca gcagtaggcc
30 26 30 DNA Artificial Sequence Oligonucleotide primer ZC19913 26
ggcctactgc tgctaaagac ccatccattg 30 27 33 DNA Artificial Sequence
Oligonucleotide primer ZC20097 27 acatctagat tagctggcct ggggtccagg
cgt 33 28 21 DNA Artificial Sequence Oligonucleotide primer ZC12700
28 ggaggtctat ataagcagag c 21 29 21 DNA Artificial Sequence
Oligonucleotide primer ZC5020 29 cactggagtg gcaacttcca g 21 30 20
DNA Artificial Sequence Oligonucleotide primer ZC6675 30 gtggatgccg
aacccagtcc 20 31 21 DNA Artificial Sequence Oligonucleotide primer
ZC7727 31 tgttcacagc
tacctgggct c 21 32 26 DNA Artificial Sequence Oligonucleotide
primer ZC8290 32 ccaccgagac tgcttggatc accttg 26 33 21 DNA
Artificial Sequence Oligonucleotide primer ZC6622 33 ctgggctgga
aactggcaca c 21 34 18 DNA Artificial Sequence Oligonucleotide
primer ZC7736 34 cactgtcaga aatggagc 18 35 24 DNA Artificial
Sequence Oligonucleotide primer ZC9273 35 ggtccctccc cgggcaccga
gaga 24 36 36 DNA Artificial Sequence Oligonucleotide primer
ZC19905 36 acaggatccg tcagcatgcc gcgtggctgg gccgcc 36 37 33 DNA
Artificial Sequence Oligonucleotide primer ZC19906 37 acagaattct
tagctggcct ggggtccagg cgt 33 38 22 DNA Artificial Sequence
Oligonucleotide primer ZC20114 38 cctgccttct acatgctgaa gg 22 39 18
DNA Artificial Sequence Oligonucleotide primer ZC19954 39
actgggctgg gggactgc 18 40 22 DNA Artificial Sequence
Oligonucleotide primer ZC20116 40 agcacagtca ctgtgtcaat gg 22 41 6
PRT Artificial Sequence Glu-Glu (CEE) tag amino acid sequence 41
Glu Tyr Met Pro Met Glu 1 5 42 36 DNA Artificial Sequence
Oligonucleotide promer ZC19931 42 ggttggtacc gcaagatgcc gcgtggctgg
gccgcc 36 43 29 DNA Artificial Sequence Oligonucleotide primer
ZC19932 43 cggaggatcc gtgagggttc cagccttcc 29 44 66 DNA Artificial
Sequence Oligonucleotide primer spanning vector flanking region and
the 5' end of the zalpha11 44 tccactttgc ctttctctcc acaggtgtcc
agggaattca tcgataatgc cgcgtggctg 60 ggccgc 66 45 699 DNA Homo
sapiens 45 gagcccagat cttcagacaa aactcacaca tgcccaccgt gcccagcacc
tgaagccgag 60 ggggcaccgt cagtcttcct cttcccccca aaacccaagg
acaccctcat gatctcccgg 120 acccctgagg tcacatgcgt ggtggtggac
gtgagccacg aagaccctga ggtcaagttc 180 aactggtacg tggacggcgt
ggaggtgcat aatgccaaga caaagccgcg ggaggagcag 240 tacaacagca
cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 300
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc catcctccat cgagaaaacc
360 atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc
cccatcccgg 420 gatgagctga ccaagaacca ggtcagcctg acctgcctgg
tcaaaggctt ctatcccagc 480 gacatcgccg tggagtggga gagcaatggg
cagccggaga acaactacaa gaccacgcct 540 cccgtgctgg actccgacgg
ctccttcttc ctctacagca agctcaccgt ggacaagagc 600 aggtggcagc
aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 660
tacacgcaga agagcctctc cctgtctccg ggtaaataa 699 46 62 DNA Artificial
Sequence First Oligonucleotide primer spanning 3' end of the
zalpha11 extracellular domain and the 5' end of Fc4 46 gcacggtggg
catgtgtgag ttttgtctga agatctgggc tcgtgagggt tccagccttc 60 ct 62 47
61 DNA Artificial Sequence Second Oligonucleotide primer spanning
3' end of the zalpha11 extracellular domain and the 5' end of Fc4
47 agacccagtc agaggagtta aaggaaggct ggaaccctca cgagcccaga
tcttcagaca 60 a 61 48 67 DNA Artificial Sequence Oligonucleotide
primer spanning the 3' end of Fc4 and the vector flanking region 48
gtgggcctct ggggtgggta caaccccaga gctgttttaa tctagattat ttacccggag
60 acaggga 67 49 8 PRT Artificial Sequence FLAG tag amino acid
sequence 49 Asp Tyr Lys Asp Asp Asp Asp Lys 1 5 50 1821 DNA
Artificial Sequence Polynucleotide encoding MBP-zalpha11 soluble
receptor fusion CDS (1)...(1821) 50 atg aaa atc gaa gaa ggt aaa ctg
gta atc tgg att aac ggc gat aaa 48 Met Lys Ile Glu Glu Gly Lys Leu
Val Ile Trp Ile Asn Gly Asp Lys 1 5 10 15 ggc tat aac ggt ctc gct
gaa gtc ggt aag aaa ttc gag aaa gat acc 96 Gly Tyr Asn Gly Leu Ala
Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 20 25 30 gga att aaa gtc
acc gtt gag cat ccg gat aaa ctg gaa gag aaa ttc 144 Gly Ile Lys Val
Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 35 40 45 cca cag
gtt gcg gca act ggc gat ggc cct gac att atc ttc tgg gca 192 Pro Gln
Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala 50 55 60
cac gac cgc ttt ggt ggc tac gct caa tct ggc ctg ttg gct gaa atc 240
His Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu Ile 65
70 75 80 acc ccg gac aaa gcg ttc cag gac aag ctg tat ccg ttt acc
tgg gat 288 Thr Pro Asp Lys Ala Phe Gln Asp Lys Leu Tyr Pro Phe Thr
Trp Asp 85 90 95 gcc gta cgt tac aac ggc aag ctg att gct tac ccg
atc gct gtt gaa 336 Ala Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro
Ile Ala Val Glu 100 105 110 gcg tta tcg ctg att tat aac aaa gat ctg
ctg ccg aac ccg cca aaa 384 Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu
Leu Pro Asn Pro Pro Lys 115 120 125 acc tgg gaa gag atc ccg gcg ctg
gat aaa gaa ctg aaa gcg aaa ggt 432 Thr Trp Glu Glu Ile Pro Ala Leu
Asp Lys Glu Leu Lys Ala Lys Gly 130 135 140 aag agc gcg ctg atg ttc
aac ctg caa gaa ccg tac ttc acc tgg ccg 480 Lys Ser Ala Leu Met Phe
Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro 145 150 155 160 ctg att gct
gct gac ggg ggt tat gcg ttc aag tat gaa aac ggc aag 528 Leu Ile Ala
Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 165 170 175 tac
gac att aaa gac gtg ggc gtg gat aac gct ggc gcg aaa gcg ggt 576 Tyr
Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly 180 185
190 ctg acc ttc ctg gtt gac ctg att aaa aac aaa cac atg aat gca gac
624 Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp
195 200 205 acc gat tac tcc atc gca gaa gct gcc ttt aat aaa ggc gaa
aca gcg 672 Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu
Thr Ala 210 215 220 atg acc atc aac ggc ccg tgg gca tgg tcc aac atc
gac acc agc aaa 720 Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile
Asp Thr Ser Lys 225 230 235 240 gtg aat tat ggt gta acg gta ctg ccg
acc ttc aag ggt caa cca tcc 768 Val Asn Tyr Gly Val Thr Val Leu Pro
Thr Phe Lys Gly Gln Pro Ser 245 250 255 aaa ccg ttc gtt ggc gtg ctg
agc gca ggt att aac gcc gcc agt ccg 816 Lys Pro Phe Val Gly Val Leu
Ser Ala Gly Ile Asn Ala Ala Ser Pro 260 265 270 aac aaa gag ctg gca
aaa gag ttc ctc gaa aac tat ctg ctg act gat 864 Asn Lys Glu Leu Ala
Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp 275 280 285 gaa ggt ctg
gaa gcg gtt aat aaa gac aaa ccg ctg ggt gcc gta gcg 912 Glu Gly Leu
Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala 290 295 300 ctg
aag tct tac gag gaa gag ttg gcg aaa gat cca cgt att gcc gcc 960 Leu
Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala 305 310
315 320 acc atg gaa aac gcc cag aaa ggt gaa atc atg ccg aac atc ccg
cag 1008 Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile
Pro Gln 325 330 335 atg tcc gct ttc tgg tat gcc gtg cgt act gcg gtg
atc aac gcc gcc 1056 Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala
Val Ile Asn Ala Ala 340 345 350 agc ggt cgt cag act gtc gat gaa gcc
ctg aaa gac gcg cag act aat 1104 Ser Gly Arg Gln Thr Val Asp Glu
Ala Leu Lys Asp Ala Gln Thr Asn 355 360 365 tcg agc tcc cac cat cac
cat cac cac gcg aat tcg gta ccg ctg gtt 1152 Ser Ser Ser His His
His His His His Ala Asn Ser Val Pro Leu Val 370 375 380 ccg cgt gga
tcc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag 1200 Pro Arg
Gly Ser Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln 385 390 395
400 acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc
1248 Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr
Leu 405 410 415 acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac
gag gcc acc 1296 Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys
Asp Glu Ala Thr 420 425 430 tcc tgc agc ctc cac agg tcg gcc cac aat
gcc acg cat gcc acc tac 1344 Ser Cys Ser Leu His Arg Ser Ala His
Asn Ala Thr His Ala Thr Tyr 435 440 445 acc tgc cac atg gat gta ttc
cac ttc atg gcc gac gac att ttc agt 1392 Thr Cys His Met Asp Val
Phe His Phe Met Ala Asp Asp Ile Phe Ser 450 455 460 gtc aac atc aca
gac cag tct ggc aac tac tcc cag gag tgt ggc agc 1440 Val Asn Ile
Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser 465 470 475 480
ttt ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act
1488 Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val
Thr 485 490 495 gtg acc ttc tca gga cag tat aat atc tcc tgg cgc tca
gat tac gaa 1536 Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg
Ser Asp Tyr Glu 500 505 510 gac cct gcc ttc tac atg ctg aag ggc aag
ctt cag tat gag ctg cag 1584 Asp Pro Ala Phe Tyr Met Leu Lys Gly
Lys Leu Gln Tyr Glu Leu Gln 515 520 525 tac agg aac cgg gga gac ccc
tgg gct gtg agt ccg agg aga aag ctg 1632 Tyr Arg Asn Arg Gly Asp
Pro Trp Ala Val Ser Pro Arg Arg Lys Leu 530 535 540 atc tca gtg gac
tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc 1680 Ile Ser Val
Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg 545 550 555 560
aaa gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc
1728 Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro
Gly 565 570 575 tcc tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg
gtc atc ttt 1776 Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp
Pro Val Ile Phe 580 585 590 cag acc cag tca gag gag tta aag gaa ggc
tgg aac cct cac tag 1821 Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly
Trp Asn Pro His * 595 600 605 51 606 PRT Artificial Sequence
Polynucleotide encoding MBP-zalpha11 soluble receptor fusion 51 Met
Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 1 5 10
15 Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr
20 25 30 Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu
Lys Phe 35 40 45 Pro Gln Val Ala Ala Thr Gly Asp Gly Pro Asp Ile
Ile Phe Trp Ala 50 55 60 His Asp Arg Phe Gly Gly Tyr Ala Gln Ser
Gly Leu Leu Ala Glu Ile 65 70 75 80 Thr Pro Asp Lys Ala Phe Gln Asp
Lys Leu Tyr Pro Phe Thr Trp Asp 85 90 95 Ala Val Arg Tyr Asn Gly
Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu 100 105 110 Ala Leu Ser Leu
Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys 115 120 125 Thr Trp
Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly 130 135 140
Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro 145
150 155 160 Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn
Gly Lys 165 170 175 Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly
Ala Lys Ala Gly 180 185 190 Leu Thr Phe Leu Val Asp Leu Ile Lys Asn
Lys His Met Asn Ala Asp 195 200 205 Thr Asp Tyr Ser Ile Ala Glu Ala
Ala Phe Asn Lys Gly Glu Thr Ala 210 215 220 Met Thr Ile Asn Gly Pro
Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys 225 230 235 240 Val Asn Tyr
Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro Ser 245 250 255 Lys
Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro 260 265
270 Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp
275 280 285 Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala
Val Ala 290 295 300 Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro
Arg Ile Ala Ala 305 310 315 320 Thr Met Glu Asn Ala Gln Lys Gly Glu
Ile Met Pro Asn Ile Pro Gln 325 330 335 Met Ser Ala Phe Trp Tyr Ala
Val Arg Thr Ala Val Ile Asn Ala Ala 340 345 350 Ser Gly Arg Gln Thr
Val Asp Glu Ala Leu Lys Asp Ala Gln Thr Asn 355 360 365 Ser Ser Ser
His His His His His His Ala Asn Ser Val Pro Leu Val 370 375 380 Pro
Arg Gly Ser Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln 385 390
395 400 Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr
Leu 405 410 415 Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp
Glu Ala Thr 420 425 430 Ser Cys Ser Leu His Arg Ser Ala His Asn Ala
Thr His Ala Thr Tyr 435 440 445 Thr Cys His Met Asp Val Phe His Phe
Met Ala Asp Asp Ile Phe Ser 450 455 460 Val Asn Ile Thr Asp Gln Ser
Gly Asn Tyr Ser Gln Glu Cys Gly Ser 465 470 475 480 Phe Leu Leu Ala
Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr 485 490 495 Val Thr
Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu 500 505 510
Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln 515
520 525 Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys
Leu 530 535 540 Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu
Glu Phe Arg 545 550 555 560 Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg
Ala Gly Pro Met Pro Gly 565 570 575 Ser Ser Tyr Gln Gly Thr Trp Ser
Glu Trp Ser Asp Pro Val Ile Phe 580 585 590 Gln Thr Gln Ser Glu Glu
Leu Lys Glu Gly Trp Asn Pro His 595 600 605 52 657 DNA Homo sapiens
52 tgccccgacc tcgtctgcta caccgattac ctccagacgg tcatctgcat
cctggaaatg 60 tggaacctcc accccagcac gctcaccctt acctggcaag
accagtatga agagctgaag 120 gacgaggcca cctcctgcag cctccacagg
tcggcccaca atgccacgca tgccacctac 180 acctgccaca tggatgtatt
ccacttcatg gccgacgaca ttttcagtgt caacatcaca 240 gaccagtctg
gcaactactc ccaggagtgt ggcagctttc tcctggctga gagcatcaag 300
ccggctcccc ctttcaacgt gactgtgacc ttctcaggac agtataatat ctcctggcgc
360 tcagattacg aagaccctgc cttctacatg ctgaagggca agcttcagta
tgagctgcag 420 tacaggaacc ggggagaccc ctgggctgtg agtccgagga
gaaagctgat ctcagtggac 480 tcaagaagtg tctccctcct ccccctggag
ttccgcaaag actcgagcta tgagctgcag 540 gtgcgggcag ggcccatgcc
tggctcctcc taccagggga cctggagtga atggagtgac 600 ccggtcatct
ttcagaccca gtcagaggag ttaaaggaag gctggaaccc tcactag 657 53 65 DNA
Artificial Sequence Oligonucleotide primer ZC20187 53 tcaccacgcg
aattcggtac cgctggttcc gcgtggatcc tgccccgacc tcgtctgcta 60 caccg 65
54 68 DNA Artificial Sequence Oligonucleotide primer ZC20185 54
tctgtatcag gctgaaaatc ttatctcatc cgccaaaaca ctagtgaggg ttccagcctt
60 cctttaac 68 55 40 DNA Artificial Sequence Oligonucleotide primer
ZC19372 55 tgtcgatgaa gccctgaaag acgcgcagac taattcgagc 40 56 60 DNA
Artificial Sequence Oligonucleotide primer ZC19351 56 acgcgcagac
taattcgagc tcccaccatc accatcacca cgcgaattcg gtaccgctgg 60 57 60 DNA
Artificial Sequence Oligonucleotide primer ZC19352 57 actcactata
gggcgaattg cccgggggat ccacgcggaa ccagcggtac cgaattcgcg 60 58 42 DNA
Artificial Sequence Oligonucleotide primer ZC19371 58 acggccagtg
aattgtaata cgactcacta tagggcgaat tg 42 59 20 DNA Artificial
Sequence Oligonucleotide primer ZC22277 59 ccaggagtgt ggcagctttc 20
60 21 DNA Artificial Sequence Oligonucleotide primer ZC22276 60
gcttgccctt cagcatgtag a 21 61 23 DNA Artificial Sequence zalpha11
TaqMan probe, ZG31 61 cggctccccc tttcaacgtg act 23 62 20 DNA
Artificial Sequence Oligonucleotide
primer ZC23684 62 tcacccttac ctggcaagac 20 63 41 DNA Artificial
Sequence Oligonucleotide primer ZC23656 63 taatacgact cactataggg
agggggagac acttcttgag t 41 64 20 DNA Artificial Sequence
Oligonucleotide primer ZC23685 64 aggtctgaat cccgactctg 20 65 41
DNA Artificial Sequence Oligonucleotide primer ZC23657 65
taatacgact cactataggg aggacgtaat tggtgtttaa t 41 66 20 DNA
Artificial Sequence Oligonucleotide primer, rRNA forward primer 66
cggctaccac atccaaggaa 20 67 18 DNA Artificial Sequence
Oligonucleotide primer, rRNA reverse primer 67 gctggaatta ccgcggct
18 68 22 DNA Artificial Sequence rRNA TaqMan probe 68 tgctggcacc
agacttgccc tc 22 69 1298 DNA Mus musculus CDS (543)...(1262) 69
aggcctttca acacggcttt ttagtaattc attccatcta taaacattta tggtacacct
60 actgtgtgcc aggtactgag gacacagttg tgatcagggc tagtgtagac
acacaagcaa 120 aactagagac atccggaagt gtcaggagac ggagtagagg
ctgggccact tagacctcag 180 gctctccctg cacacgtcct caagacctta
ggacttagga acctggtccc agcacccagc 240 tgttccttgg ctggggcact
ggtaactagc gtggatatga gacagaggac agtcagtcct 300 tactaaaggt
gggaacacgg gctctgagaa cggacagtat tgggaaccca ctgggcaggg 360
ggttcacaga cagacatcat ggcgcgctct ctctctctct ctctctcctg ttttcttgtt
420 cttctgcttt ccccgtctct ggcttgtccc tgtactcccc cccccacccc
catctttggc 480 tctctctgtt cacacccgac cttgttgtcc ccagctcatg
actgtgtgtt tctttctcat 540 ag aaa tgg gtt aat acc cct ttc acg gcc
tcc agc ata gag ttg gtg 587 Lys Trp Val Asn Thr Pro Phe Thr Ala Ser
Ser Ile Glu Leu Val 1 5 10 15 cca cag agt tcc aca aca aca tca gcc
tta cat ctg tca ttg tat cca 635 Pro Gln Ser Ser Thr Thr Thr Ser Ala
Leu His Leu Ser Leu Tyr Pro 20 25 30 gcc aag gag aag aag ttc ccg
ggg ctg ccg ggt ctg gaa gag caa ctg 683 Ala Lys Glu Lys Lys Phe Pro
Gly Leu Pro Gly Leu Glu Glu Gln Leu 35 40 45 gag tgt gat gga atg
tct gag cct ggt cac tgg tgc ata atc ccc ttg 731 Glu Cys Asp Gly Met
Ser Glu Pro Gly His Trp Cys Ile Ile Pro Leu 50 55 60 gca gct ggc
caa gcg gtc tca gcc tac agt gag gag aga gac cgg cca 779 Ala Ala Gly
Gln Ala Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro 65 70 75 tat
ggt ctg gtg tcc att gac aca gtg act gtg gga gat gca gag ggc 827 Tyr
Gly Leu Val Ser Ile Asp Thr Val Thr Val Gly Asp Ala Glu Gly 80 85
90 95 ctg tgt gtc tgg ccc tgt agc tgt gag gat gat ggc tat cca gcc
atg 875 Leu Cys Val Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala
Met 100 105 110 aac ctg gat gct ggc cga gag tct ggc cct aat tca gag
gat ctg ctc 923 Asn Leu Asp Ala Gly Arg Glu Ser Gly Pro Asn Ser Glu
Asp Leu Leu 115 120 125 ttg gtc aca gac cct gct ttt ctg tct tgc ggc
tgt gtc tca ggt agt 971 Leu Val Thr Asp Pro Ala Phe Leu Ser Cys Gly
Cys Val Ser Gly Ser 130 135 140 ggt ctc agg ctt gga ggc tcc cca ggc
agc cta ctg gac agg ttg agg 1019 Gly Leu Arg Leu Gly Gly Ser Pro
Gly Ser Leu Leu Asp Arg Leu Arg 145 150 155 ctg tca ttt gca aag gaa
ggg gac tgg aca gca gac cca acc tgg aga 1067 Leu Ser Phe Ala Lys
Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg 160 165 170 175 act ggg
tcc cca gga ggg ggc tct gag agt gaa gca ggt tcc ccc cct 1115 Thr
Gly Ser Pro Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser Pro Pro 180 185
190 ggt ctg gac atg gac aca ttt gac agt ggc ttt gca ggt tca gac tgt
1163 Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp
Cys 195 200 205 ggc agc ccc gtg gag act gat gaa gga ccc cct cga agc
tat ctc cgc 1211 Gly Ser Pro Val Glu Thr Asp Glu Gly Pro Pro Arg
Ser Tyr Leu Arg 210 215 220 cag tgg gtg gtc agg acc cct cca cct gtg
gac agt gga gcc cag agc 1259 Gln Trp Val Val Arg Thr Pro Pro Pro
Val Asp Ser Gly Ala Gln Ser 225 230 235 agc tagcatataa taaccagcta
tagtgagaag aggcct 1298 Ser 240 70 240 PRT Mus musculus 70 Lys Trp
Val Asn Thr Pro Phe Thr Ala Ser Ser Ile Glu Leu Val Pro 1 5 10 15
Gln Ser Ser Thr Thr Thr Ser Ala Leu His Leu Ser Leu Tyr Pro Ala 20
25 30 Lys Glu Lys Lys Phe Pro Gly Leu Pro Gly Leu Glu Glu Gln Leu
Glu 35 40 45 Cys Asp Gly Met Ser Glu Pro Gly His Trp Cys Ile Ile
Pro Leu Ala 50 55 60 Ala Gly Gln Ala Val Ser Ala Tyr Ser Glu Glu
Arg Asp Arg Pro Tyr 65 70 75 80 Gly Leu Val Ser Ile Asp Thr Val Thr
Val Gly Asp Ala Glu Gly Leu 85 90 95 Cys Val Trp Pro Cys Ser Cys
Glu Asp Asp Gly Tyr Pro Ala Met Asn 100 105 110 Leu Asp Ala Gly Arg
Glu Ser Gly Pro Asn Ser Glu Asp Leu Leu Leu 115 120 125 Val Thr Asp
Pro Ala Phe Leu Ser Cys Gly Cys Val Ser Gly Ser Gly 130 135 140 Leu
Arg Leu Gly Gly Ser Pro Gly Ser Leu Leu Asp Arg Leu Arg Leu 145 150
155 160 Ser Phe Ala Lys Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg
Thr 165 170 175 Gly Ser Pro Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser
Pro Pro Gly 180 185 190 Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Ala
Gly Ser Asp Cys Gly 195 200 205 Ser Pro Val Glu Thr Asp Glu Gly Pro
Pro Arg Ser Tyr Leu Arg Gln 210 215 220 Trp Val Val Arg Thr Pro Pro
Pro Val Asp Ser Gly Ala Gln Ser Ser 225 230 235 240 71 23 DNA
Artificial Sequence Oligonucleotide primer ZC24432 71 atgtctgagc
ctggtcactg gtg 23 72 23 DNA Artificial Sequence Oligonucleotide
primer ZC24433 72 tctgaacctg caaagccact gtc 23 73 27 DNA Artificial
Sequence Oligonucleotide primer ZC9739 73 ccatcctaat acgactcact
atagggc 27 74 22 DNA Artificial Sequence Oligonucleotide primer
ZC24434 74 caccagtgac caggctcaga ca 22 75 23 DNA Artificial
Sequence Oligonucleotide primer ZC24431 75 ccatcacact ccagttgctc
ttc 23 76 23 DNA Artificial Sequence Oligonucleotide primer ZC9719
76 actcactata gggctcgagc ggc 23 77 23 DNA Artificial Sequence
Oligonucleotide primer ZC24511 77 tccagcatag agttggtgcc aca 23 78
592 DNA Mus musculus CDS (436)...(592) 78 cgcccgggca ggtctccgct
ggtggccctg tgtttcagtc gcgcacagct gtctgcccac 60 ttctcctgtg
gtgtgcctca cggtcacttg cttgtctgac cgcaagtctg cccatccctg 120
gggcagccaa ctggcctcag cccgtgcccc aggcgtgccc tgtctctgtc tggctgcccc
180 agccctactg tcttcctctg tgtaggctct gcccagatgc ccggctggtc
ctcagcctca 240 ggactatctc agcagtgact cccctgattc tggacttgca
cctgactgaa ctcctgccca 300 cctcaaacct tcacctccca ccaccaccac
tccgagtccc gctgtgactc ccacgcccag 360 gagaccaccc aagtgcccca
gcctaaagaa tggctttctg aggaagatcc tgaaggagta 420 ggtctgggac acagc
atg ccc cgg ggc cca gtg gct gcc tta ctc ctg ctg 471 Met Pro Arg Gly
Pro Val Ala Ala Leu Leu Leu Leu 1 5 10 att ctc cat gga gct tgg agc
tgc ctg grc ctc act tgc tac act gac 519 Ile Leu His Gly Ala Trp Ser
Cys Leu Xaa Leu Thr Cys Tyr Thr Asp 15 20 25 tac ctc tgg acc atc
acc tgt gtc ctg gag aca cgg agc ccc aac ccc 567 Tyr Leu Trp Thr Ile
Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro 30 35 40 agc ata ctc
agt ctc acc tgg caa g 592 Ser Ile Leu Ser Leu Thr Trp Gln 45 50 79
52 PRT Mus musculus VARIANT (1)...(52) Xaa = Any Amino Acid 79 Met
Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly 1 5 10
15 Ala Trp Ser Cys Leu Xaa Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
20 25 30 Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile
Leu Ser 35 40 45 Leu Thr Trp Gln 50 80 1229 DNA Mus musculus CDS
(3)...(1196) 80 ga cgc tat gat atc tcc tgg gac tca gct tat gac gaa
ccc tcc aac 47 Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu Pro
Ser Asn 1 5 10 15 tac gtg ctg aga ggc aag cta caa tat gag ctg cag
tat cgg aac ctc 95 Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln
Tyr Arg Asn Leu 20 25 30 aga gac ccc tat gct gtg agg ccg gtg acc
aag ctg atc tca gtg gac 143 Arg Asp Pro Tyr Ala Val Arg Pro Val Thr
Lys Leu Ile Ser Val Asp 35 40 45 tca aga aac gtc tct ctt ctc cct
gaa gag ttc cac aaa gat tct agc 191 Ser Arg Asn Val Ser Leu Leu Pro
Glu Glu Phe His Lys Asp Ser Ser 50 55 60 tac cag ctg cag atg cgg
gca gcg cct cag cca ggc act tca ttc agg 239 Tyr Gln Leu Gln Met Arg
Ala Ala Pro Gln Pro Gly Thr Ser Phe Arg 65 70 75 ggg acc tgg agt
gag tgg agt gac ccc gtc atc ttt cgg acc cag gct 287 Gly Thr Trp Ser
Glu Trp Ser Asp Pro Val Ile Phe Arg Thr Gln Ala 80 85 90 95 ggg gag
ccc gag gca ggc tgg gac cct cac atg ctg ctg ctc ctg gct 335 Gly Glu
Pro Glu Ala Gly Trp Asp Pro His Met Leu Leu Leu Leu Ala 100 105 110
gtc ttg atc att gtc ctg gtt ttc atg ggt ctg aag atc cac ctg cct 383
Val Leu Ile Ile Val Leu Val Phe Met Gly Leu Lys Ile His Leu Pro 115
120 125 tgg agg cta tgg aaa aag ata tgg gca cca gtg ccc acc cct gag
agt 431 Trp Arg Leu Trp Lys Lys Ile Trp Ala Pro Val Pro Thr Pro Glu
Ser 130 135 140 ttc ttc cag ccc ctg tgc agg gag cac agc ggg aac ttc
aag aaa tgg 479 Phe Phe Gln Pro Leu Cys Arg Glu His Ser Gly Asn Phe
Lys Lys Trp 145 150 155 gtt aat acc cct ttc acg gcc tcc agc ata gag
ttg gtg cca cag agt 527 Val Asn Thr Pro Phe Thr Ala Ser Ser Ile Glu
Leu Val Pro Gln Ser 160 165 170 175 tcc aca aca aca tca gcc tta cat
ctg tca ttg tat cca gcc aag gag 575 Ser Thr Thr Thr Ser Ala Leu His
Leu Ser Leu Tyr Pro Ala Lys Glu 180 185 190 aag aag ttc ccg ggg ctg
ccg ggt ctg gaa gag caa ctg gag tgt gat 623 Lys Lys Phe Pro Gly Leu
Pro Gly Leu Glu Glu Gln Leu Glu Cys Asp 195 200 205 gga atg tct gag
cct ggt cac tgg tgc ata atc ccc ttg gca gct ggc 671 Gly Met Ser Glu
Pro Gly His Trp Cys Ile Ile Pro Leu Ala Ala Gly 210 215 220 caa gcg
gtc tca gcc tac agt gag gag aga gac cgg cca tat ggt ctg 719 Gln Ala
Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro Tyr Gly Leu 225 230 235
gtg tcc att gac aca gtg act gtg gga gat gca gag ggc ctg tgt gtc 767
Val Ser Ile Asp Thr Val Thr Val Gly Asp Ala Glu Gly Leu Cys Val 240
245 250 255 tgg ccc tgt agc tgt gag gat gat ggc tat cca gcc atg aac
ctg gat 815 Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Met Asn
Leu Asp 260 265 270 gct ggc cga gag tct ggc cct aat tca gag gat ctg
ctc ttg gtc aca 863 Ala Gly Arg Glu Ser Gly Pro Asn Ser Glu Asp Leu
Leu Leu Val Thr 275 280 285 gac cct gct ttt ctg tct tgc ggc tgt gtc
tca ggt agt ggt ctc agg 911 Asp Pro Ala Phe Leu Ser Cys Gly Cys Val
Ser Gly Ser Gly Leu Arg 290 295 300 ctt gga ggc tcc cca ggc agc cta
ctg gac agg ttg agg ctg tca ttt 959 Leu Gly Gly Ser Pro Gly Ser Leu
Leu Asp Arg Leu Arg Leu Ser Phe 305 310 315 gca aag gaa ggg gac tgg
aca gca gac cca acc tgg aga act ggg tcc 1007 Ala Lys Glu Gly Asp
Trp Thr Ala Asp Pro Thr Trp Arg Thr Gly Ser 320 325 330 335 cca gga
ggg ggc tct gag agt gaa gca ggt tcc ccc cct ggt ctg gac 1055 Pro
Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser Pro Pro Gly Leu Asp 340 345
350 atg gac aca ttt gac agt ggc ttt gca ggt tca gac tgt ggc agc ccc
1103 Met Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp Cys Gly Ser
Pro 355 360 365 gtg gag act gat gaa gga ccc cct cga agc tat ctc cgc
cag tgg gtg 1151 Val Glu Thr Asp Glu Gly Pro Pro Arg Ser Tyr Leu
Arg Gln Trp Val 370 375 380 gtc agg acc cct cca cct gtg gac agt gga
gcc cag agc agc tag 1196 Val Arg Thr Pro Pro Pro Val Asp Ser Gly
Ala Gln Ser Ser * 385 390 395 catataataa ccagctatag tgagaagagg cct
1229 81 397 PRT Mus musculus 81 Arg Tyr Asp Ile Ser Trp Asp Ser Ala
Tyr Asp Glu Pro Ser Asn Tyr 1 5 10 15 Val Leu Arg Gly Lys Leu Gln
Tyr Glu Leu Gln Tyr Arg Asn Leu Arg 20 25 30 Asp Pro Tyr Ala Val
Arg Pro Val Thr Lys Leu Ile Ser Val Asp Ser 35 40 45 Arg Asn Val
Ser Leu Leu Pro Glu Glu Phe His Lys Asp Ser Ser Tyr 50 55 60 Gln
Leu Gln Met Arg Ala Ala Pro Gln Pro Gly Thr Ser Phe Arg Gly 65 70
75 80 Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Arg Thr Gln Ala
Gly 85 90 95 Glu Pro Glu Ala Gly Trp Asp Pro His Met Leu Leu Leu
Leu Ala Val 100 105 110 Leu Ile Ile Val Leu Val Phe Met Gly Leu Lys
Ile His Leu Pro Trp 115 120 125 Arg Leu Trp Lys Lys Ile Trp Ala Pro
Val Pro Thr Pro Glu Ser Phe 130 135 140 Phe Gln Pro Leu Cys Arg Glu
His Ser Gly Asn Phe Lys Lys Trp Val 145 150 155 160 Asn Thr Pro Phe
Thr Ala Ser Ser Ile Glu Leu Val Pro Gln Ser Ser 165 170 175 Thr Thr
Thr Ser Ala Leu His Leu Ser Leu Tyr Pro Ala Lys Glu Lys 180 185 190
Lys Phe Pro Gly Leu Pro Gly Leu Glu Glu Gln Leu Glu Cys Asp Gly 195
200 205 Met Ser Glu Pro Gly His Trp Cys Ile Ile Pro Leu Ala Ala Gly
Gln 210 215 220 Ala Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro Tyr
Gly Leu Val 225 230 235 240 Ser Ile Asp Thr Val Thr Val Gly Asp Ala
Glu Gly Leu Cys Val Trp 245 250 255 Pro Cys Ser Cys Glu Asp Asp Gly
Tyr Pro Ala Met Asn Leu Asp Ala 260 265 270 Gly Arg Glu Ser Gly Pro
Asn Ser Glu Asp Leu Leu Leu Val Thr Asp 275 280 285 Pro Ala Phe Leu
Ser Cys Gly Cys Val Ser Gly Ser Gly Leu Arg Leu 290 295 300 Gly Gly
Ser Pro Gly Ser Leu Leu Asp Arg Leu Arg Leu Ser Phe Ala 305 310 315
320 Lys Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg Thr Gly Ser Pro
325 330 335 Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser Pro Pro Gly Leu
Asp Met 340 345 350 Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp Cys
Gly Ser Pro Val 355 360 365 Glu Thr Asp Glu Gly Pro Pro Arg Ser Tyr
Leu Arg Gln Trp Val Val 370 375 380 Arg Thr Pro Pro Pro Val Asp Ser
Gly Ala Gln Ser Ser 385 390 395 82 23 DNA Artificial Sequence
Oligonucleotide primer ZC24616 82 ctgcccacct caaaccttca cct 23 83
24 DNA Artificial Sequence Oligonucleotide primer ZC24615 83
atgctagctg ctctgggctc cact 24 84 1735 DNA Mus musculus CDS
(143)...(1729) 84 ctgcccacct caaaccttca cctcccacca ccaccactcc
gagtcccgct gtgactccca 60 cgcccaggag accacccaag tgccccagcc
taaagaatgg ctttctgaga aagaccctga 120 aggagtaggt ctgggacaca gc atg
ccc cgg ggc cca gtg gct gcc tta ctc 172 Met Pro Arg Gly Pro Val Ala
Ala Leu Leu 1 5 10 ctg ctg att ctc cat gga gct tgg agc tgc ctg gac
ctc act tgc tac 220 Leu Leu Ile Leu His Gly Ala Trp Ser Cys Leu Asp
Leu Thr Cys Tyr 15 20 25 act gac tac ctc tgg acc atc acc tgt gtc
ctg gag aca cgg agc ccc 268 Thr Asp Tyr Leu Trp Thr Ile Thr Cys Val
Leu Glu Thr Arg Ser Pro 30 35 40 aac ccc agc ata ctc agt ctc acc
tgg caa gat gaa tat gag gaa ctt 316 Asn Pro Ser Ile Leu Ser Leu Thr
Trp Gln Asp Glu Tyr Glu Glu Leu 45
50 55 cag gac caa gag acc ttc tgc agc cta cac agg tct ggc cac aac
acc 364 Gln Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly His Asn
Thr 60 65 70 aca cat ata tgg tac acg tgc cat atg cgc ttg tct caa
ttc ctg tcc 412 Thr His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln
Phe Leu Ser 75 80 85 90 gat gaa gtt ttc att gtc aat gtg acg gac cag
tct ggc aac aac tcc 460 Asp Glu Val Phe Ile Val Asn Val Thr Asp Gln
Ser Gly Asn Asn Ser 95 100 105 caa gag tgt ggc agc ttt gtc ctg gct
gag agc atc aaa cca gct ccc 508 Gln Glu Cys Gly Ser Phe Val Leu Ala
Glu Ser Ile Lys Pro Ala Pro 110 115 120 ccc ttg aac gtg act gtg gcc
ttc tca gga cgc tat gat atc tcc tgg 556 Pro Leu Asn Val Thr Val Ala
Phe Ser Gly Arg Tyr Asp Ile Ser Trp 125 130 135 gac tca gct tat gac
gaa ccc tcc aac tac gtg ctg agg ggc aag cta 604 Asp Ser Ala Tyr Asp
Glu Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu 140 145 150 caa tat gag
ctg cag tat cgg aac ctc aga gac ccc tat gct gtg agg 652 Gln Tyr Glu
Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg 155 160 165 170
ccg gtg acc aag ctg atc tca gtg gac tca aga aac gtc tct ctt ctc 700
Pro Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val Ser Leu Leu 175
180 185 cct gaa gag ttc cac aaa gat tct agc tac cag ctg cag gtg cgg
gca 748 Pro Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln Val Arg
Ala 190 195 200 gcg cct cag cca ggc act tca ttc agg ggg acc tgg agt
gag tgg agt 796 Ala Pro Gln Pro Gly Thr Ser Phe Arg Gly Thr Trp Ser
Glu Trp Ser 205 210 215 gac ccc gtc atc ttt cag acc cag gct ggg gag
ccc gag gca ggc tgg 844 Asp Pro Val Ile Phe Gln Thr Gln Ala Gly Glu
Pro Glu Ala Gly Trp 220 225 230 gac cct cac atg ctg ctg ctc ctg gct
gtc ttg atc att gtc ctg gtt 892 Asp Pro His Met Leu Leu Leu Leu Ala
Val Leu Ile Ile Val Leu Val 235 240 245 250 ttc atg ggt ctg aag atc
cac ctg cct tgg agg cta tgg aaa aag ata 940 Phe Met Gly Leu Lys Ile
His Leu Pro Trp Arg Leu Trp Lys Lys Ile 255 260 265 tgg gca cca gtg
ccc acc cct gag agt ttc ttc cag ccc ctg tac agg 988 Trp Ala Pro Val
Pro Thr Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg 270 275 280 gag cac
agc ggg aac ttc aag aaa tgg gtt aat acc cct ttc acg gcc 1036 Glu
His Ser Gly Asn Phe Lys Lys Trp Val Asn Thr Pro Phe Thr Ala 285 290
295 tcc agc ata gag ttg gtg cca cag agt tcc aca aca aca tca gcc tta
1084 Ser Ser Ile Glu Leu Val Pro Gln Ser Ser Thr Thr Thr Ser Ala
Leu 300 305 310 cat ctg tca ttg tat cca gcc aag gag aag aag ttc ccg
ggg ctg ccg 1132 His Leu Ser Leu Tyr Pro Ala Lys Glu Lys Lys Phe
Pro Gly Leu Pro 315 320 325 330 ggt ctg gaa gag caa ctg gag tgt gat
gga atg tct gag cct ggt cac 1180 Gly Leu Glu Glu Gln Leu Glu Cys
Asp Gly Met Ser Glu Pro Gly His 335 340 345 tgg tgc ata atc ccc ttg
gca gct ggc caa gcg gtc tca gcc tac agt 1228 Trp Cys Ile Ile Pro
Leu Ala Ala Gly Gln Ala Val Ser Ala Tyr Ser 350 355 360 gag gag aga
gac cgg cca tat ggt ctg gtg tcc att gac aca gtg act 1276 Glu Glu
Arg Asp Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr 365 370 375
gtg gga gat gca gag ggc ctg tgt gtc tgg ccc tgt agc tgt gag gat
1324 Val Gly Asp Ala Glu Gly Leu Cys Val Trp Pro Cys Ser Cys Glu
Asp 380 385 390 gat ggc tat cca gcc atg aac ctg gat gct ggc cga gag
tct ggc cct 1372 Asp Gly Tyr Pro Ala Met Asn Leu Asp Ala Gly Arg
Glu Ser Gly Pro 395 400 405 410 aat tca gag gat ctg ctc ttg gtc aca
gac cct gct ttt ctg tct tgc 1420 Asn Ser Glu Asp Leu Leu Leu Val
Thr Asp Pro Ala Phe Leu Ser Cys 415 420 425 ggc tgt gtc tca ggt agt
ggt ctc agg ctt gga ggc tcc cca ggc agc 1468 Gly Cys Val Ser Gly
Ser Gly Leu Arg Leu Gly Gly Ser Pro Gly Ser 430 435 440 cta ctg gac
agg ttg agg ctg tca ttt gca aag gaa ggg gac tgg aca 1516 Leu Leu
Asp Arg Leu Arg Leu Ser Phe Ala Lys Glu Gly Asp Trp Thr 445 450 455
gca gac cca acc tgg aga act ggg tcc cca gga ggg ggc tct gag agt
1564 Ala Asp Pro Thr Trp Arg Thr Gly Ser Pro Gly Gly Gly Ser Glu
Ser 460 465 470 gaa gca ggt tcc ccc cct ggt ctg gac atg gac aca ttt
gac agt ggc 1612 Glu Ala Gly Ser Pro Pro Gly Leu Asp Met Asp Thr
Phe Asp Ser Gly 475 480 485 490 ttt gca ggt tca gac tgt ggc agc ccc
gtg gag act gat gaa gga ccc 1660 Phe Ala Gly Ser Asp Cys Gly Ser
Pro Val Glu Thr Asp Glu Gly Pro 495 500 505 cct cga agc tat ctc cgc
cag tgg gtg gtc agg acc cct cca cct gtg 1708 Pro Arg Ser Tyr Leu
Arg Gln Trp Val Val Arg Thr Pro Pro Pro Val 510 515 520 gac agt gga
gcc cag agc agc tagcat 1735 Asp Ser Gly Ala Gln Ser Ser 525 85 529
PRT Mus musculus 85 Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu
Ile Leu His Gly 1 5 10 15 Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr
Thr Asp Tyr Leu Trp Thr 20 25 30 Ile Thr Cys Val Leu Glu Thr Arg
Ser Pro Asn Pro Ser Ile Leu Ser 35 40 45 Leu Thr Trp Gln Asp Glu
Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe 50 55 60 Cys Ser Leu His
Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr 65 70 75 80 Cys His
Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val 85 90 95
Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe 100
105 110 Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr
Val 115 120 125 Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala
Tyr Asp Glu 130 135 140 Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln
Tyr Glu Leu Gln Tyr 145 150 155 160 Arg Asn Leu Arg Asp Pro Tyr Ala
Val Arg Pro Val Thr Lys Leu Ile 165 170 175 Ser Val Asp Ser Arg Asn
Val Ser Leu Leu Pro Glu Glu Phe His Lys 180 185 190 Asp Ser Ser Tyr
Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr 195 200 205 Ser Phe
Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln 210 215 220
Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Met Leu Leu 225
230 235 240 Leu Leu Ala Val Leu Ile Ile Val Leu Val Phe Met Gly Leu
Lys Ile 245 250 255 His Leu Pro Trp Arg Leu Trp Lys Lys Ile Trp Ala
Pro Val Pro Thr 260 265 270 Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg
Glu His Ser Gly Asn Phe 275 280 285 Lys Lys Trp Val Asn Thr Pro Phe
Thr Ala Ser Ser Ile Glu Leu Val 290 295 300 Pro Gln Ser Ser Thr Thr
Thr Ser Ala Leu His Leu Ser Leu Tyr Pro 305 310 315 320 Ala Lys Glu
Lys Lys Phe Pro Gly Leu Pro Gly Leu Glu Glu Gln Leu 325 330 335 Glu
Cys Asp Gly Met Ser Glu Pro Gly His Trp Cys Ile Ile Pro Leu 340 345
350 Ala Ala Gly Gln Ala Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro
355 360 365 Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Gly Asp Ala
Glu Gly 370 375 380 Leu Cys Val Trp Pro Cys Ser Cys Glu Asp Asp Gly
Tyr Pro Ala Met 385 390 395 400 Asn Leu Asp Ala Gly Arg Glu Ser Gly
Pro Asn Ser Glu Asp Leu Leu 405 410 415 Leu Val Thr Asp Pro Ala Phe
Leu Ser Cys Gly Cys Val Ser Gly Ser 420 425 430 Gly Leu Arg Leu Gly
Gly Ser Pro Gly Ser Leu Leu Asp Arg Leu Arg 435 440 445 Leu Ser Phe
Ala Lys Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg 450 455 460 Thr
Gly Ser Pro Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser Pro Pro 465 470
475 480 Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp
Cys 485 490 495 Gly Ser Pro Val Glu Thr Asp Glu Gly Pro Pro Arg Ser
Tyr Leu Arg 500 505 510 Gln Trp Val Val Arg Thr Pro Pro Pro Val Asp
Ser Gly Ala Gln Ser 515 520 525 Ser 86 16 DNA Artificial Sequence
Oligonucleotide primer ZC3424 86 aacagctatg accatg 16 87 20 DNA
Artificial Sequence Oligonucleotide primer ZC694 87 taatacgact
cactataggg 20 88 20 DNA Artificial Sequence Oligonucleotide primer
ZC24399 88 agcggtctca gcctacagtg 20 89 20 DNA Artificial Sequence
Oligonucleotide primer ZC24400 89 tgagctgggg acaacaaggt 20 90 20
DNA Artificial Sequence Oligonucleotide primer ZC24806 90
tgacgaaccc tccaactacg 20 91 20 DNA Artificial Sequence
Oligonucleotide primer ZC24807 91 tgctctcagc caggacaaag 20 92 4 PRT
Artificial Sequence WXXW peptide motif VARIANT (1)...(4) Xaa = Any
Amino Acid 92 Trp Xaa Xaa Trp 1
* * * * *
References